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The practice of sequential testing is followed by the evaluation of accuracy, but often not 
by the evaluation of cost. This research described and compared three sequential testing 
strategies: believe the negative (BN), believe the positive (BP) and believe the extreme 
(BE), the latter being a less-examined strategy. All three strategies were used to combine 
results of two medical tests to diagnose a disease or medical condition. Descriptions of 
these strategies were provided in terms of accuracy (using the maximum receiver operating 
curve or MROC) and cost of testing (defined as the proportion of subjects who need 2 tests 
to diagnose disease), with the goal to minimize the number of tests needed for each subject 
while maintaining test accuracy. It was shown that the cost of the test sequence could be 
iv 
 
reduced without sacrificing accuracy beyond an acceptable range by setting an acceptable 
tolerance (q) on maximum test sensitivity. This research introduced a newly-developed 
ROC curve reflecting this reduced sensitivity and cost of testing called the Minimum Cost 
Maximum Receiver Operating Characteristic (MCMROC) curve. Within these strategies, 
four different parameters that could influence the performance of the combined tests were 
examined: the area under the curve (AUC) of each individual test, the ratio of standard 
deviations (b) from assumed underlying disease and non-disease populations, correlation 
(rho) between underlying disease populations, and disease prevalence. The following 
patterns were noted:  Under all parameter settings, the MROC curve of the BE strategy 
never performed worse than the BN and BP strategies, and it most frequently had the 
lowest cost.  The parameters tended to have less of an effect on the MROC and MCMROC 
curves than they had on the cost curves, which were affected greatly. The AUC values and 
the ratio of standard deviations both had a greater effect on cost curves, MROC curves, and 
MCMROC curves than prevalence and correlation. The use of BMI and plasma glucose 
concentration to diagnose diabetes in Pima Indians was presented as an example of a real-
world application of these strategies.  It was found that the BN and BE strategies were the 
most consistently accurate and least expensive choice. 
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Chapter 1: Introduction 
 
1.1 Definition of Problem 
In response to the current economic slowdown and increasing healthcare costs in the 
United States, patients, health insurance companies, healthcare professionals, and 
government agencies are interested in reducing health care spending. Therefore, economic 
assessment is important in the field of healthcare.  
In clinical practice, multiple tests are often used in diagnosing a patient. Performing 
several diagnostic tests on an individual provides multiple measures with additional 
information that can be combined in order to improve the overall accuracy of the 
diagnostic process, compared to that of a single test. However, multiple testing could be 
more costly than using a single test strategy. The consequence of this is that significant 
cost is added to healthcare. Consequently, medical tests should be evaluated individually 
and in combination to assure appropriate accuracy while limiting healthcare costs.  
There are several techniques available to combine multiple tests in order to classify 
subjects into one of two groups (diseased or non-diseased) and these techniques will 
depend on the type of testing. In clinical settings, two types of testing are considered: non-
sequential and sequential testing. Non-sequential testing is the method of performing all 
tests simultaneously on all subjects or performing all tests prior to deciding on the 
diagnosis. Techniques to combine test results in order to make a diagnosis, in non-
sequential testing include logistic regression, which uses likelihood ratios and linear 
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combinations of variables, as well as classification trees.  Sequential testing is the method 
of performing a secondary test based on the results of the previous test.  
The research here concentrates on sequential testing, in which decisions on whether 
or not to order subsequent tests are based on the results of a previous test. In sequential 
testing, the most popular technique to combine multiple sequences of tests is to use 
combinations of logic rules (Ruczinski, Kooperberg, LeBlanc, 2003). An example of some 
of these logic rules are believe the positive (BP), and believe the negative (BN), which will 
be described in detail in Chapter 2. Logic rules can be used to construct predictors that are 
logical combinations of the original predictors. This research focused on three forms of 
these logic rules: believe the positive (BP), believe the negative (BN), and believe the 
extreme (BE). These will be described and compared, in the coming chapters, in terms of 
accuracy and cost of testing.   
Since cost is the main issue in this research, it must be given a narrow definition 
from the beginning.  Cost can be thought of from many different perspectives:  the patient 
could worry about the financial cost or physical burden of each individual test, while 
governments and health insurance companies may think about cost economically.  In this 
research, cost will primarily be thought of in terms of the cost of the sequenced tests, 
called hereafter the cost of testing (no non-sequential testing strategies were considered).  
Since the goal here is to reduce the numbers of tests administered to each patient, ‘low 
cost’ could be defined as a reduction in the number of tests performed.     
To evaluate the sequence of tests, several traditional measures of diagnostic 
accuracy can be employed. The most popular measures are the test’s sensitivity and 
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specificity. Sensitivity is the probability that the test or testing strategy correctly identifies 
the subject with disease as having the disease. This is estimated by computing the 
proportion of subjects with the disease that the test or testing strategy correctly identifies as 
having disease. Specificity is the probability that the test or testing strategy correctly 
identifies the subject without disease as not having the disease.  This is estimated by 
computing the proportion of subjects without the disease that the test or strategy correctly 
identifies as non-disease.  
In this study, tests using continuous measures will be considered.  Thus, thresholds 
for each measure are used to dichotomize the test results into diseased and non-diseased.  
The measures of sensitivity and specificity are estimated using these thresholds. Because 
the disease detectability of these thresholds varies, clinicians will want to know what 
thresholds to use to diagnose new patients as having disease or not. The combination of 
thresholds that produce the best trade-off in sensitivity and specificity is considered the 
optimal operating point (OOP). 
In later chapters, another cost will be considered when calculating the optimal 
operating point.  This is the cost of misclassification.  Misclassification could be defined as 
declaring a test result as positive erroneously for a patient who is actually negative for a 
disease, or declaring a test result as negative for a patient who actually has disease.  Each 
test has four possible outcomes for diagnosis:  False Positive (FP), in which the patient is 
falsely classified as positive, False Negative (FN), in which the patient is falsely classified 
as negative, True Positive (TP), in which the patient is correctly classified as positive, and 
finally, True Negative (TN), in which the patient is correctly classified as negative.  The 
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risks in falsely classified tests are many. A patient, falsely believing to be positive, may 
undergo harmful, unnecessary treatments to combat a disease they do not have.  
Conversely, a patient, falsely believing to be negative for disease, could avoid treatments 
that may be necessary for recovery. The total cost of misclassification could be either the 
total proportion of these misclassified subjects or a function of the misclassification errors. 
A ROC curve demonstrates the characteristics of a diagnostic test by graphing the 
false-positive rate (1-specificity) on the horizontal axis and the true-positive rate 
(sensitivity) on the vertical axis for various cutoff values. As the false-positive rate 
increases, so does the true-positive rate. The diagonal line connecting the points (0, 0) and 
(1, 1), i.e. the chance line, is used to divide the plot into two spaces (bad or good).  Points 
falling above the chance line indicate test performance better than chance and points 
falling below the chance line indicate performance worse than chance. Perfect 
classification occurs at the (0, 1) point which corresponds to a specificity and sensitivity of 
1.0. The closer the ROC curve is to this point, the more accurate the test is.  
Single tests defining a binary outcome such as disease/non-disease, typically use a 
single threshold, thus resulting in a single (1-Specificity, Sensitivity) pair on the ROC 
curve. However, the use of logic rules in a sequence of tests may be associated with more 
than one threshold (at least one from each test) which may produce more than one 
sensitivity value corresponding to a fixed specificity.  
Thompson (2003) and Shen (2008) refer to the plot of maximum value of 
sensitivity for each false-positive rate as the maximum ROC (MROC) curve, but cost of 
testing was not considered from their analysis.  This research extends previous research by 
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evaluating the three sequential strategies mentioned above by comparing the accuracy and 
cost of testing of combined tests. It also considers thresholds that produce the same or 
slightly lower sensitivity than the maximum sensitivity. 
1.2 Motivation and Goals 
Considering two tests given sequentially, it is possible that the second test could be 
uninformative or might add too little information to the diagnostic process. Although the 
practice of sequential testing is followed by the evaluation of accuracy, it is often not by 
the evaluation of cost of testing. Consequently, much work remains to be done to evaluate 
sequences of tests using both accuracy and cost of testing.   
The motivation here is to consider a sequential strategy to reduce cost of testing, as 
defined in section 1.1. Performing multiple tests can be expensive. Some tests may not 
provide relevant information and conducting many tests does not ensure accuracy. Instead, 
multiple tests could be difficult to interpret, risky or painful. Government agencies will 
benefit from this research because reducing the number of tests for all patients could 
reduce the cost of testing. The innovative approach of not performing all tests on every 
patient, as well as improving the accuracy of diagnosis, can make an important 
contribution in reducing the number of tests, thus limiting health care costs. 
Further, the goal is to give a general direction on the choice of an optimal operating 
point (OOP); this is the point that produces the best set of sensitivity and specificity 
considering restriction on the cost of testing. In this research, the benefits of lowering the 
number of tests were considered. Increasing the number of tests makes healthcare costs 
rise, thus causing financial problems for those who have no health insurance, and possibly 
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increasing the insurance premiums for those who are well-insured. In summary, the goal of 
this research is to offer solutions for medical testing to be accurate while lowering the cost 
of testing.  
1.3 Prospectus  
This research is organized as follows: Chapter 2 begins with a review of the strategies to 
consider for sequential testing. Early work regarding sequential testing and a special ROC 
curve adapted to such testing (called MROC curves) will be considered as well.  Chapter 3 
demonstrates how to obtain an MROC curve, the newly developed Minimum Cost 
Maximum ROC (MCMROC) and cost curves. Formulas are derived for sensitivity, 
specificity, false-positive rate and cost of testing for each of the strategies, and a technique 
to find optimal operating points is provided. Chapters 4 and 5 are devoted to describing 
and comparing the strategies in terms of cost of testing, and accuracy.  Chapter 6 applies 
these techniques to real data, obtaining MROC, MCMROC and cost curves. Chapter 7 
concentrates on discussion and directions for future research.  
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Chapter 2: Review of Relevant Statistical Topics 
  
2.1 Review of sequential testing and literature 
In sequential settings, a diagnostic decision is made based on earlier test results as to 
whether to continue testing another subject. The research described here concentrates on 
combining two medical tests administered in a sequence. The first test, Test 1, is measured 
on all subjects. Sometimes a diagnosis can be made with Test 1 only.   If a diagnosis 
cannot be made by Test 1, then Test 2 is administered. A sequence is used in order to avoid 
administering Test 2 to all subjects, because of the cost of testing. Therefore, it can be 
understood that the reason for using sequential testing is to reduce cost of testing and 
burden by decreasing the number of subjects taking all tests.  
This study considered three logic rules that allow combining multiple sequences of 
tests. The following sequential testing strategies (logic rules) were considered: believe the 
negative (BN), believe the positive (BP) and believe the extreme (BE). In the scenario of 
two tests (Test 1 and Test 2), these strategies could be written as follows:   
• Assuming that Test 1 and Test 2 are a sequence of tests, the BN strategy will 
classify the subject as non-diseased if the result of Test 1 is negative. If the result is 
not negative, the subject will take the second test.  If the result for Test 2 is 
negative, the subject will be classified as non-diseased.  Otherwise, the subject will 
be classified as diseased.  Thus, in the BN strategy, Test 1 is administered to each 
subject, while Test 2 is administered only for those whose test values are positive 
for disease in order to confirm if disease is really present. 
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• Assuming that Test 1 and Test 2 are a sequence of tests, the BP strategy will 
classify the subject as diseased if the result of Test 1 is positive. If the result is not 
positive, the subject will take the second test.  If the result for Test 2 is positive, the 
subject will be classified as diseased.  Otherwise, the subject will be classified as 
non-diseased.  Thus, in the BP strategy, Test 1 is administered to each subject, 
while Test 2 is administered only for those whose test values are negative for 
disease in order to confirm if disease is really absent. 
• Assuming that Test 1 and Test 2 are a sequence of tests, the BE strategy will 
classify a subject as diseased if 1) the results of Test 1 say the subject is diseased, 
or 2) the results of Test 1 are in an intermediate range and the results of Test 2 say 
the subject is diseased. If not, the subject is classified as non-diseased. Thus, for the 
BE strategy, Test 1 is administered to each subject, but Test 2 is administered only 
for those whose test values fall in an intermediate unfixed range.  
The BE strategy has only rarely been mentioned in the literature. Etzioni (2003) utilized 
the BE strategy for screening of prostate cancer, but did not call it by that name. The 
research considered here will examine BE as an alternative strategy to BN and BP. 
Marshall, writing about sequential strategies BN and BP, notes, “These rules do not 
necessarily have better predictive values than a single test” (1989). Etzioni (2003) 
proposed sequencing tests to improve overall accuracy over the single test.  
The decision rules presented above are used to combine sequences of tests using 
Boolean logic rules of “OR” and “AND” combinations to predict a binary outcome. BN 
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and BP are well known in clinical settings and currently are the most popular techniques 
for combining sequential tests; they were discussed and utilized in research by Marshall 
(1989), Zhou, Obuchowski, and McClish (2002), Pepe (2003), Thompson (2003), and 
Shen (2008).  
Thompson (2003) focused on BP and BN strategies to combine two diagnostic 
tests, the ratio of free to total Prostate-Specific Antigen (RPSA) and total Prostate-Specific 
Antigen (TPSA). The BP strategy increased sensitivity but decreased specificity to be 
lower than either individual test. Conversely, the BN strategy increased specificity but 
decreased the sensitivity to be lower than either individual test.  Marshall (1989),  Geisser 
and Johnson (1992), Macaskill et al. (2002), Pepe (2003), Man-Lai Tang (2004), and Kelly 
et al. (2006) focused their work primarily on combining multiple binary or discrete tests 
using BN and BP. Binary tests will not be considered here; this research focuses on 
combining multiple continuous sequences of tests.  
When considering continuous tests, the use of BP, BN and BE strategies are 
associated with more than one threshold and as such, may produce more than one 
sensitivity value corresponding to each fixed false positive rate (FPR). FPR is the 
probability that the test incorrectly identifies a subject without disease as having the 
disease (e.g, 1-specificity). The graph of every pair of FPR and sensitivity values for the 
ROC curve appears as a cloud of points, as mentioned by Baker (2000).  This cloud is 
made up of an infinite number of ROC curves. Consequently, a special point of concern is 
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how one can maximize sensitivity for each at each specificity level. Several authors have 
addressed this question. 
Baker (2000, 2003), who focused primarily on evaluating the performance of early 
detection tests, was the first to mention the cloud of points.  Baker proposed a 
nonparametric approach and used logic rules to combine diagnostic tests and introduced a 
utility function to “to identify the point on the ROC curve with the highest utility” (2000).  
This utility function maximized the product of sensitivity and benefit to determine the 
acceptable FPRs that were clinically relevant. For this research, the parametric approach, 
assuming a binormal model, e.g., tests are normally distributed for diseased and non-
diseased populations, is used. Also, rather than looking at a portion of the ROC curve, this 
research examines the ROC curve in its entirety.   
Etzioni (2003) used logic rules to combine diagnostic tests by minimizing an 
objective function called weighted misclassification error which could be given by the 
equation L(α) = αFP + FN where a higher value of α led to lower FPR and vice versa. 
Here, FP referred to the false positive result; FN, the false negative result.  Etzioni created 
optimal logic rules by varying α while minimizing the weighted misclassification error. 
The ROC(α) curve represented the sensitivity produced by the thresholds that minimized 
the weighted misclassification error function.  
Thompson (2003) used a more general approach to evaluate accuracy of a sequence 
of tests, focusing primarily on BP.  Her choice of threshold for each test was set at specific 
percentile values in the non-diseased distribution. Thompson let future thresholds depend 
on the results from previous tests.  She also developed the MaxROC curve that maximized 
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the overall sensitivity at a fixed specificity.  This allowed the researcher to choose a 
threshold for a non-diseased population and apply it to the diseased; however she did not 
address which threshold should be used in implementation of a test sequence. Such choices 
will depend on issues such as disease prevalence as well as the costs of false positives and 
false negatives, and the costs of the tests themselves. Rather than following the Thompson 
percentile approach, this research tries to maximize the sensitivity with the lowest cost.   
Finally, Shen (2008) examined the BP and BN strategies, using the maximum of 
sensitivity values and plotting it against each FPR (MROC). Shen compared the BP and 
BN strategies by finding the maximum sensitivity across both strategies. Shen considered 
identical-negative correlation, identical-positive correlation, and different sign correlation 
for diseased and non-diseased population. She saw that one strategy (BP or BN) was 
always better than the other when the correlation was of a different sign. When the 
correlation sign was the same, she found the BP strategy inferior to the BN strategy at the 
low FPR region; the opposite occurred at the low specificity region. The research detailed 
in this paper will also include the cost of testing as to evaluate the combined tests that 
MROC and ROC curves do not provide.  Also, it introduces BE as an alternative to BN 
and BP.  
2.2 Discussion of cost in the literature 
This research incorporates the cost of testing to evaluate testing strategies. Cost is defined 
in this research as the proportion of subjects who need 2 tests to diagnose disease.  The 
goal here is to look at cost in terms of a sequence of tests, and compare strategies for the 
same sequence of tests, not different tests. Some of the literature, for example (Pepe, 
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2003), considered cost, as it is defined here, in terms of performing a single test, not of a 
sequence of tests.  Very little research has dealt with the cost of sequenced testing. 
However, Geisser and Johnson (1992) used two binary tests in a sequence to develop a 
Bayesian approach to estimating posterior distributions for the prevalence and the accuracy 
of the tests. Also, they considered calculating the cost of testing. Gardner et al.  (2004) 
mentioned that sequential testing strategies are often applied in order to reduce the cost of 
testing.  
The reader must be careful to recognize ‘cost of testing’ and ‘misclassification cost’ 
as different terms. ‘Cost,’ for some researchers, has primarily been misclassification cost, 
or the cost of making a wrong decision.  While this research focuses on a different aspect 
of cost (here, called cost of testing), misclassification cost is still important to consider in 
deriving the optimal operating point, as shown in Section 2.2.  Zweig and Campbell (1993) 
defined an optimal operating point that minimized the average overall cost, including both 
the cost of performing the test as well as misclassification costs. Their definition of cost 
used Metz’ formula (1995), and was defined as the ratio of the net costs for a test subject 
without the disease to a test subject with the disease. Metz et al. (1995) used the expected 
utilities and costs associated with the true positive and false-positive rates to determine the 
location of the optimal operating point of the ROC curve.   
From the literature presented above, the issue of cost of testing remains little 
addressed.  The motivation behind sequential testing is that it allows for reduced costs by 
reducing the number of subjects that need Test 2.  
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2.3 Review of optimal operating point and the Youden’s Index 
In clinical practice, a threshold is required to classify subjects as to diseased or non-
diseased from a given test. Therefore, many thresholds can be compared for this 
classification. However, the efficiency of these thresholds varies. While high specificity 
and sensitivity have been preferred in the past, it could be valuable to choose the 
thresholds that will reduce the costs of error and cost of testing as well. Such a point is 
known as an optimal operating point. Optimal operating points have an important purpose 
to improve the classification condition; it helps clinicians decide at which point to choose 
to “operate” the test, that is, what threshold to use to diagnose new patients as having 
disease or not. The search for optimal operating points should include either maximizing a 
function of the number of correctly classified subjects or minimizing a function of the 
number of misclassified subjects. This results in a small misclassification error rate. 
 Youden's index (Youden, 1950) for selecting the optimal operating point is used 
to choose a point with the largest sum of sensitivity and specificity, which relates to 
maximizing the probability of being correctly classified. A higher Youden's index 
corresponds to higher probabilities of correct classification and the ROC points associated 
with these probabilities can be used to identify the thresholds that produce this level of 
classification. There are two versions of the Youden's index. The first version does not 
consider misclassification costs or prevalence of disease.  This version of the Youden's 
index can be defined a max { ( ) ( ) 1)}TPR TNRθ θ θ+ −   which is equivalent to maxθ  
{ ( )TPR θ −  ( )}FPR θ over all thresholds. Here, TPR is the true positive rate (sensitivity), 
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TNR is the true negative rate (specificity), θ  represents the threshold.  This version of the 
Youden’s index chooses the point furthest from the ROC chance line as the optimal 
operating point.   
The second version of Youden's index determines the optimal operating point that 
minimizes the average cost. Zweig and Campbell (1993) defined optimal operating point 
as max { ( ) *(1 ( ))}TPR m TNRθ θ θ− −   which is equivalent to max { ( ) *( ( ))}TPR m FPRθ θ θ−  over all 
thresholds, where [ ] ( ) ( )FP TN FN TP(1 ) / / C C ,m p p C C= − × − −⎡ ⎤⎣ ⎦  as defined in work by 
Metz (1978) is the slope of the combined diagnostic tests’ ROC curve (a straight line that 
passes through the ROC curve in the small FPR region, in a point called the optimal point), 
p is the prevalence of disease, ( ) ( )FP TN FN TP/ C CC C− −⎡ ⎤⎣ ⎦ is the cost/benefit ratio of false-positive 
compared to false-negative results, CFP is the cost associated with a false positive, CTN is 
the cost associated with a true negative, CFN is the cost associated with a false negative, 
and CTP is the cost associated with a true positive. When 1m = , this version of the 
Youden’s index yields the original Youden's index (which implies that the product of the 
cost/benefit ratio and the prevalence is 1). However, Zweig and Campbell’s criterion 
would not assess the cost of the number of tests. What this research adds for consideration 
is the cost of testing as a constraint on finding the optimal operating point. 
Different values of cost/benefit ratio have been used in various applications. Cantor 
et al. (1999) looked at previous studies to search for cost/benefit ratios that were used in 
determining the optimal operating point, finding cost/benefit ratios ranging between 
0.0025 and 2.70. Metz et al., writing about the slope, m, mentioned that varying the values 
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of the slope from 0.1 to 3.0, could produce an OOP that could be considered clinically 
relevant (1996).  
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Chapter 3: Methods 
 
3.1 Sequential testing strategies 
This research offers a method to examine the cost of testing by introducing a new technique 
which accounts for cost called the Minimum Cost Maximum Receiver Operating 
Characteristic (MCMROC) curve. Here, think of cost in terms of the number of tests not in 
terms of dollars. This research will describe three sequential testing strategies in terms of 
the MCMROC: “believe the positive” (BP), “believe the negative” (BN), and “believe the 
extreme” (BE). The first two are known in the literature as techniques for combining two 
continuous tests, e.g. repeated screening tests, (Thompson, 2003) and non-sequential 
combination of tests (Shen, 2008). The less examined strategy, called BE, has been used 
for prostate cancer screening (Etzioni, 2003). The BP strategy classifies a subject as 
positive for disease if either of two tests are positive. The BN strategy classifies a subject as 
positive for disease if both of the tests are positive. The BE strategy classifies a subject as 
positive for disease if the first test is positive, or if the result for the first test is neither 
positive or negative (ambiguous) and the second test is positive for disease.  BP and BN 
strategies have two thresholds with which to dichotomize subjects as diseased or not 
diseased, one threshold for each test. The BE strategy has two thresholds for the first test 
(separating the disease positive, disease negative and ambiguous regions) and one threshold 
for the second test. 
Comparison between these strategies will provide indications that one strategy may 
be less costly or more accurate than the others. This information may be used to suggest 
which strategy should be used in clinical practice. Figure 3.1 shows a tree diagram for the 
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application of Test1 and Test 2, where 1 2 3( , , and )θ θ θ represent threshold values or 
decision levels from which to classify subjects as disease positive or negative.  In the 
figures, the +/- symbols indicate a positive or negative test result. 
 
Figure 3.1 Tree diagram of the structure for three sequential testing strategies 
3.2 Developing the Maximum ROC (MROC) curve 
This section deals with the MROC curve, mentioned in Chapters 1 and 2.  The BP, BN and 
BE testing strategies are each associated with more than one threshold value.  As such, this 
may produce multiple sensitivity values for some or all FPRs.  These points can be thought 
of as an infinite number of ROC curves, whose projection onto the FPR-true positive rate 
(TPR) plane appears as a cloud of points, as mentioned by Baker (2000).  A graph of such a 
cloud (for the BP strategy) is given in Figure 3.2.  The light blue represents the infinite 
number of ROC curves projected onto the FPR-TPR plane that is produced by all possible 
combinations of the thresholds. 
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Figure 3.2: Projections of the ROC surface producing a cloud of false and true positive 
pairs 
The ROC “function” for the graph in Figure 3.3 can be written as the set of ordered pairs: 
ROC {( ( ), ( )), }nFPR TPRθ θ θ= ∈\                                                                                        (3.1) 
where ROC  is the entire set of all possible TPR and FPR values, and θ  represents the set 
of all possible thresholds. Note that the word “function” is written in quotes because 
equation (3.1) is not a true function as multiple TPR values are associated with a single 
FPR value (thus violating the definition of a function). 
In order to create a single ROC curve with which to describe each sequential strategy, the 
MROC curve (Thompson, 2003) will be used.  The MROC curve is created from the 
collection of points that correspond to the maximum sensitivity for each, fixed FPR.  There 
are two approaches considered here which may be used to define the MROC function: 
( )FPR( ) tMROC t, Max (TPR( )) : 0 t 1, nθ θ θ≤⎧ ⎫⎛ ⎞= < < ∈⎨⎜ ⎟⎬⎝ ⎠⎩ ⎭ \                                                       (3.2) 
( )FPR( )=tMROC = t, Max (TPR( )) : 0 t 1, nθ θ θ⎧ ⎫⎛ ⎞< < ∈⎨⎜ ⎟⎬⎝ ⎠⎩ ⎭ \                                                       (3.3) 
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The difference between these two expressions is in how the maximum TPR is chosen.  
Equation 3.2 choose the maximum TPR for all FPR value less than or equal to a fixed 
value (t), whereas equation 3.3 choose the maximum TPR for a FPR value equal to t. 
Unlike equation 3.3, the first expression in equation 3.2 assures that the MROC curve is 
non-decreasing.  For this reason, this research used equation 3.2. This can be formulated as 
a nonlinear optimization problem to find the thresholds that give the maximum TPR for 
each .FPR t≤ Using equation 3.2, the MROC curve for the cloud of ROC points from 
Figure 3.2 was generated and is plotted in Figure 3.3 where the cloud of ROC points is 
shown in “light blue” and the MROC curve is shown in “black.” 
 
Figure 3.3: MROC curves for an example of the BP strategy 
3.3 Expected cost of testing 
The cost of the testing will be defined as the expected number of the 2nd tests that need to 
be performed to arrive at a diagnostic decision out of the total number of patients.  The cost 
of performing tests for sample of size n, for a particular strategy would be:  
1 2{ [perform the second test]}n C C P× + ×  
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where 1C  is the actual cost of performing Test 1 and 2C  is the actual cost of performing 
Test 2, [perform the second test]P  is the proportion of subjects undergoing both tests. Here, 
the goal is not trying to compare the strategies based on cost in terms of dollars, but instead 
to compare these three strategies based on the proportion of subjects who must undergo 
both tests.  The cost formula can be written as: 
( )C θ = P [perform the 2
nd test]. 
( )C θ  is the proportion of subjects undergoing both tests. Note that this does not consider 
either the actual cost of performing each test or the sample size.  The sample size, n, is 
assumed to be a fixed value; for purposes of comparing a specific sequence of tests 
between strategies only, n=1 is assumed and the economic cost of the individual tests can 
be ignored.   
Formulas for the cost for each sequencing test strategy, BP, BN and BE are in next 
sections. From the equations below, conclusions about the nature of cost calculation can be 
drawn.  In particular, it can be seen that cost calculation is dependent on sensitivity and 
specificity of the first test, and the disease prevalence. Though it appears that the second 
test is not involved, the cost calculation indirectly incorporates the effect of the second test 
because the choice of operating point will involve constraints on the cost of testing. 
3.3.1 Cost of testing computation for the BP strategy 
This section derives the cost of testing for the BP strategy. Recall that Test 1 is measured 
on all subjects. For the BP strategy, Test 2 is only administered to those whose test results 
from Test 1 are negative for disease.  Then the cost of testing for BP strategy is given in the 
following theorem: 
Theorem 3.1 Cost of testing for the Believe the Positive (BP) strategy 
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Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2, 
respectively.  Let 1NX  and 2NX  represent the test results of non-diseased (N) population 
for tests 1 and 2 respectively. Let 
1DX
F ,
2 DX
F , 
1NX
F and 
2 NX
F denote the CDF functions of 
test results for those with (D) and without (N) disease and P(D) represent disease 
prevalence.  Then the cost of testing for the BP strategy, denoted by 1C ( ),
BP θ  is given by: 
( ) ( )1 1BP 1 1 1C ( )  = ( ) ( ) ( ) (1 ( )D NX XF P D F P Dθ θ θ× + × − .                                                             (3.4) 
Proof: 
BP
1 1 1C ( )  = ( )P Xθ θ≤  
( )1 1= ( )P X and D or Nθ≤  
( )1 1 1 1( ) ( )P X and D or P X and Nθ θ= ≤ ≤  
1 1 1 1= ( ) ( )P X and D P X and Nθ θ≤ + ≤  
( ) ( )1 1 1 1=  ( | ) ( ) ( | ) ( )P X D P D P X N P Nθ θ≤ × + ≤ ×  
( ) ( )( )1 1 1 1=  ( | ) ( ) ( | ) 1 ( )P X D P D P X N P Dθ θ≤ × + ≤ × −  
This can be rewritten in terms of cumulative distribution functions as 
= ( ) ( )1 11 1( ) ( ) ( ) (1 ( )D NX XF P D F P Dθ θ× + × −  
3.3.2 Cost of testing computation for the BN strategy 
This section derives the cost of testing for the BN strategy. Recall that Test 1 is measured 
on all subjects. For the BN strategy, Test 2 is administered only to those whose test values 
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are positive for disease. Then the cost of testing for BN strategy is given in the following 
theorem: 
Theorem 3.2 Cost of testing for the Believe the Negative (BN) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2, 
respectively.   Let 1NX  and 2NX  represent the test results of non-diseased (N) population 
for tests 1 and 2, respectively. Let
1DX
F ,
2 DX
F , 
1NX
F and 
2 NX
F denote the CDF functions of 
test results for those with (D) and without (N) disease and P(D) represent disease 
prevalence.  Then the cost of testing for the BN strategy, denoted by 1C ( ),  
BN θ is given by: 
( ) ( ) ( )( )1 11 1 1C ( ) = (1- ( )) ( ) 1 ( ) 1 ( )D NBN X XF P D F P Dθ θ θ× + − × −                                                   (3.5) 
Proof: 
1 1 1C ( )  = ( )
BN P Xθ θ≥  
( )1 1= ( )P X and D or Nθ≥  
1 1 1 1= ( ) ( )P X and D P X and Nθ θ≥ + ≥  
( ) ( )1 1 1 1= ( | ) ( ) ( | ) ( )P X D P D P X N P Nθ θ≥ × + ≥ ×  
( ) ( )( )1 1 1 1= ( | ) ( ) ( | ) 1 ( )P X D P D P X N P Dθ θ≥ × + ≥ × −  
Using cumulative distribution functions, this can be rewritten as 
( ) ( ) ( )( )1 11 1 = (1- ( )) ( ) 1 ( ) 1 ( )D NX XF P D F P Dθ θ× + − × −  
3.3.3 Cost of testing computation for the BE strategy 
This section shows how cost of testing can be derived for the BE strategy. Recall that Test 
1 is measured on all subjects. For the BE strategy, Test 2 is administered only for those 
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whose test values fall in an intermediate unfixed range. The cost of testing for BE strategy 
is given in the following theorem: 
Theorem 3.3 Cost of testing for the Believe the Extreme (BE) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2, 
respectively. Let 1NX  and 2NX  represent the test results of non-diseased (N) population for 
tests 1 and 2 respectively. Let
1DX
F ,
2 DX
F , 
1NX
F and 
2 NX
F denote the CDF functions of test 
results for those with (D) and without (N) disease and P(D) represent disease prevalence.  
Then the cost of testing of the BE strategy, denoted by 1 2C ( , ),  
BE θ θ is given by:                                 
( )( ) ( )( )1 1 1 11 2 1 2 1 2C ( , ) = ( ) ( ) ( ) ( ) ( ) (1 ( ))D D N NBE X X X XF F P D F F P Dθ θ θ θ θ θ− × + − × −      (3.6) 
Proof: 
1 2( , )
BEC θ θ = 2 1 1( )P Xθ θ≤ ≤  
= ( )2 1 1 ( )P X and D or Nθ θ≤ ≤  
= ( )2 1 1 2 1 1( ) ( )P X and D or X and Nθ θ θ θ≤ ≤ ≤ ≤  
= ( ) ( )2 1 1 2 1 1P X and D P X and Nθ θ θ θ≤ ≤ + ≤ ≤  
= ( )2 1 1( | ) ( )P X D P Dθ θ≤ ≤ ×  + ( )2 1 1( | ) ( )P X N P Nθ θ≤ ≤ ×  
= ( )2 1 1( | ) ( )P X D P Dθ θ≤ ≤ ×  + ( )2 1 1( | ) (1 ( ))P X N P Dθ θ≤ ≤ × −  
= ( )( )1 1 1 2( | ) ( | ) ( )P X D P X D P Dθ θ≤ − ≤ ×  + ( )( )1 1 1 2( | ) ( | ) (1 ( ))P X N P X N P Dθ θ≤ − ≤ × −  
Using cumulative distribution functions, this can be rewritten as 
( )( ) ( )( )1 1 1 11 2 1 2 1 2C ( , ) = ( ) ( ) ( ) ( ) ( ) (1 ( ))D D N NBE X X X XF F P D F F P Dθ θ θ θ θ θ− × + − × −  
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3.4 Cost Curves 
A limitation of the MROC curve is that it does not directly incorporate the effect of cost of 
testing. Therefore, since the primary focus of this study is the cost of testing, it is important 
to consider cost, particularly because sometimes the MROC curves do now show clear 
differences between strategies. Cost curves demonstrate the characteristics of a testing 
strategy by graphing the false-positive rate (1-specificity) on the horizontal axis and the 
cost of testing (cost) on the vertical axis. For example, Figure 3.4 shows the MROC curves 
and cost curves for the three strategies. From this graph, it can be seen that the BE strategy 
has equal or lower cost of testing as compared to BP and BN over the entire range of FPRs.  
The MROC curve, however, shows little difference between the three strategies.  For this 
reason, cost curves add another factor to consider in describing and evaluating the BN, BP, 
and BE strategies.   
 
Figure 3.4: Example of MROC and Cost curves for the BE, BN, and BP strategies 
3.5 Acceptable accuracy (q) 
Typically, for a fixed false positive rate, the set of thresholds that produce the maximum 
sensitivity are considered best. However, there may be a set of thresholds that produces 
sensitivity that are essentially equivalent or slightly lower than maximum sensitivity yet 
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lowers the cost of a sequence of tests by reducing the number of subjects that need the 
second test to reach a diagnosis.  One can define a set of sensitivities that are “close 
enough” that is, are within an acceptable tolerance.  Two approaches that could be 
considered to determine a minimal acceptable tolerance are an additive or multiplicative 
approach. The additive approach subtracts a fixed constant (epsilon or ε ) from the 
maximum sensitivity at each FPR. 
For each fixed FPR, this can be written as: 
maxTPR = max[TPR( )]ε θ ε−                                                                                        (3.7) 
where maxTPRε  represent the minimal acceptable value for TPR,ε ∈[0,1] 
         The second approach is multiplicative and involves multiplying maximum sensitivity 
by the percent of the accuracy that clinicians are willing to accept (q). 
For each FPR, this can be written as: 
qmaxTPR = q max[TPR( )]θ×                                                                                         (3.8) 
where qmaxTPR  represents minimal acceptable value of sensitivity, q  represents the 
percent of the accuracy (tolerance) that clinicians are willing to accept, [0,1]q∈ .  The first 
approach subtracts a constant value from the maximum TPR.  This approach produces a 
consistent difference across all TPRs.  The latter approach has a tolerance that varies, in 
fact increasing as the TPR increases.  This research will explore the effects of using 
q max[TPR( )]θ×   to set an acceptable tolerance on sensitivity. Figure 3.5 shows the 
minimal acceptable tolerance on sensitivity in ‘green’ for a q value of 0.95, for the same 
distribution as above. By multiplying the maximum sensitivity by the q=0.95 the minimal 
acceptable tolerance stretches outside of the cloud of points at higher FPRs.  This is 
because there are no thresholds which give sensitivity values that different from the 
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maximum sensitivity. Represented in light blue, as before, is the cloud of points.  The black 
line represents the MROC curve. 
 
Figure 3.5: Minimal acceptable sensitivity when a tolerance is set, for an example of the BP 
strategy 
3.5.1 The Minimum Cost Maximum ROC (MCMROC) curve 
The Minimum Cost Maximum Receiver Operating Characteristic (MCMROC) curve is 
developed to show, graphically, the sensitivity (within an acceptable tolerance q of the 
maximum sensitivity) that is associated with the lowest cost. 
Considering only values of sensitivity within the acceptable tolerance allows the 
researcher to consider more points in the cloud in addition to those lying on the MROC.  
The purpose of this is to examine thresholds associated with the lowest cost as long as the 
corresponding sensitivity is above the minimal acceptable sensitivity.  This can be written 
as a set of ordered pairs: 
( )( ){ }qf FPR( ), ( ) : ( ) qmaxTPR, FPR( ) t, nTPR TPRθ θ θ θ θ= ≥ ≤ ∈\                               (3.9) 
qf  is a subset of the entire set of all possible TPR and FPR values, constrained to the values 
within the minimal acceptable tolerance and including the constraint on the FPR.  From 
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these pairs, the ones with the lowest cost for a fixed FPR will be used to define the 
MCMROC.  Calculating the cost of testing for every threshold set in Equation 3.9, the 
MCMROC can be defined as: 
( )min ( )MCMROC t, max ( ( )) : ( ) qmaxTPR, FPR( ) t,
n
C
TPR TPRθ θ θ θ θ
⎧ ⎫⎛ ⎞⎛ ⎞= ≥ ≤ ∈⎜ ⎟⎨ ⎬⎜ ⎟⎝ ⎠⎝ ⎠⎩ ⎭
\      (3.10) 
where, for every pair of FPR and TPR within the minimal acceptable tolerance, the highest 
true positive rate with the lowest cost for each fixed FPR t,≤ will be chosen. Because cost 
of testing could be varied for each FPR t≤ , the lowest cost is preferred. However, because 
there are two or more thresholds, there may be more than one sensitivity value with 
identical costs corresponding to a false positive rate.  Thus the maximum sensitivity at each 
FPR t≤  with the lowest cost will be the sensitivity value associated with the MCMROC 
curve. This can be formulated as a nonlinear optimization problem to find the thresholds 
that maximize TPR with lowest cost, subject to multiple constraints that need to be 
satisfied: ,nθ ∈\ ( ) qmaxTPR,TPR θ ≥ and .FPR t≤  
Defining the MCMROC function depends on the way one defines the MROC curve.  
For example, if one defines the MROC curve by using FPR( ) tθ = , then FPR( ) tθ =  will be 
substituted for FPR( ) tθ ≤  in the above equations. The MCMROC curve for the graphs 
from Figure 3.5 are plotted in Figure 3.6.  In this figure, the MCMROC curve is shown in 
“red” for BP strategy, the cloud of ROC points is shown in “light blue”, the MROC curve 
is shown in “black”, and the minimal acceptable tolerance on sensitivity is shown in 
“green”. 
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Figure 3.6: MCMROC curve for an example of the BP strategy 
3.6 Computing sensitivity and specificity for the three strategies 
The formulas for computing sensitivity and FPR (FPR=1-specificity), for each strategy are 
introduced in the next sections. 
3.6.1 Believe the positive (BP) 
The BP strategy uses a combination of “AND” and “OR” statements to define test overall 
positive or negative.  The key rules of testing for this strategy may be expressed as follows: 
Test positive if  1 1X orθ> 2 2 1 1( )X and Xθ θ> ≤                                                          (3.11)                       
Negative result if 1 1X andθ≤ 2 2X θ≤                                                                          (3.12) 
Theorem 3.4 FPR of the Believe the Positive (BP) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2, 
respectively. Let 1NX  and 2NX  represent the test results of non-diseased (N) population for 
tests 1 and 2 respectively. Let 1θ  represent the threshold associated with test 1, and 2θ  is 
the threshold associated with test 2. Let 
1DX
F ,
2 DX
F , 
1NX
F and 
2 NX
F denote the CDF functions 
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of test results for those with (D) and without (N) disease. Let 
1 2 1 2, ,
,
D D N NX X X X
F F denote the 
joint distribution functions of test results for those with (D) and without (N) disease 
between tests 1 and 2. 
Assuming some level of non-zero correlation (dependency) between the two tests for the 
non-diseased population, the formula for FPR of the BP strategy, denoted by ( ),BPFPR θ  is 
given by  
1 2, 1 2
( ) 1 ( , )
N N
BP
X XFPR Fθ θ θ= −                                                                                        (3.13) 
Proof: 
1 1 2 2Specificity  ( )N NP X and Xθ θ= ≤ ≤  
This can be rewritten in terms of cumulative distribution functions as 
=
1 2, 1 2
( , )
N NX X
F θ θ  
( ) 1 SpecificityBPFPR θ = −  
1 2, 1 2
( ) 1 ( , )
N N
BP
X XFPR Fθ θ θ= −  
Corollary If the two tests are independent for the non-diseased population, then 
1 21 2
( ) 1 ( ) ( )
N N
BP
X XFPR F Fθ θ θ= − ×     
Proof: 
Since the two tests for the non-diseased population are independent, then  
1 2 1 2
, ( , )
N NX X
F θ θ =  
1 21 2
( ) ( )
N NX X
F Fθ θ×  
and 
1 2 1 2, 1 2 1 2
( ) 1 ( , ) 1 ( ) ( )
N N N N
BP
X X X XFPR F F Fθ θ θ θ θ= − = − ×  
Theorem 3.5 TPR of the Believe the Positive (BP) strategy 
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Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2, 
respectively. Let 1NX  and 2NX  represent the test results of non-diseased (N) population for 
tests 1 and 2 respectively. Let 1θ  represent the threshold associated with test 1, and 2θ  is 
the threshold associated with test 2. Let 
1DX
F ,
2 DX
F , 
1NX
F and 
2 NX
F denote the CDF functions 
of test results for those with (D) and without (N) disease. Let 
1 2 1 2, ,
,
D D N NX X X X
F F denote the 
joint distribution functions of test results for those with (D) and without (N) disease 
between tests 1 and 2. 
Assuming some level of non-zero correlation (dependency) between the two tests for the 
diseased population, the formula for TPR of the BP strategy, denoted by ( ),BPTPR θ  is 
given by 
1 2, 1 2
( ) 1 ( , )
D D
BP
X XTPR Fθ θ θ= −                                                                                         (3.14) 
Proof: 
( )1 1 2 2 1 1Sensitivity ( )P X or X and Xθ θ θ= > > ≤     
                  ( )( )1 1 2 2 1 1( ) ( ) ( )D D DP X X Xθ θ θ= > ∪ > ∩ ≤  
                  ( ) ( )( )1 1 2 2 1 1 1 1( ) ( ) ( ) ( )D D D DP X X X Xθ θ θ θ= > ∪ > ∩ > ∪ ≤  
                  ( )1 1 2 2( ) ( )D DP X Xθ θ= > ∪ >  
                  ( )1 1 2 21 ( ) ( )D DP X Xθ θ= − ≤ ∩ ≤  
This can be rewritten in terms of cumulative distribution functions as 
1 2, 1 2
( ) 1 ( , )
D D
BP
X XTPR Fθ θ θ= −  
Corollary If the two tests are independent for the diseased population, then 
 
1 2 1 21 2 1 2
, ( , ) ( ) ( )
D D D DX X X X
F F Fθ θ θ θ= ×                                                                            (3.15) 
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Proof: 
Since the two tests for the diseased population are independent, then  
1 2 1 21 2 1 2
, ( , ) ( ) ( )
D D D DX X X X
F F Fθ θ θ θ= ×   
1 2
1 2
, 1 2
1 2
and ( ) 1 ( , )
1 ( ) ( )
D D
D D
BP
X X
X X
FPR F
F F
θ θ θ
θ θ
= −
= −  
3.6.2 Believe the negative (BN) 
The BN strategy uses combinations of “AND” and “OR” statements to define test overall 
positive or negative. The key rules of testing for this strategy were the following: 
Positive result if ( 2 2X θ> ) and ( 1 1X θ> )                                                                     (3.16) 
Negative result if ( 1 1X θ≤ ) or ( 2 2X θ≤  and 1 1X θ> )                                                    (3.17) 
Theorem 3.6 FPR of the Believe the Negative (BN) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2 
respectively.  Let 1NX  and 2NX  represent the test results of non-diseased (N) population 
for tests 1 and 2 respectively. Let 1θ  represents the threshold associated with test 1, and 
2θ  is the threshold associated with test 2. Let 1DXF , 2 DXF , 1NXF and 2 NXF denote the CDF 
functions of test results for those with (D) and without (N) disease. Let 
1 2 1 2, ,
,
D D N NX X X X
F F denote the joint distribution functions of test results for those with (D) and 
without (N) disease between tests 1 and 2. 
Assuming some level of non-zero correlation (dependency) between the two tests for the 
non-diseased population, the formula for FPR of the BN strategy, denoted by ( ),BNFPR θ  is 
given by  
1 2 1 21 2 1 2
( ) 1 ( ) ( ) , ( , )
N N N N
BN
X X X XFPR F F Fθ θ θ θ θ= − − +                                                    (3.18) 
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Proof: 
Specificity = ( )1 1 2 2 1 1( )N N NP X or X and Xθ θ θ≤ ≤ >  
                  = ( )( )1 1 2 2 1 1( ) ( ) ( )N N NP X X Xθ θ θ≤ ∪ ≤ ∩ >  
                  = ( ) ( )( )1 1 2 2 1 1 1 1( ) ( ) ( ) ( )N N N NP X X X Xθ θ θ θ≤ ∪ ≤ ∩ ≤ ∪ >  
                  = ( )1 1 2 2( ) ( )N NP X Xθ θ≤ ∪ ≤  
                  = ( )1 1 2 2 1 1 2 2( ) ( ) ( ) ( )N N N NP X P X P X Xθ θ θ θ≤ + ≤ − ≤ ∩ ≤  
This can be rewritten in terms of cumulative distribution functions as 
1 2 1 21 2 1 2
( ) ( ) , ( , )
N N N NX X X X
F F Fθ θ θ θ= + −            
( )BNFPR θ =1- Specificity 
1 2 1 21 2 1 2
( ) 1 ( ) ( ) , ( , )
N N N N
BN
X X X XFPR F F Fθ θ θ θ θ= − − +  
Corollary If the correlation between the two tests is zero (independent tests) for the non-
diseased population, then  
1 2 1 21 2 1 2
( ) 1 ( ) ( ) ( ) ( )
N N N N
BN
X X X XFPR F F F Fθ θ θ θ θ= − − + ×                                           (3.19) 
Proof: 
Since the two tests for the non-diseased population are independent, then  
1 2 1 21 2 1 2
, ( , ) ( ) ( )
N N N NX X X X
F F Fθ θ θ θ= ×   
1 2 1 2
1 2 1 2
1 2 1 2
1 2 1 2
and ( ) 1 ( ) ( ) , ( , )
1 ( ) ( ) ( ) ( )
N N N N
N N N N
BN
X X X X
X X X X
FPR F F F
F F F F
θ θ θ θ θ
θ θ θ θ
= − − +
= − − + ×        
Theorem 3.7 TPR of the Believe the Positive (BN) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2, 
respectively. Let 1NX  and 2NX  represent the test results of non-diseased (N) population for 
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tests 1 and 2 respectively. Let 1θ  represent the threshold associated with test 1, and 2θ  is 
the threshold associated with test 2. Let 
1DX
F ,
2 DX
F , 
1NX
F and 
2 NX
F denote the CDF functions 
of test results for those with (D) and without (N) disease. Let 
1 2 1 2, ,
,
D D N NX X X X
F F denote the 
joint distribution functions of test results for those with (D) and without (N) disease 
between tests 1 and 2. 
Assuming some level of non-zero correlation (dependency) between the two tests for the 
diseased population, the formula for TPR of the BN strategy, denoted by ( ),BNTPR θ  is 
given by  
1 2 1 21 2 1 2
( ) 1 ( ) ( ) , ( , )
D D D D
BN
X X X XTPR F F Fθ θ θ θ θ= − − +                                                   (3.20) 
Proof: 
( )2 2 1 1( )BN D DTPR P X and Xθ θ θ= > >  
                ( )2 2 1 1( ) ( )D DP X Xθ θ= > ∩ >  
                ( ) ( )( )2 2 1 1 2 2 1 11 ( ) ( ) ( ) ( )D D D DP X P X P X Xθ θ θ θ= − ≤ + ≤ − ≤ ∩ ≤  
                ( )2 2 1 1 2 2 1 11 ( ) ( ) ( ) ( )D D D DP X P X P X Xθ θ θ θ= − ≤ − ≤ + ≤ ∩ ≤  
                
1 2 1 21 2 1 2
1 ( ) ( ) , ( , )
D D D DX X X X
F F Fθ θ θ θ= − − +  
Corollary If the correlation between the two tests is zero (independent tests) for the non-
diseased population, then  
1 2 1 21 2 1 2
( ) 1 ( ) ( ) ( ) ( )
D D D D
BN
X X X XTPR F F F Fθ θ θ θ θ= − − + ×                                               (3.21) 
Proof: 
Since the two tests for the diseased population are independent, then  
1 2 1 21 2 1 2
, ( , ) ( ) ( )
D D D DX X X X
F F Fθ θ θ θ= ×   
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1 2 1 2
1 2 1 2
1 2 1 2
1 2 1 2
and ( ) 1 ( ) ( ) , ( , )
1 ( ) ( ) ( ) ( )
D D D D
D D D D
BN
X X X X
X X X X
TPR F F F
F F F F
θ θ θ θ θ
θ θ θ θ
= − − +
= − − + ×  
3.6.3 Believe the negative (BE) 
The BE strategy also uses combinations of “AND” and “OR” statements to define overall 
disease positive or negative test results.  The key rules of testing for this strategy were the 
following: 
Positive result if 1 1X θ>  or ( 2 3X θ>  and 2 1 1Xθ θ≤ ≤ )                                             (3.22) 
Negative result if 1 2X θ<  or ( 2 3X θ≤  and 2 1 1Xθ θ≤ ≤ ), where 2 1θ θ≤                    (3.23) 
Theorem 3.8 FPR of the Believe the Extreme (BE) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2 
respectively.  Let 1NX  and 2NX  represent the test results of non-diseased (N) population 
for tests 1 and 2 respectively. Let 1θ  and 2θ  represent the threshold associated with test 1, 
and 3θ  is the threshold associated with test 2. Let 1DXF , 2 DXF , 1NXF and 2 NXF denote the 
CDF functions of test results for those with (D) and without (N) disease. Let 
1 2 1 2, ,
,
D D N NX X X X
F F denote the joint distribution functions of test results for those with (D) and 
without (N) disease between tests 1 and 2. 
Assuming some level of non-zero correlation (dependency) between the two tests for the 
non-diseased population, the formula for FPR of the BE strategy, denoted by ( ),BEFPR θ  is 
given by  
1 1 2 1 22 , 2 3 , 1 3
( ), 1 ( ) ( , ) ( , )
N N N N N
BE
X X X X XFPR F F Fθ θ θ θ θ θ= − + −                                               (3.24) 
Proof: 
( )1 2 2 3 2 1 1Specificity ( )N N NP X or X and Xθ θ θ θ= < ≤ ≤ ≤  
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            = ( )( )1 2 2 3 2 1 1( ) ( ) ( )N N NP X X Xθ θ θ θ< ∪ < ∩ ≤ ≤  
            = ( ) ( )( )1 2 2 3 1 2 2 1 1( ) ( ) ( ) ( )N N N NP X X X Xθ θ θ θ θ< ∪ < ∩ < ∪ ≤ ≤  
            = ( )( )1 2 2 3 1 1( ) ( ) ( )N N NP X X Xθ θ θ< ∪ < ∩ <  
            = ( ) ( )( )1 1 1 2 1 1 2 3( ) ( ) ( ) ( )N N N NP X X X Xθ θ θ θ< ∩ < ∪ < ∩ <  
            = ( )( )1 2 1 1 2 3( ) ( ) ( )N N NP X X Xθ θ θ< ∪ < ∩ <  
            = ( ) ( )( )1 2 1 1 2 3 1 1 1 2 2 3( ) ( ) ( ) ( ) ( ) ( )N N N N N NP X X X X X Xθ θ θ θ θ θ< + < ∩ < − < ∩ < ∩ <  
           ( ) ( )1 2 1 1 2 3 1 2 2 3( ) ( ) ( ) ( ) ( )N N N N NP X P X X P X Xθ θ θ θ θ= < + < ∩ < − < ∩ <  
This can be rewritten in terms of cumulative distribution functions as 
1 1 2 1 22 , 1 3 , 2 3
( ) ( , ) ( , )
N N N N NX X X X X
F F Fθ θ θ θ θ= + −  
( )BEFPR θ =1- Specificity 
1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
N N N N N
BE
X X X X XFPR F F Fθ θ θ θ θ θ= − + −                                                
Corollary If the correlation between the two tests is zero (independent tests) for the non-
diseased population, then 
1 1 2 1 22 2 3 1 3
( ) 1 ( ) ( ) ( ) ( ) ( )
N N N N N
BE
X X X X XFPR F F F F Fθ θ θ θ θ θ= − + × − ×                                 (3.25) 
Proof: 
Since the two tests for the non-diseased population are independent, then  
1 2 1 3
, ( , )
N NX X
F θ θ =
1 21 3
( ) ( ),
N NX X
F Fθ θ×  
1 2 2 3
, ( , )
N NX X
F θ θ =  
1 22 3
( ) ( ),
N NX X
F Fθ θ×  
1 1 2 1 2
1 1 2 1 2
2 , 2 3 , 1 3
2 2 3 1 3
and ( ) 1 ( ) ( , ) ( , )
1 ( ) ( ) ( ) ( ) ( )
N N N N N
N N N N N
BE
X X X X X
X X X X X
FPR F F F
F F F F F
θ θ θ θ θ θ
θ θ θ θ θ
= − + −
= − + × − ×  
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Theorem 3.9 TPR of the Believe the Extreme (BE) strategy 
Let 1DX  and 2DX  represent the test results of the diseased (D) population for tests 1 and 2 
respectively.  Let 1NX  and 2NX  represent the test results of non-diseased (N) population 
for tests 1 and 2 respectively. Let 1θ  and 2θ  represent the threshold associated with test 1, 
and 3θ  is the threshold associated with test 2. Let 1DXF , 2 DXF , 1NXF and 2 NXF denote the 
CDF functions of test results for those with (D) and without (N) disease. Let 
1 2 1 2, ,
,
D D N NX X X X
F F denote the joint distribution functions of test results for those with (D) and 
without (N) disease between tests 1 and 2. 
Assuming some level of non-zero correlation (dependency) between the two tests for the 
diseased population, the formula for TPR of the BE strategy, denoted by ( ),BETPR θ  is 
given by  
1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
D D D D D
BE
X X X X XTPR F F Fθ θ θ θ θ θ= − + −                                             (3.26) 
Proof: 
( )1 1 2 3 2 1 1Sensitivity ( )D D DP X or X and Xθ θ θ θ= > > ≤ ≤  
           ( )( )1 1 2 3 2 1 1( ) ( ) ( )D D DP X X Xθ θ θ θ= > ∪ > ∩ ≤ ≤  
           ( ) ( )( )1 1 2 3 1 1 2 1 1( ) ( ) ( ) ( )D D D DP X X X Xθ θ θ θ θ= > ∪ > ∩ > ∪ ≤ ≤  
           ( )( )1 1 2 3 1 2( ) ( ) ( )D D DP X X Xθ θ θ= > ∪ > ∩ >  
           ( ) ( )( )1 1 1 2 1 2 2 3( ) ( ) ( ) ( )D D D DP X X X Xθ θ θ θ= > ∩ > ∪ > ∩ >  
           ( )( )1 1 1 2 2 3( ) ( ) ( )D D DP X X Xθ θ θ= > ∪ > ∩ >  
           ( ) ( )( )1 1 1 2 2 3 1 1 1 2 2 3( ) ( ) ( ) ( ) ( ) ( )D D D D D DP X X X X X Xθ θ θ θ θ θ= > + > ∩ > − > ∩ > ∩ >  
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              ( ) ( )( )1 1 1 2 2 3 1 1 2 3( ) ( ) ( ) ( ) ( )D D D D DP X X X X Xθ θ θ θ θ= > + > ∩ > − > ∩ >  
              ( ) ( )1 1 1 2 2 3 1 1 2 3( ) ( ) ( ) ( ) ( )D D D D DP X P X X P X Xθ θ θ θ θ= > + > ∩ > − > ∩ >  
              ( ) ( )1 2 1 1 2 3 1 2 2 31 ( ) 1 ( ) ( ) 1 ( ) ( )D D D D DP X P X X P X Xθ θ θ θ θ= − ≤ + − ≤ ∩ ≤ − + ≤ ∩ ≤  
              ( ) ( )1 2 1 1 2 3 1 2 2 31 ( ) ( ) ( ) ( ) ( )D D D D DP X P X X P X Xθ θ θ θ θ= − ≤ − ≤ ∩ ≤ + ≤ ∩ ≤  
              ( ) ( )1 2 1 2 2 3 1 1 2 31 ( ) ( ) ( ) ( ) ( )D D D D DP X P X X P X Xθ θ θ θ θ= − ≤ + ≤ ∩ ≤ − ≤ ∩ ≤  
This can be rewritten in terms of cumulative distribution functions as 
1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
D D D D D
BE
X X X X XTPR F F Fθ θ θ θ θ θ= − + −  
Corollary if the correlation between the two tests is zero (independent tests) for the 
diseased population, then 
1 1 2 1 22 2 3 1 3
( ) 1 ( ) ( ) ( ) ( ) ( )
D D D D D
BE
X X X X XTPR F F F F Fθ θ θ θ θ θ= − + × − ×                          (3.27) 
Proof: 
Since the two tests for the diseased population are independent, then  
1 2 1 3
, ( , )
D DX X
F θ θ =
1 21 3
( ) ( ),
D DX X
F Fθ θ×  
1 2 2 3
, ( , )
D DX X
F θ θ =  
1 22 3
( ) ( ),
D DX X
F Fθ θ×  
1 1 2 1 2
1 1 2 1 2
2 , 2 3 , 1 3
2 2 3 1 3
and ( ) 1 ( ) ( , ) ( , )
1 ( ) ( ) ( ) ( ) ( )
D D D D D
D D D D D
BE
X X X X X
X X X X X
TPR F F F
F F F F F
θ θ θ θ θ θ
θ θ θ θ θ
= − + −
= − + × − ×          
3.7 Special relationships between the BP, BN and BE strategies 
It can be shown through asymptotic properties of the thresholds from the first test of the BE 
strategy, i.e. as the thresholds approach +∞  or −∞ , that the MROC curves for the BP and 
BN strategies cannot be better than the MROC curve for the BE strategy.  Specifically, it 
can be shown that a set of thresholds for the BE strategy gives a particular FPR, and TPR 
that will be at least as good as the  FPR and TPR of the BP or BN strategy. 
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Theorem 10: For any (FPR, TPR) pair found in the BP strategy, a set of thresholds can be 
found (in the limit) in the BE strategy with equivalent FPR and TPR values.   
Let 1
BEθ  and 2 BEθ  represent the BE strategy’s threshold associated with test 1 and 3 BEθ  
represent the BE strategy’s threshold associated with test 2.  Let 1
BPθ  and 2 BPθ  represent 
the BP strategy’s threshold associated with test 1 and test 2. Then values of 
1 2 3( , , )
BE BE BE BEθ θ θ θ=  can be found such that, in the limit, formulas for TPR and FPR of the 
BE strategy, denoted by ( )BE BETPR θ and ( )
BE BEFPR θ are given by 
I. 
2
1 2lim ( ) ( , )
BE BE BP BP BPTPR TPRθ θ θ θ→ −∞ =  
II. 
2
1 2lim ( ) ( , )
BE BE BP BP BPFPR FPRθ θ θ θ→ −∞ =  
Proof I:  
From theorem 3.9, it has been shown that: 
1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
D D D D D
BE BE BE BE BE BE BE
X X X X XTPR F F Fθ θ θ θ θ θ= − + −  
Assume that 1 1
BE BPθ θ= , 3 2BE BPθ θ= . As 2BEθ  approaches−∞ , then 
1 1 2 1 2
2 2 2
2 , 2 3 , 1 3lim ( ) 1 lim ( ) lim ( , ) ( , )BE BE BED D D D D
BE BE BE BE BE BE BE
X X X X XTPR F F Fθ θ θθ θ θ θ θ θ→ −∞ → −∞ → −∞= − + −  
                               
1 2, 1 3
1 0 0 ( , )
D D
BE BE
X XF θ θ= − + −  
                               
1 2, 1 3
1 ( , )
D D
BE BE
X XF θ θ= −  
                               
1 2, 1 2
1 ( , )
D D
BP BP
X XF θ θ= −  
This has been shown, by Theorem 3.5 to be equal to 1 2( , )
BP BP BPTPR θ θ  
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Proof II:  
From theorem 3.8, it has been shown that: 
1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
N N N N N
BE BE BE BE BE BE BE
X X X X XFPR F F Fθ θ θ θ θ θ= − + −  
Assume that 1 1
BE BPθ θ= , 3 2BE BPθ θ= . As 2BEθ  approaches−∞ , then 
1 1 2 1 2
2 2 2
2 , 2 3 , 1 3lim ( ) 1 lim ( ) lim ( , ) ( , )BE BE BEN N N N N
BE BE BE BE BE BE BE
X X X X XFPR F F Fθ θ θθ θ θ θ θ θ→ −∞ → −∞ → −∞= − + −  
                               
1 2, 1 3
1 0 0 ( , )
N N
BE BE
X XF θ θ= − + −  
                               
1 2, 1 3
1 ( , )
N N
BE BE
X XF θ θ= −  
                               
1 2, 1 2
1 ( , )
N N
BP BP
X XF θ θ= −  
This has been shown, by Theorem 3.4 to be equal to 1 2( , )
BP BP BPFPR θ θ . 
Theorem 11: For any (FPR, TPR) pair found in the BN strategy, a set of thresholds can be 
found (in the limit) in the BE strategy with equivalent FPR and TPR values.   
Let 1
BEθ  and 2 BEθ  represent the BE strategy’s threshold associated with test 1 and 3 BEθ  
represent the BE strategy’s threshold associated with test 2. Let 1
BNθ  and 2 BNθ  represent 
the BN strategy’s threshold associated with test 1 and test 2. Then values of 
1 2 3( , , )
BE BE BE BEθ θ θ θ=  can be found such that, in the limit, formulas for TPR and FPR of the 
BE strategy, denoted by ( )BE BETPR θ and ( )
BE BEFPR θ are given by 
I. 
1
1 2lim ( ) ( , )
BE BE BN BN BNTPR TPRθ θ θ θ→ + ∞ =  
II. 
1
1 2lim ( ) ( , )
BE BE BN BN BNFPR FPRθ θ θ θ→ + ∞ =  
Proof I:  
From theorem 3.9, it has been shown that: 
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1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
D D D D D
BE BE BE BE BE BE BE
X X X X XTPR F F Fθ θ θ θ θ θ= − + −  
Assume that 2 1
BE BNθ θ= , 3 2BE BNθ θ= . As 1BEθ  approaches ,+∞ then 
1 1 2 1 2
1 1
2 , 2 3 , 1 3lim ( ) 1 ( ) ( , ) lim ( , )BE BED D D D D
BE BE BE BE BE BE BE
X X X X XTPR F F Fθ θθ θ θ θ θ θ→ +∞ → +∞= − + −  
                             
1 1 2 22 , 2 3 3
1 ( ) ( , ) ( )
D D D D
BE BE BE BE
X X X XF F Fθ θ θ θ= − + −  
                             
1 2 1 22 3 , 2 3
1 ( ) ( ) ( , )
D D D D
BE BE BE BE
X X X XF F Fθ θ θ θ= − − +  
                             
1 2 1 22 3 , 2 3
1 ( ) ( ) ( , )
D D D D
BN BN BN BN
X X X XF F Fθ θ θ θ= − − +  
This has been shown, by Theorem 3.7 to be equal to 1 2( , )
BN BN BNTPR θ θ  
Proof II: 
From theorem 3.8, it has been shown that: 
1 1 2 1 22 , 2 3 , 1 3
( ) 1 ( ) ( , ) ( , )
N N N N N
BE BE BE BE BE BE BE
X X X X XFPR F F Fθ θ θ θ θ θ= − + −  
Assume that 2 1
BE BPθ θ= , 3 2BE BPθ θ= . As 1BEθ  approaches+∞ , then 
1 1 2 1 2
1 1
2 , 2 3 , 1 3lim ( ) 1 ( ) ( , ) lim ( , )BE BEN N N N N
BE BE BE BE BE BE BE
X X X X XFPR F F Fθ θθ θ θ θ θ θ→ +∞ → +∞= − + −  
                        
1 1 2 22 , 2 3 3
1 ( ) ( , ) ( )
N N N N
BE BE BE BE
X X X XF F Fθ θ θ θ= − + −  
                        
1 2 1 22 3 , 2 3
1 ( ) ( ) ( , )
N N N N
BE BE BE BE
X X X XF F Fθ θ θ θ= − − +  
                       
1 2 1 21 2 , 1 2
1 ( ) ( ) ( , )
N N N N
BN BN BN BN
X X X XF F Fθ θ θ θ= − − +  
This has been shown, by Theorem 3.6 to be equal to 1 2( , )
BN BN BNFPR θ θ . 
The above proofs are only true if the assumptions given in each proof are satisfied 
3.8 Optimal operating points 
An optimal operating point corresponds to the threshold combination that produces the best 
accuracy used to classify subjects with respect to disease, often while considering the 
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prevalence of the disease and misclassification costs.  Since this work is concerned with the 
cost of administering a number of tests, the technique of finding the optimal operating point 
should take the cost of sequencing two tests under consideration in addition to 
misclassification costs. 
3.8.1 Generalized Youden index 
Recall that the Generalized Youden Index (GYI) can be given by 
maxθ { ( )TPR θ − *( ( ))}m FPR θ                                                                                    (3.28) 
where m is given by 
[ ](1 ) /m p p= − × ( ) ( )FP TN FN TP/ C CC C− −⎡ ⎤⎣ ⎦                                                                           (3.29) 
The cost/benefit ratio of false-positive compared to false-negative results weighs four 
outcomes: CFP is the cost associated with a false positive, CTN is the cost associated with a 
true negative, CFN is the cost associated with a false negative, CTP is the cost associated 
with a true positive. When 1m = , equation (3.28)  above yields the original Youden's index 
which indicates product of cost/benefit ratio and prevalence ratio is 1. To incorporate 
testing cost into finding the optimal point, the thresholds can be limited such that the 
testing cost (probability of a second test) will be no larger than a give value (C0).  This can 
be written as an optimization problem as follows: 
Objective function          maxθ  { ( )TPR θ − *( ( ))}m FPR θ                                           (3.30) 
Subject to                    0( )C Cθ ≤ , 
The objective function is the Generalized Youden index (GYI) that needs to be maximized, 
subject to constraints that need to be satisfied. ( )C θ  is the cost of testing (probability of a 
second test) which is being limited to a maximum of some fixed value, 0C , 00 1C≤ ≤ .  It 
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will be shown in later chapters that this constraint essentially restricts the false positive 
rates which can be considered in the objective function. 
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Chapter 4 
4.1 Strategy Properties 
This research aims to evaluate three sequential testing strategies for distinguishing between 
two medical conditions, such as diseased/non-diseased, by using two diagnostic tests 
measured in a sequence. In this chapter, properties of the sequential testing strategies will 
be described based on the following factors:  MROC curve, cost curve, and test thresholds.  
This work introduces BE as an alternative strategy to the BN and BP strategies and seeks to 
describe the three strategies as well as examine whether the BE strategy is better than the 
BN and BP strategies.  
The sensitivity and FPR formulas presented in Chapter 3 are defined in terms of 
general cumulative distribution functions (CDFs) of test results for those with disease (D) 
and without (N) disease. In this chapter, the strategies will be described and compared, 
assuming that the tests will follow a normal distribution. The estimation of these accuracy 
measures (sensitivity and FPR) were obtained by using normal distribution CDFs for those 
with and without disease. Together, these are referred to as the binormal model.  The 
binormal model, derived from the normal distribution of test results, is recommended 
because it has a smooth ROC curve and this makes comparison between strategies easier. 
In addition, Swets (1986) found the binormal ROC curve of individual tests to be a good 
approximation to numerous empirical ROC curves. The requirement of the binormal model 
is that the test results or their transformed values follow a normal distribution with means 
and variances for diseased and non-diseased populations.  
To be able to compare the strategies, the effect of four different parameters 
associated with the assumptions of normality of the diseased and non-diseased 
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populations was examined; these parameters were the area under the ROC curve 
(AUC), correlation, standard deviation and prevalence. The parameters that were 
identified could influence the performance of the combined tests: 
• The area under the ROC curve (AUC) 
o The values of AUC considered were: (0.90, 0.90), (0.70, 0.90), and (0.70, 
0.70), for (Test1, Test2) respectively. 
The assumption of each scenario was different; the first assumed that both tests had high 
accuracy. The second assumed that the first test was not as accurate as the second test, and 
the third assumed that both tests had only fair or moderate accuracy. The AUC value has an 
important effect on the shape of the ROC curve of an individual test. Also, combining two 
tests with identical AUC values improved diagnostic accuracy. This is shown in Figure 4.1 
C. 
• The ratio of the standard deviations for the diseased and non-diseased populations 
(b) 
o Three values of the ratio of disease and non-disease standard deviations (b) 
were considered: b=0.5; b =1; and b=2.  Using these three values, nine 
possible combinations of standard deviations for test 1 (b1) and test 2 (b2), 
considered were: (b1=1, b2=1), (b1=2, b2=2), (b1=0.5, b2=0.5), (b1=1, b2=2), 
(b1=1, b2=0.5), (b1=2, b2=1), (b1=1, b2=0.5), (b1=0.5, b2=1), and (b1=0.5, 
b2=2). 
This research looked at various values of b, because the shape of the ROC curve of an 
individual test depended on the ratio of the standard deviations between the diseased and 
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non-diseased populations, even when the area was the same (see Figures 4.2.1a and b). The 
assumption of each scenario was different; b=1 assumes the distribution of test results for 
the diseased subjects had the same spread as that for the distribution of the non-diseased 
subjects ( D Nσ σ= ) where D represented the diseased subject distribution and N 
represented the non-diseased subject distribution; b = 0.5 assumed that the distribution of 
test results for the diseased subjects was more heterogeneous than that for the non-diseased 
subjects; and b=2 assumed that the distribution of test results for the diseased subjects was 
more homogenous than that for non-diseased subjects. The b value had an important effect 
on the shape of the ROC curve of an individual test. This is shown in Figure 4.1 A and B. 
Figures 4.1 show the effect of AUC values and b values on the shape of the ROC 
curves. Graphs A and B in Figure 4.2 show individual ROC curves and graph C shows the 
ROC curve for the combined tests. Graph A was derived using a binormal ROC curve for a 
single test with b=0.5, b=1 and b=2 and AUC =0.9. Graph B was derived using a binormal 
ROC curve for a single test with b=0.5, b=1 and b=2 and AUC =0.7. Graph C combines the 
two tests where AUC=0.9 and 1 0.5b = (blue dashed line) and 2 2b =  (red dashed line).  The 
combined test was represented by the color “green”.  In this case, it can be seen that 
combined tests improved diagnostic accuracy at the small FPR values of the ROC curve as 
compared to the individual tests. This motivated the use of the combined tests using 
sequential testing to improve the diagnostic accuracy. This motivated the use of the 
combined tests using sequential testing to improve the diagnostic accuracy. 
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A                                         B                                            C 
 
Figure 4.1: The effect of b and AUC on the shape of individual ROC curves (A, and B) and 
combined tests (C) 
• Prevalence 
o The prevalence of disease considered was: 0.1 and 0.7. 
Prevalence rates vary depending on the population under study.  This research examined 
two different prevalence of disease (low or high).  It may seem that a prevalence of 0.7 was 
too high to be seriously considered, however in extreme cases, like the prevalence of HIV 
in certain parts of Africa, the prevalence values approach or even exceed 0.6. 
• Correlation between test results ( )ρ  
o Five combination of correlation between the tests for both the diseased and 
non-diseased populations were considered: ( 0, 0)D Nρ ρ= = , 
( 0.3, 0.3)D Nρ ρ= = , ( 0.3, 0.7)D Nρ ρ= = , ( 0.7, 0.3)D Nρ ρ= = , and ( 0.7, 0.7)D Nρ ρ= =  where 
Dρ  refers to the correlation between the two tests for the diseased 
47 
 
populations, and Nρ  refers to the correlation between the two tests for the 
non-diseased populations. 
The first combination of  and  N Dρ ρ  assumed independence between the diseased and non-
diseased populations between the two tests. The second, ( 0.3, 0.3)D Nρ ρ= = , assumed weak 
correlations.  The third, ( 0.3, 0.7)D Nρ ρ= = , assumed that the diseased populations would be 
less correlated than the non-diseased populations. The fourth, ( 0.7, 0.3)D Nρ ρ= = , assumed that 
the diseased populations were more correlated than the non-diseased populations, and the 
fifth, ( 0.7, 0.7)D Nρ ρ= = , assumed strong correlations between the diseased and non-diseased 
populations. 
4.2 Generating MROC curve and Cost curve 
Under different parameter combinations presented above, sensitivity and FPR was 
estimated based on normal distribution CDFs by varying the test thresholds. The BP and 
BN strategies had two thresholds, one for each test. For the BE strategy, two thresholds 
were used for the first test and one threshold for the second test. Here, the thresholds were 
quantities which can be varied to dichotomize the test results for subjects into diseased or 
non-diseased classifications. Because the binormal model assumption was made, the 
thresholds theoretically range between and−∞ +∞ , however these were impractical limits 
to evaluate. There were several methods for determining lower and upper bounds on test 
thresholds (Greiner et al, 2000). Because a normal distribution has a bell-curve shape,  
thresholds were chosen which covered 99.7% of the distribution of test results for those 
with and without disease, by including all values within 3 standard deviations of the mean. 
The lower and upper intervals for the thresholds for non-diseased population were defined 
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as 3*N Nμ σ± , where Nμ  was the mean for non-diseased and where Nσ  was the standard 
deviation for non-diseased. The lower and upper intervals for the diseased population was 
defined by 3*D Dμ σ± , where Dμ  was the mean for diseased and where Dσ  is the standard 
deviation for diseased.  Since test thresholds had to include values from the distribution of 
both those with and without disease, the range of test thresholds used the minimum of 
lower limits of the diseased and non-diseased distributions, and the maximum of the upper 
limits of diseased and non-diseased distributions, given by 
( ) ( )min 3* , 3* ,max 3* , 3*N N D D N N D Dμ σ μ σ μ σ μ σ− − + +⎡ ⎤⎣ ⎦                                    (4.1) 
For an individual test, the binormal ROC curve was defined by two components 
( )D N Da μ μ σ= − and N Db σ σ= , where a  was the normalized difference between the 
diseased and non-diseased population means, b  the ratio of the diseased and non-diseased 
population  standard deviations. Without loss of generality, the ROC curves were estimated 
assuming a standard normal distribution for the non-diseased population, ie. 0Nμ = , 1Nσ = .  
The parameters described above, AUC and b, were then used to calculate the parameters of 
the diseased population, such as Dσ , and .Dμ  The standard deviation of diseased population 
was calculated as follows: since 1N D Db bσ σ σ= ⇒ = , then 1D bσ = . The mean of 
diseased population was calculated given these components: 
( 0)D D D Da aμ σ μ σ= − ⇒ = , D Daμ σ= , D a bμ = .  Then a  was estimated from 
( )2AUC 1a b= Φ +  so that  2 11 (AUC)a b −= + ×Φ  and Dμ  was written in terms of 
AUC and b as 2 11 (AUC)D b bμ −= + ×Φ . 
The estimate of sensitivity and false positive rate of individual tests were: 
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TPR( )  [   | ]P Y Dθ θ= ≥ = ( )
1 1 1
D
D
a b a b a b
b b b
μ θ θ θ θσ
⎛ ⎞ ⎛ ⎞ ⎛ ⎞− −Φ =Φ =Φ − =Φ −⎜ ⎟ ⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠⎝ ⎠
 and  
FPR( )  [   | ]P Y Nθ θ= ≥ = N
N
μ θ
σ
⎛ ⎞−Φ =⎜ ⎟⎝ ⎠ ( )
0 1 ( )
1
θ θ θ−⎛ ⎞Φ =Φ − = −Φ⎜ ⎟⎝ ⎠  
Now, considering two tests, let 1X and 2X  be random variables that denote the 
outcomes of two continuous tests with the convention that higher values indicate disease or 
the test results of diseased subjects were expected to be higher than those of healthy 
subjects, and a binary outcome variable denoting disease condition. 1DX and 2DX ; 1NX  and 
2NX  were used to denote the test results for diseased and non-diseased subjects, 
respectively. Assuming normality, this was written as: 
2 2
1 1 1 2 2 2~ ( , ), ~ ( , )N N N N N NX N X Nμ σ μ σ and 
2 2
1 1 1 2 2 2~ ( , ), ~ ( , )D D D D D DX N X Nμ σ μ σ ,  
where the parameters of the normal distribution were determined from AUC and b as 
described above.  These parameters are summarized in Table 4.1 through 4.3 
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Table 4.1: ROC curve parameters for AUC1 = 0.90, AUC2 = 0.90 
 
1 2(AUC ,AUC )   1 2,b b  1 2,N Nσ σ
 
 1 2,N Nμ μ   1 2,D Dσ σ  1 2,D Dμ μ  Lower and Upper  bounds of 
thresholds(Test1);(Test2) 
(0.90,0.90) (1,1) (1,1) (0,0) (1,1) (1.81, 1.81) (-3, 4.81);(-3, 4.81) 
 (1,2) (1,1) (0,0) (1,0.5) (1.81, 1.43) (-3, 4.81);(-3, 3 ) 
 (1,0.5) (1,1) (0,0) (1,2) (1.81, 2.86) (-3, 4.81);(-3.14, 8.86) 
 (2,1) (1,1) (0,0) (0.5,1) (1.43, 1.81) (-3, 3);(-3, 4.81) 
 (2,2) (1,1) (0,0) (0.5,0.5) (1.43, 1.43) (-3, 3);(-3, 3) 
 (2,0.5) (1,1) (0,0) (0.5,2) (1.43, 2.86) (-3, 3);(-3.14, 8.86) 
 (0.5,1) (1,1) (0,0) (2,1) (2.86, 1.81) (-3.14, 8.86);(-3, 4.81) 
 (0.5,2) (1,1) (0,0) (2,0.5) (2.86, 1.43) (-3.14, 8.86);(-3, 3) 
  (0.5,0.5) (1,1) (0,0) (2,2) (2.86, 2.86) (-3.14, 8.86);(-3.14, 8.86) 
 
Table 4.2: ROC curve parameters for AUC1 = 0.70, AUC2 = 0.90 
 
1 2(AUC ,AUC )   1 2,b b  1 2,N Nσ σ   1 2,N Nμ μ   1 2,D Dσ σ  1 2,D Dμ μ  Lower and Upper  bounds of 
thresholds(Test1);(Test2) 
(0.70,0.90) (1,1) (1,1) (0,0) (1,1) (0.74, 1.81) (-3, 3.74);(-3, 3.74) 
 (1,2) (1,1) (0,0) (1,0.5) (0.74, 1.43) (-3, 3.74);(-3, 3) 
 (1,0.5) (1,1) (0,0) (1,2) (0.74, 2.86) (-3, 3.74);(-3.14, 8.86) 
 (2,1) (1,1) (0,0) (0.5,1) (0.59, 1.81) (-3, 3);(-3, 3.74) 
 (2,2) (1,1) (0,0) (0.5,0.5) (0.59, 1.43) (-3, 3);(-3, 3) 
 (2,0.5) (1,1) (0,0) (0.5,2) (0.59, 2.86) (-3, 3);(-3.14, 8.86) 
 (0.5,1) (1,1) (0,0) (2,1) (1.17, 1.81) (-4.83, 7.17);(-3, 3.74) 
 (0.5,2) (1,1) (0,0) (2,0.5) (1.17, 1.43) (-4.83, 7.17);(-3, 3) 
  (0.5,0.5) (1,1) (0,0) (2,2) (1.17, 2.86) (-4.83, 7.17);(-3.14, 8.86) 
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Table 4.3: ROC curve parameters for AUC1 = 0.70, AUC2 = 0.70 
Lower and Upper  bounds  
1 2(AUC ,AUC )   1 2,b b  1 2,N Nσ σ   1 2,N Nμ μ   1 2,D Dσ σ  1 2,D Dμ μ  
of thresholds(Test1);(Test2) 
(0.70,0.70) (1,1) (1,1) (0,0) (1,1) (0.74, 0.74) (-3, 3.74); (-3, 3.74) 
 (1,2) (1,1) (0,0) (1,0.5) (0.74, 0.59) (-3, 3.74);     (-3, 3) 
 (1,0.5) (1,1) (0,0) (1,2) (0.74, 1.17) (-3, 3.74);(-4.83, 7.17) 
 (2,1) (1,1) (0,0) (0.5,1) (0.59, 0.74) (-3, 3);(-3, 3.74) 
 (2,2) (1,1) (0,0) (0.5,0.5) (0.59, 0.59) (-3, 3);(-3, 3) 
 (2,0.5) (1,1) (0,0) (0.5,2) (0.59, 1.17) (-3, 3);(-4.83, 7.17) 
 (0.5,1) (1,1) (0,0) (2,1) (1.17, 0.74) (-4.83, 7.17);(-3, 3.74) 
 (0.5,2) (1,1) (0,0) (2,0.5) (1.17, 0.59) (-4.83, 7.17);(-3, 3) 
  (0.5,0.5) (1,1) (0,0) (2,2) (1.17, 1.17) (-4.83, 7.17);(-4.83, 7.17) 
 
Since two continuous tests were considered, the use of logic rules were sometimes 
associated with more than one set of thresholds which produced more than one sensitivity 
value corresponding to a fixed specificity level. As described in Chapter 3, in such cases, 
thresholds associated with maximum sensitivity were most desirable.  The following are 
steps of how the MROC curves were constructed. Graph A in Figure 4.1 was produced by 
estimating sensitivity and FPR for all possible combinations of threshold values (within the 
above specified limits) of the test results in increments.  Here, threshold increments of 0.04 
were used. It is possible that two sets of thresholds may have had the same maximum 
sensitivity but a different cost.  Since these threshold sets had the same sensitivity, it was 
most desirable to take the threshold set with the lowest cost. Graph B identified maximum 
sensitivity with lowest cost for each FPR t≤ , where t was 200 equally spaced values 
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between 0 and 1 (increment of 0.005). The MROC curve was represented here as a black 
line. 
A                                                                         B 
 
Figure 4.2: Steps in producing the MROC curve 
The ‘black’ curve in Figure 4.2 B is identical to MROC curve, but the difference 
between the two curves is that the point on the MROC curve in Figure 4.2 B had the lowest 
cost at each FPR t≤ .  
4.3 Description and comparison of strategies 
In the previous section, four different parameters from the assumption of normality were 
identified that could influence the performance of the combined tests: AUC of each 
individual test, the ratio of the diseased and non-diseased population standard deviations 
(b), correlation ( rho ) between the diseased and non-diseased populations, and disease 
prevalence.  In the remainder of this chapter the three strategies, BE, BP and BN will be 
compared and described using the accuracy, cost of sequential of testing, and test 
thresholds. Although recent articles by Etzioni (2003), Thompson (2003), and Shen (2008) 
presented the use of the BP and BN strategies in clinical settings to assess the overall 
diagnostic accuracy of a continuous sequence of tests, these articles ignored the cost of 
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performing such tests. If the competing strategies have similar or the same accuracy, the 
MROC curve is unable to show any real difference between strategies. However, as will be 
seen, differences in strategies often become apparent when describing the cost curves.  The 
following sections examine the effect of the AUC values, correlation, standard deviation, 
and prevalence on the MROC curves, cost curves, and test threshold. 
4.3.1 The effect of area under the ROC curve (AUC) 
In Section 3.7 it was proven that for a fixed FPR, the TPR of the BE strategy were at least 
as good as the TPR of the BP or BN strategy. On the graph series in Appendix A, the BE 
strategy is represented in green. The accuracy of the BE strategy does not change as much 
as the accuracy of the BP or BN strategy under different parameters. Regardless of the 
parameters, the BE strategy had similar or preferable accuracy; the BN or BP strategy 
consistently had the same or lower accuracy than the BE strategy, but never surpassed the 
accuracy of that strategy. 
The MROC curve of the BE strategy often had the appearance of a combination of 
the MROC curves of the BN and BP strategies.  There was one exception to this pattern.  
When identical AUC values, such as (AUC1 = 0.90, AUC2 = 0.90), and (AUC1 = 0.70, 
AUC2 = 0.70) with (b1=1, b2=1), the BE strategy had a slightly higher accuracy than both 
the BN and BP strategies combined, rather than appearing as a combination of either 
strategy (see Appendix A1 Figure A1.1a).  This served to reinforce the idea that, in these 
testing situations, BE was a better strategy than the BN and BP strategies.  Here the 
maximum sensitivity across the BN and BP strategies did not achieve the sensitivity of the 
BE strategy at a low FPR region.  
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MROC curves sometimes were unable to show any real differences between the strategies 
(see Figure 4.3 A1, B1, and C1). However, cost curves could play a major role in 
differentiating between strategies. It was seen that the cost of differing AUC values, 
specifically when the first test had a smaller AUC than the second test, creates a higher cost 
compared to the cost of identical, low or high accuracy for both tests (see Figure 4.3 A2, 
B2, and C2).  With differing AUC values (e.g., AUC1 = 0.70, AUC2 = 0.90), Test 1, as 
compared to Test 2, was not as accurate in detecting disease which is why more patients 
were sent to the second test and cost was higher.  With identical AUC values (e.g., AUC1 = 
0.90, AUC2= 0.90) and similarly (e.g. AUC1 = 0.70, AUC2= 0.70), Test 1 and Test 2 had 
similar accuracies and fewer patients went to the second test, as compared to when AUC 
values differed. 
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A2                                    B2                                 C2                                  
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Figure 4.3: The effect of AUC values on the MROC and cost curves of competing 
strategies 
Figure 4.3 demonstrates that cost, rather than the MROC curve, was affected by the 
AUC of the individual tests.  For the BN strategy, as the FPR rose, the cost also roses since 
a high number of positive results (as demonstrated through the FPR) increased the number 
of individuals that must take the second test. Recall that for the BN strategy, those with a 
positive result must take the second test. For the BP strategy, as the FPR roses, the cost 
decreased since a low number of negative results (as demonstrated through the FPR) 
decreased the number of individuals that must take the second test.  Recall that for the BP 
strategy, those with a negative result must take the second test. 
Figure 4.4 demonstrates how the AUC had an important effect on the shape of the 
MROC and cost curves of each individual strategy. Certain exceptions to the pattern in 
effect on MROC were seen with the following parameters (here, the subscripts refer to Test 
1 and Test 2): (AUC1=0.90, AUC2 = 0.90) and (AUC1 = 0.70, AUC2 = 0.90) with (b1=2, 
b2=2), where the MROC curves of the BP strategy were identical. (see Figure 4.4 C2 and 
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B3). Overall, the varying AUC’s had a major effect on the MROC curves for each strategy, 
because if the tests were not accurate, such as (AUC1 = 0.70, AUC2 = 0.70), the sensitivity 
was lower than (AUC1 = 0.70, AUC2 = 0.90) and (AUC1 = 0.90, AUC2 = 0.90).  
One can see from the Figure 4.5 C5 and some graphs in Appendix A, that 
discontinuity sometimes occurred.  One explanation for these was that two sets of 
thresholds produced the same FPR, but a slightly different sensitivity.  For example, Table 
4.4 contains points on the MROC curve and cost curve of the BP strategy. Table 4.5 
contains points not on the MROC curve and cost curve of the BP strategy because it did not 
achieve the maximum sensitivity. Here, a slight difference in the two sensitivity values 
(0.5957142114 compared to 0.5876595627) in the threshold set (2.08, 0.52) vs. (0.52, 2.08) 
could have had a significant impact on cost (0.9741012430 compared to 0.6699149489). 
The point, then, chosen to be on the MROC curve was the point with the maximum 
sensitivity (FPR=0.315, maxTPR=0.5957142114), but a higher cost (0.9741012430). The 
point, not chosen to be on the MROC curve was the point with (FPR=0.315, 
TPR=0.5876595627), but a lower cost (0.6699149489). The choice of this slight higher 
point causes the discontinuity. This problem is considered further in the next chapter.  See 
Tables 4.4 and 4.5 for the TPR, FPR and cost values where discontinuity occurs. 
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Table 4.4: The points on the discontinuity chosen to be on the MROC curve of BP strategy 
(AUC1 = 0.70, AUC2 = 0.70), and (b1 = 1, b2 = 2). 
Cost 1θ  2θ  FPR Sensitivity strategy 
0.6699149489 0.52 2.28 0.310 0.5872140825 BP 
0.9741012430 2.08 0.52 0.315 0.5957142114 BP 
 
Table 4.5: The points not chosen to be on the MROC curve of BP strategy (AUC1 = 0.70, 
AUC2 = 0.70), and (b1 = 1, b2 = 2). 
Cost 1θ  2θ  FPR Sensitivity strategy 
0.6699149489 0.52 2.08 0.315 0.5876595627 BP 
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Figure 4.4: The effect of AUC values on the MROC and cost curves of individual strategies 
4.3.2 The effect of standard deviation 
As shown in Figure 4.5 for (AUC1 = 0.90, AUC2 = 0.90), in terms of accuracy, either the 
BN or BP strategy were, at most, as good as the BE strategy, regardless of the standard 
deviations of the diseased and non-diseased populations.  In Appendix A, it can be seen 
that the performance of BP and BN depended on the parameter setting. For example, if the 
standard deviation was higher for the diseased population than the non-diseased population, 
then one strategy was better than the other and vice versa.  This pattern was also seen in 
Shen (2008).     
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In this research, one can see clearly that the accuracy of the BN and BP strategy 
depended on the ratio of the standard deviations. When (b1=1, b2=0.5), (b1=0.5, b2=1), or 
(b1=0.5, b2=0.5), the BE and BP strategies had the same accuracy, higher than the BN 
strategy, which had the worst accuracy. When (b1=1, b2=2), (b1=2, b2=1), or (b1=2, b2=2), 
the BE and BN strategies had the same accuracy, higher than the BP strategy, which had 
the worst accuracy.  When b1=0.5 and b2=2 or b1=2 and b2=0.5, the accuracy of the BE 
strategy was never worse, while the accuracy of the BN and BP strategies depends on the 
FPR region. Here, the BP strategy had the worst accuracy at small FPRs, whereas the BN 
strategy had the worst accuracy at large FPRs.  
 In Figure 4.5 and in Appendix A, the following patterns can be noted: 
1.) The BN and BE strategies were less costly than the BP strategy at lower FPRs, and the 
BP and BE strategies were less costly than the BN strategies at higher FPRs, when b1=2, 
b2=2 (Graphs A3, B3, and C3 in Figure 4.5). 
2.) BN and BE were less costly than BP at lower FPRs, and BP and BE were less costly 
than BN at higher FPRs, when b1=1, b2=2; b1=2, b2=1; and b1=2, b2=2 (Graphs A3, B3, and 
C3 in Figure 4.5). 
3.) BN was less costly than BP and BE at lower FPRs, and BP and BE was less costly than 
BN at higher FPRs (see Appendix Figure A1.1i). 
4.) BE was less costly than BP and BN, when b1=2, b2=1 (Graph B3 in Figure 4.5).  
5.) BE and BP were less costly than BN, when b1=1, b2=0.5 (Graph A4 in Figure 4.5). 
6.) BE and BN were less costly than BP, when b1=2, b2=2 (Graph B4 in Figure 4.5). 
Consequently, fewer subjects were required to take the second test for the BE strategy at 
low and high FPR values (see Appendix A). 
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Figure 4.5: The effect of standard deviation on the MROC and cost curves of competing 
strategies 
        Figure 4.6 A1 shows that the MROC curves for varying ratios of standard deviations 
did not have a major effect on the BE strategy.  For the BN strategy (graph B1) and the BP 
strategy (graph C1), however, the ratio of standard deviations did have an effect on the 
MROC curves, especially for extreme values of b, for which the MROC curves switched. 
The BN strategy’s sensitivity was the best when (b1=2, b2=2), represented in blue, and its 
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sensitivity was the worst when (b1=0.5, b2=0.5), represented in red. This result occurs 
because when (b1=0.5, b2=0.5), there are no thresholds which give sensitivity values that 
different from the maximum sensitivity. This is why the sensitivity of (b1=2, b2=2) is higher 
than the sensitivity of (b1=0.5, b2=0.5). In contrast, BP’s sensitivity was the best when 
(b1=0.5, b2=0.5) represented in red, and worst when (b1=2, b2=2), represented in blue. This 
result occurs because when (b1=2, b2=2), there are no thresholds which give sensitivity 
values that different from the maximum sensitivity. This is why the sensitivity of (b1=0.5, 
b2=0.5) is higher than the sensitivity of (b1=2, b2=2). Figure 4.6 shows that the BE 
strategy’s cost curves for the varying ratios of standard deviations spread to most portions 
of the graph.  BN’s and BP’s cost curves, in contrast, were found in one diagonal portion of 
the graph.  For BN, the curves were found in the above left diagonal, while for BP, they 
were found in the above right diagonal.  The reader should remember that the BN strategy 
only classifies a patient as positive if both tests have confirmed that classification.  
Therefore, the BN strategy would be associated with low cost at low FPRs.  Conversely, 
the BP strategy was associated with high cost at low FPRs, because more patients in the 
sample was classified as positive.  For all strategies, it was seen that (b1=0.5, b2=1), (b1=1, 
b2=2), and (b1=0.5, b2=2), all have high cost. 
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Figure 4.6: The effect of standard deviations on the MROC and cost curves of an individual 
strategy            
4.3.3 The effect of prevalence 
In general, prevalence did not have an effect on the MROC curves, but prevalence did have 
an effect on the cost curves for the three strategies. Figure 4.7 examines cost curves for a 
high (0.70) and low (0.10) prevalence.  The cost associated with low prevalence shifted to 
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higher FPR values as compared to high prevalence. When a disease is common, or, has 
high prevalence, the first test will be sufficient in detecting it, because its symptoms will be 
more common to diagnose. When a disease is rare, having low prevalence, more subjects 
were likely to be sent to have the second test, because its symptoms were seen less often by 
clinicians. Therefore, prevalence had an effect on the cost curves.  For example, in Figure 
4.7, as compared to low prevalence, cost was lower for the BE strategy for higher 
prevalence when FPR > 0.2. Similarly, cost was lower for the BP strategy for high 
prevalence and all FPR. Cost was lower for the BN strategy for low prevalence and all 
FPR. 
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Figure 4.7: The effect of prevalence on cost curves of competing strategies  
4.3.4 The effect of correlation 
The presence and absence of correlation between the two tests for both the diseased and 
non-diseased populations was examined. It was found that correlation has an effect on the 
MROC curves of all three strategies.  It was apparent that, in the weak (strong) correlations 
for the diseased and non-diseased populations, the MROC curves of the strategies became 
moderately (marginally) closer to each other and cost modestly (significantly) decreased 
with more scattered points than the uncorrelated tests.  For example, in Figure 4.8, the BE 
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strategy (graph A1), the BN strategy (graph B1), and the BP strategy (graph C1) show that 
the MROC curves were affected by varying correlations, especially for extreme values of 
correlation: absence of correlation and strong correlation. MROC curves seemed higher for 
absence of correlation than strong correlation (see Figure 4.8). Also, identical or differing 
correlations of the diseased and non-diseased populations affected the BP strategy and the 
BN strategy by switching their performances, or making their performance identical to one 
another, depending on the parameter settings. For example, as shown in graph B1 and C1, 
BN’s sensitivity was the best when ( 0, 0)D Nρ ρ= =  and ( 0.7, 0.3)D Nρ ρ= =  represented in orange and 
red, and its sensitivity was the worst when ( 0.7, 0.7)D Nρ ρ= =  and ( 0.3, 0.7)D Nρ ρ= =  represented in 
blue and dark blue. In contrast, the BP strategy’s sensitivity was the best when ( 0, 0)D Nρ ρ= =  
and ( 0.3, 0.7)D Nρ ρ= =  represented in orange and dark blue, and its sensitivity was the worst 
when ( 0.7, 0.7)D Nρ ρ= =  and ( 0.7, 0.3)D Nρ ρ= = represented in dark blue and red. Figure 4.9 
demonstrates the effect of correlation on the cost curves for each individual strategy.  In 
summary, both BN and BP were best at ( 0, 0)D Nρ ρ= =  and worst at ( 0.7, 0.7)D Nρ ρ= = .  Where 
they differed was ( 0.3, 0.7)D Nρ ρ= =  and ( 0.7, 0.3)D Nρ ρ= = . Graphs in Figure 4.8 A4, A5, and 
A6 show that cost curves of all strategies remained high when correlations existed. There 
was little or no effect of correlations on the basic shape of the cost curves for the BN and 
BP strategy (see Figure 4.8 graphs B6 and C6).  
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Figure 4.8: The effect of correlation on the MROC and cost curves  
4.4 Optimality criterion 
The optimal operating points (OOP) were commonly defined as the thresholds 
corresponding to the best balance of specificity and sensitivity (this “best balance” may be 
defined differently depending on the criteria chosen). This research can also be used to give 
guidance in selecting the optimal operating points specifically when there is interest in 
controlling the cost of testing. Zweig and Campbell’s criterion which minimizes the overall 
average cost was used. As described in Chapters 2 and 3, this was formulated as an 
optimization problem:  
Objective function         maxθ  { ( )TPR θ − ( ( ))}m FPR θ×                                             (4.2) 
Subject to       0( )C Cθ ≤ , 
where [ ] ( ) ( )FP TN FN TP(1 ) / / C C ,m p p C C= − × − −⎡ ⎤⎣ ⎦  as defined in work by Metz (1978) is 
the slope of the combined diagnostic tests’ ROC curve (a straight line that passes through 
the ROC curve in the small FPR values, in a point called optimal point). ( )C θ  was the cost 
of testing which satisfies up to fixed value, 0C , 00 1C≤ ≤ . The following values of cost of 
constraint were considered here: 1 and 0.75.  The assumption of each scenario was 
different. A cost constraint of 1 means there was no constraint at all.  A cost of less than 1 
means not all of the subjects have the second test.  The 75% constraint means that you will 
only consider thresholds which result in no more than 75% needing to take the 2nd test.  
These values helped show how much was saved at a particular optimal operating point. 
Table 4.6 considers the values of C/B and slopes.  
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Table 4.6: C/B ratios and slope  
    Prevalence    
     0.1   0.7  
    C/B       slope               
      
C/B 
     
slope 
0.01 0.1  0.23 0.1 
0.11 1   1 0.43 
0.33 3   2.33 1 
1 9   7 3 
 
The above values of slopes were suggested because they were within the range of 
0.1-3.0 used in previous literature (Metz et al., 1996). Values not in this range were not 
considered by Metz et al. to be clinically relevant. While the slope of 9.0 may not be 
clinically relevant, it is it important to observe it here because the C/B ratio was 1.0, which 
assumed that the cost of misclassifying the non-diseased was the same as the cost of 
misclassifying the diseased. The C/B of 0.11 for prevalence of 0.1 and 2.33 for prevalence 
of 0.7 assumed that the product of C/B ratio and prevalence term ( (1 ) /p p− ) was 1.0 (i.e., 
slope=1.0). This produces a formula for the optimal point which was the same as Youden's 
index. Here the OOP was found by measuring the maximum distance from the chance line.  
This study does not intend to use the optimality criterion to choose a strategy. 
However, the goal was to give guidance on how the cost of sequential of testing affects the 
choice of optimal operating points once a strategy was chosen. One can illustrate the 
regions of the MROC curve which satisfied the fixed cost constraints (1 or 0.75) from 
which the optimal points may be chosen.  Effectively, this was a graphical depiction on the 
MROC curve of the feasible and infeasible regions for optimal points. The optimal point 
from the feasible regions was found by maximizing the GYI from Equation 4.2. This 
section shows how the feasible region of the optimal points changes by varying the cost 
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constraint. The example presented here assumed equal standard deviations for the diseased 
and non-diseased populations. This example was chosen because the cost curves show 
different cases (in particular when prevalence was 0.10, graph B) where  
o The BE strategy and  the BN strategy produced similar results for cost at 
low FPR values 
o The BE strategy and the BP strategy produced similar results for cost at high 
FPR values 
o  The BE strategy and the BP strategy do not produced similar results for cost 
at low FPR values  
o The BE strategy and the BN strategy do not produced similar results for cost 
at high FPR values 
o Neither the BP strategy nor the BN strategy produced similar results for cost 
for BE at a range of FPR. 
The graph in Figures 4.9 A shows the competing strategies had similar MROC curves, 
graphs B and C shows the cost curves for low and high prevalence, respectively, with fixed 
cost constraints (1 or 0.75) represented by a “black” dashed line.  It was obvious that the 
BE strategy was not affected by cost constraints at any FPR values. In contrast, cost 
constraints restricted the FPRs that could be considered for the BP and BN strategies. 
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                           A                                         B                                            C                                                      
 
Figure 4.9: The effect of cost constraint on determining the feasible region of the MROC 
curve for finding optimal operating point 
 
As shown in Table 4.7 and 4.8, when the prevalence was 0.1 and the cost 
constraints were 0.75 or 1, the optimal points for the BN and BE strategies were the same. 
This indicates that the cost of testing constraint did not affect the choice of optimal point. 
As shown in graph 4.10 B, the constraint didn’t effect the cost curves of the BE and BN 
strategies in any way at a low FPR values. In contrast, the optimal points for the BP 
strategy did change. This was because the shape of the cost curve for BP found above the 
right diagonal was affected by cost constraint at a low FPR values.  
Overall, the cost constraint in this example did not restrict the FPRs that could be 
considered for the BE strategy, but there were restrictions for the others: FPRs < 0.58 for 
the BN strategy and >0.25 for the BP strategy. 
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Table 4.7: OOP when prevalence was 0.1 and cost of testing no larger than 75% 
C/B Slope Strategy GYI 1θ  2θ       3θ  TPR FPR Cost 
0.01 0.10 BE 0.947 0.72 -0.96 0.36 0.987 0.450 0.550
  BN 0.936 -0.56  -0.72 0.985 0.545 0.740
    BP 0.945 0.52  0.68 0.987 0.475 0.638
0.11 1.00 BE 0.761 1.68 0.04 0.92 0.885 0.125 0.435
  BN 0.730 0.36 . 0.32 0.863 0.135 0.416
    BP 0.667 0.88 . 1.16    0.955 0.290 0.747
0.33 3.00 BE 0.612 2.16 0.48 1.2 0.761 0.050 0.325
  BN 0.579 0.8 . 0.72 0.727     0.050 0.275
  BP 0.093 0.88 . 1.16 0.955    0.290 0.747
1.00 9.00 BE 0.439 2.8 0.96 1.44 0.574     0.015 0.214
  BN 0.412 1.28 . 1.04 0.547     0.015 0.160
    BP -1.655 0.88 . 1.16 0.955    0.290 0.747
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Table 4.8: OOP when prevalence was 0.1 and no cost constraint 
C/B Slope Strategy GYI 1θ  2θ       3θ  TPR FPR Cost 
0.01 0.10 BE 0.947 0.72 -0.96 0.36 0.987 0.450 0.550 
  BN 0.936 -0.6 . -0.72 0.986 0.555 0.752 
    BP 0.945 0.52 . 0.68 0.987 0.475 0.638 
0.11 1.00 BE 0.761 1.68 0.04 0.92 0.885 0.125 0.435 
  BN 0.730 0.36 . 0.32 0.863 0.135 0.416 
    BP 0.730 1.4 . 1.4 0.884 0.155 0.861 
0.33 3.00 BE 0.612 2.16 0.48 1.2 0.761 0.050 0.325 
  BN 0.579 0.8 . 0.72 0.727 0.050 0.275 
  BP 0.545 1.8 . 1.88 0.738 0.065 0.917 
1.00 9.00 BE 0.439 2.8 0.96 1.44 0.574 0.015 0.214 
  BN 0.412 1.28 . 1.04 0.547 0.015 0.160 
    BP 0.331 2.24 . 2.24 0.556 0.025 0.955 
 
For example, the plots in Figures 4.10 identify the feasible region for optimal points 
when prevalence was 0.1 and the C/B ratio was 0.11, so that the slope was 1.0. The points 
shown in “green” on the MROC curve satisfied the fixed cost constraint (identified the 
feasible region). The points shown in “red” on the MROC curve did not satisfy the fixed 
cost constraint, (the infeasible region). The point that lay in the feasible region in light blue 
maximized the GYI amongst all points in the feasible region, which was the best operating 
point that a clinician could use to classify a subject as diseased or not. It was seen that the 
cost constraints affected the optimal point because it restricted the feasible region.  For 
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example, in Figure 4.10, a cost constraint of 0.75 provided fewer points to pick from as 
compared to a cost constraint of 1. Using no cost constraint allowed one to operate at the 
point with the maximum GYI over the whole curve. In Figure 4.10, the BE and BN 
strategies each found the same optimal operating point, regardless of cost constraint. This 
means that both the BE and BN strategies were not affected by the cost constraint. The 
same graph shows that the BP strategy’s optimal operating point was greatly affected by 
the cost constraint.  For other scenarios, this will be different; when a small slope of 0.01 
was considered, the C/B ratio was 0.1. At this point, the FPR was less important than the 
sensitivity, which got very high. However, the FPR increased drastically, making this 
threshold unacceptable to clinicians concerned with FPR.  When a large slope of 1 was 
considered, the C/B ratio was 1; at this point FPR and sensitivity had the same importance; 
when the sensitivity decreased, so did the FPR.  This resulted in a very low FPR, but also a 
very low sensitivity, making this threshold unacceptable to clinicians concerned with 
sensitivity. 
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Figure 4.10: The effect of cost constraint in finding the optimal operating point for a 
prevalence of 0.1 and C/B ratio of 0.11 
 
 As shown in Table 4.9 and 4.10, when the prevalence is 0.7 and the cost 
constraints were 0.75 or 1, the optimal points found by the BP and BE strategies did not 
change. The BE and BP strategies were not affected by cost constraint at a high FPR 
because of the shape of the respective cost curves. In contrast, the optimal point found by 
the BN strategy changed because the shape of the cost curve was affected by cost constraint 
(see graph 4.11 C).  
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Table 4.9: OOP when prevalence was 0.7 and cost of testing no larger than 75% 
C/B Slope Strategy GYI 1θ  2θ  
     
3θ  TPR FPR Cost 
0.23 0.10 BE 0.943 0.84 -0.88 0.36 0.984 0.420 0.297 
  BN 0.857 0.4  0.20 0.871 0.145 0.748 
    BP 0.941 0.6  0.68 0.985 0.455 0.297 
1.00 0.43 BE 0.849 1.4 -0.24 0.64 0.941 0.215 0.379 
  BN 0.809 0.4  0.20 0.871 0.145 0.748 
    BP 0.834 1.08  1.20 0.937 0.240 0.421 
2.33 1.00 BE 0.760 1.8 0.12 0.88 0.875 0.115 0.440 
  BN 0.728 0.4  0.36 0.853 0.125 0.748 
    BP 0.729 1.4  1.40 0.884 0.155 0.514 
7.00 3.00 BE 0.611 2.16 0.48 1.2 0.761 0.050 0.472 
  BN 0.577 0.8  0.72 0.727 0.050 0.654 
    BP 0.543 1.8  1.88 0.738 0.065 0.636 
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Table 4.10: OOP when prevalence is 0.7 and no cost constraint 
C/B Slope Strategy GYI 1θ  2θ       3θ  TPR FPR Cost 
0.23 0.10 BE 0.943 0.84 -0.88 0.36 0.984 0.420 0.297 
  BN 0.932 -0.56  -0.56 0.982 0.510 0.907 
    BP 0.941 0.6  0.68 0.985 0.455 0.297 
1.00 0.43 BE 0.849 1.4 -0.24 0.64 0.941 0.215 0.379 
  BN 0.824 0.04  0.04 0.925 0.235 0.818 
    BP 0.834 1.08  1.20 0.937 0.240 0.421 
2.33 1.00 BE 0.760 1.8 0.12 0.88 0.875 0.115 0.440 
  BN 0.729 0.36  0.32 0.863 0.135 0.756 
    BP 0.729 1.4  1.40 0.884 0.155 0.514 
7.00 3.00 BE 0.611 2.16 0.48 1.2 0.761 0.050 0.472 
  BN 0.577 0.8  0.72 0.727 0.050 0.654 
    BP 0.543 1.8  1.88 0.738 0.065 0.636 
 
The plots in Figure 4.11 examines high prevalence (e.g 0.7), as compared to Figure 
4.10 which examines low prevalence (e.g 0.1).  The feasible region for optimal points 
increased for BP and decreased for BN. For example, in Figure 4.11, a cost constraint of 
0.75 provided fewer feasible points as compared to a cost constraint of 1. In this case, BN’s 
optimal operating point was affected by cost constraint. The formulas for BE and BP 
strategies individually found the optimal point for the strategies at the same place on the 
MROC curve, regardless of cost constraint. This means that neither were affected by the 
cost constraint, even with a cost constraint of 0.50 (see Table 4.11).  The exception to this 
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pattern occurred with a slope of 3 and a C/B ratio of 7; the BE strategy selected the same 
point twice, regardless of cost constraint, but BP selected two different points.    
 
Table 4.11: OOP when prevalence was 0.7 and cost of testing was no larger than 50% 
C/B Slope Strategy GYI 1θ  2θ       3θ  TPR FPR Cost 
0.23 0.1 BE 0.943 0.84 -0.88 0.36 0.984 0.420 0.297 
  BN 0.488 1.4   1.16 0.489 0.010 0.486 
    BP 0.941 0.6   0.68 0.985 0.455 0.297 
1 0.43 BE 0.849 1.4 -0.24 0.64 0.941 0.215 0.379 
  BN 0.485 1.4   1.16 0.489 0.010 0.486 
    BP 0.834 1.08   1.2 0.937 0.240 0.421 
2.33 1 BE 0.760 1.8 0.12 0.88 0.875 0.115 0.440 
  BN 0.479 1.4   1.16 0.489 0.010 0.486 
    BP 0.726 1.24   1.52 0.890 0.165 0.467 
7 3 BE 0.611 2.16 0.48 1.2 0.761 0.050 0.472 
  BN 0.459 1.4   1.16 0.489 0.010 0.486 
    BP 0.405 1.28   1.52 0.885 0.160 0.479 
 
81 
 
 
 
Figure 4.11: The effect of cost constraint in finding the optimal operating point for a 
prevalence of 0.1 and C/B ratio of 2.33 
4.5 Examining the test thresholds 
The BE strategy performed in three different ways as compared to the BP and BN strategy.  
o The BE strategy produced results similar to the BN strategy 
o The BE strategy produced results similar to the BP strategy 
o The BE strategy produced results similar to the BN strategy and the BP 
strategy for some FPR values 
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In the next sections, the characteristics of these three performance types will be explored.  
The following examines the instances in which the BE strategy produced similar results as 
the BN strategy.  The section following that will examine the instances in which the BE 
strategy produced similar results as both the BN and BP strategy for some FPRs.      
4.5.1 The BE strategy produced results similar to the BN strategy  
Figure 4.12 shows the MROC and cost curves when b1=2 and b2=2.  The BE and BN 
strategies had the same accuracy with MROC curves higher than the BP strategy. In terms 
of cost, the BE and BN strategies had the same cost, lower than the BP strategy for FPR < 
0.35; and the BP strategy was less costly than the BN and BE strategies for FPR > 0.35. 
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Figure 4.12: MROC curves and cost curves for (b1=2 ,b2=2), (AUC1 = 0.70, AUC2 = 0.70), 
( 0, 0)D Nρ ρ= = , and prevalence of 0.1 
Looking at this example, one might suspect that the decision rule for the BE 
strategy was similar to that for the BN strategy: i.e. the upper threshold for test 1 in the BE 
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strategy ( 1θ ) was very large, and the lower threshold ( 2θ ) was similar to the test 1 
threshold for the BN strategy. If that were the case, then the BE strategy would essentially 
send all subjects with a value for test 1 greater than 2θ  to a second test (similar to the BN 
strategy).  To investigate this, the thresholds were graphed. Figure 4.13 A plots the test 1 
thresholds of the BE strategy (vertical axis) vs. the threshold of the BP strategy (horizontal 
axis). Graph B plots the test 1 thresholds of the BE strategy (vertical axis) vs. the threshold 
of the BN strategy (horizontal axis). Graph C plots the test 1 thresholds of the BE strategy 
(vertical axis) vs. FPR (horizontal axis). The diagonal line on the first two graph 
connecting the two points (0, 0) and (5, 5), was used to determine if test thresholds were 
identical. Points falling on the diagonal line indicate test thresholds were identical. The 
points in Figure 4.13 A were not on the diagonal line.  The threshold values for 1θ  from BE 
were large (approaches+∞ ), and the thresholds 1θ  from BP and 2θ  from BE were similar 
for small threshold values but deviated off diagonal as the threshold increased. This 
indicates that both test thresholds for the BE strategy were different than the thresholds for 
test 1 of the BP strategy.  This was as expected.  Conversely, Figure 4.13B shows that the 
pattern that 2θ  takes was a diagonal pattern, meaning that the BE strategy’s thresholds ( 2θ ) 
were equivalent to the BN strategy’s thresholds ( 1θ ). The same graph shows 1θ  from the 
BE strategy approaching +3. This was equivalent to +∞  because for this normal 
distribution, only a small percent of the distribution was larger than that 3. Taken together, 
this means decisions for Test 1 for the BE strategy were similar to those for the BN 
strategy. Graphs in Figure 4.13A and B do not show the change of Test thresholds over 
FPR. The graph in Figure 4.13C shows for all FPR values, the threshold 1θ  from the BE 
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strategy approaches+∞ , meaning that the BE strategy produced similar results as the BN 
strategy.  
A                                                B                                                   C 
 
Figure 4.13: Comparison of threshold values: 2θ  from the BE strategy similar to 1θ  from 
the BN strategy 
4.5.2. The BE strategy produced similar results as the BP strategy and the BN 
strategy for some FPRs  
Figure 4.14 focuses on MROC curves and cost curves.  When b1=1 and b2=1, the 
competing strategies have the same accuracy. In terms of cost, the BE and BN strategies 
have a similar cost for FPR < 0.30, lower than the BP strategy; the BE and BP strategies 
have a similar cost for FPR > 0.58, lower than the BN strategy; and the BE strategy was 
less costly for FPR between 0.30 and 0.58. 
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Figure 4.14: MROC curves and cost curves for (b1=1 ,b2=1), (AUC1 = 0.90, AUC2 = 0.90), 
( 0, 0)D Nρ ρ= = , and prevalence of 0.1 
Here, the cost above curves show that the BE strategy produced similar results to 
both the BN and BP strategies for some FPR values. It was shown graphically that the BE 
strategy produced similar results as the BN strategy if 1θ  from the BE strategy 
approaches+∞  and that the BE strategy produced similar results as the BP strategy if 2θ  
from the BE strategy approaches−∞ .  It was true that, in Figure 4.14, the BE strategy 
produces similar results to both the BN and BP strategies for some FPR values, but it was 
not certain that their thresholds were equivalent until the threshold values were examined. 
Figure 4.15 A shows that 2θ  from the BE strategy versus 1θ  from the BP strategy do not 
form an equivalent diagonal but 1θ  from the BE strategy versus 1θ  from the BP strategy 
was close to a diagonal line, meaning that the BE strategy’s thresholds 1θ  were close to the 
BP strategy’s thresholds 1θ . Figure 4.15 B shows that 1θ  from the BE strategy versus 1θ  
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from the BN strategy do not form a closer equivalent diagonal but 2θ  from the BE strategy 
versus 1θ  from the BN strategy was close to a diagonal line, meaning that the BE strategy’s 
thresholds 2θ  were close to the BN strategy’s thresholds 1θ . Figure 4.15 A and B do not 
show the change of Test thresholds over FPR values. The graph in Figure 4.15 C shows for 
all FPR values, the thresholds 1θ  approaches+∞ at a low FPR values, and 2θ  
approaches−∞  at a high FPR values. This means that the BE strategy produced similar 
results as the BP strategy at a high FPR values and the BE strategy produced similar results 
as the BN strategy at a low FPR values. 
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Figure 4.15: Comparison of threshold values: 2θ  from the BE strategy similar to 1θ  from 
the BN strategy and 1θ  from the BE strategy similar to 1θ  from the BP strategy 
4.6 Final notes 
This research used the increment of 0.04 for the Test thresholds because a similar pattern 
emerged with finer increments such as 0.03 and 0.02 and the conclusion was the same in 
terms of the properties of the three strategies. Figures 4.16 through 4.18 shows that the 
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MROC curves were identical, regardless of the thresholds increment. For cost curves, the 
differences between increments were hard to see on a graph.  Since the curves with finer 
increments take longer for a computer to process, if we get similar results from a large 
increment, there was no need to take time computing the finer one.  
In real life data, however, a slight change in increment could affect the results; 
therefore, a finer increment could be considered.  Chapter 6 applied the techniques 
developed in this research thus far to actual data, where test results might be transformed to 
satisfy normality. For this reason one can use finer increments to evaluate the diagnostic 
test. 
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Figure 4.16: Thresholds increment 0.04 
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Figure 4.17: Thresholds increment 0.03 
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Figure 4.18 : Thresholds increment 0.02 
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Chapter 5: Results II 
 
5.1 The acceptable accuracy ( q ) 
When evaluating two medical tests with continuous results to diagnose a disease or medical 
condition, the use of sequential testing will be associated with more than one threshold that 
produces sensitivity values that are essentially equivalent or slightly lower than the 
maximum sensitivity. These values may lower the cost of a sequence of tests by reducing 
the number of subjects that need the second test to reach a diagnosis. This is an important 
goal, as the second test could be costly (painful, expensive, etc.) to the patient.  To achieve 
this, a minimal acceptable value of sensitivity must be determined ( q max[TPR( )]θ×   is 
defined at the end of this section).  The steps for generating the minimal acceptable 
tolerance will be described in section 5.2.   
In past research, a variety of methods have been proposed to combine two tests in 
non-sequential order to increase diagnostic accuracy, for example (e.g., Pepe and 
Thompson, 2000; Su and Liu, 1993). There, both tests were measured on all subjects. 
Hence they do not consider lessening the cost of testing and burden on the patient because 
they cannot avoid administering Test 2. The motivation behind sequential testing is that it 
allows for reduced costs by reducing the number of subjects that need Test 2. Yet, little 
research has been done in terms of how the cost of testing is related to a sequence of tests. 
Chapters 3 and 4 address this issue. It was shown there that cost could remain high for all 
strategies. This chapter seeks to further reduce the cost of testing. Therefore, it is important 
to consider the minimal acceptable accuracy, as this will allow for a reduction in cost. In 
Chapter 3 the acceptable accuracy ( q ) was defined as the percent of the accuracy 
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(tolerance) that clinicians are willing to accept. It used q max[TPR( )]θ×   to set an 
acceptable tolerance on sensitivity. When q=1, the MROC curve from Chapter 4 was 
produced, which did not consider lowering sensitivity in any way. To reduce cost and still 
retain acceptable accuracy, a slightly lower value for q, such as that which corresponds to a 
0.1% reduction in TPR (equivalent to q=0.999) or perhaps a slightly lower sensitivity, such 
as 5% reduction (equivalent to q=0.95) could be considered.  Since the value of q=0.999 
was very close to 1, the MCMROC curve of q=0.999 was virtually identical to MROC 
curve in Chapter 4 (equivalent to q=1), where there was no reduction in sensitivity. 
The previous chapter sought to calculate the lowest cost associated with the MROC 
curve. Chapter 4 also made clear another issue: discontinuity occurred in some graphs in 
which two sets of thresholds produced the same FPR values, but slightly different TPR 
values with different associated costs. The effect of this was shown in Chapter 4.  At times, 
cost remained high for some of the strategies and in some cases, the cost curves spread over 
the graph creating ‘fuzz’ and discontinuity. It will be seen in this chapter that this problem 
was partially solved by sacrificing a very small percentage of sensitivity, such as up to 
0.1% reduction; in some situations; though, it was found that heavy discontinuity could not 
be solved even by sacrificing a larger percentage, such as up to 5% reduction.     
5.2 Generating Minimum Cost Maximum ROC (MCMROC) Curve  
This section re-introduces Minimum Cost Maximum ROC (MCMROC) Curve, which 
directly incorporates the effect of cost, which was first introduced in Chapter 3. The 
MCMROC curve showed the results of accepting a lower sensitivity within q of the 
maximum sensitivity, which was associated with the lowest cost. Figure 5.1 demonstrates 
the steps that generate the MCMROC curve. Graph A of Figure 5.1 was produced by 
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estimating sensitivity and FPR for all possible combinations of threshold values. Graph B 
of Figure 5.1 identifies the maximum sensitivity for each FPR t≤ , where t was 200 
equally spaced values between 0 and 1 (increment of 0.005). It was represented here as a 
black line.  Graph C of Figure 5.1 was produced by setting a minimal acceptable value of 
sensitivity by considering sensitivity values greater than or equal to max[TPR( )]q θ×  . 
Graph D of Figure 5.1 identifies sensitivity with lowest cost at each FPR t≤ . If one 
observes multiple sensitivities with the same lowest cost, the maximum sensitivity at 
each FPR t≤  was found. Represented in red was the MCMROC curve for q=0.95.   
                    A                                B                                C                                D 
 
Figure 5.1: Steps in producing the MCMROC curve for q=0.95 
5.3 The effect of parameter settings  
Appendix C1 through C5 shows how the MCMROC and cost curves change when a 
slightly lower sensitivity (up to 5% reduction) was accepted. Appendix B1 through B5 
shows how the MCMROC and cost curves changed when a negligible lower sensitivity (up 
to 0.1% reduction) was accepted. Similar to Chapter 4, it was seen that the AUC values, 
correlation, and standard deviation had an effect on the MCMROC and cost curves. In 
Chapter 3, it was proven that the BE strategy was never the worst compared to the BN and 
BP strategies.  However, this does not apply when 1.0q < .   
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In this chapter, a lower sensitivity ( 1.0q < ) was being allowed. The graph series in 
Appendix B1 through B5 shows that AUC values, standard deviation, prevalence, and 
correlation had an effect on cost curves for a reduction in sensitivity of 0.1%. The graph 
series in Appendix C1 through C5 shows that AUC values, standard deviation, prevalence, 
and correlation had an effect on MCMROC/cost curves for a reduction in sensitivity of 5%.  
This chapter will mainly focus on the effect of q, rather than the effect of other parameters 
on the MCMROC and cost curves, such as AUC value, standard deviation, prevalence, and 
correlation.  The primary focus, then, was to find how q affected the MCMROC curves and 
cost curves and the choice of optimal point.  
5.4 The effect of q on the MCMROC curves 
Figure 5.2 uses the values q=1, q=0.999, and q=0.95, respectively.  In graphs A1, A2 and 
A3, the MCMROC curve for q=0.999 was virtually identical to the MROC curve when 
q=1.  The patterns of the three q’s shown in these graphs did not change the ways in which 
the MCMROC curves of each strategies differed from one another (the exception to this is 
noted in Graph C3).  Only when up to 5% reduction in sensitivity was used, the MCMROC 
curves could be close to the minimal acceptable value of sensitivity. In graphs B1, B2 and 
B3, when there was 0.1% reduction, there were no clinically relevant changes to the graph.  
Graphs C1, C2 and C3 show that, by sacrificing up to 5% sensitivity, the MCMROC curve 
was lowered.  Looking at graph C3, it was seen that, of our three strategies, the sensitivity 
of the BN strategy was the lowest, while the BP and BE strategies had a negligible 
difference in sensitivity. This occurred when the (b1=0.5, b2=0.5).  See Appendix A, B, and 
C for situations in which this happened.                  
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Figure 5.2: The effect of q on the MCMROC curves  
5.5 The effect of q on the cost curves 
Figure 5.3 uses the values q=1, q=0.999, and q=0.95, respectively.  In graphs A1, A2, A3, 
and A4, one can see how the cost remained high when no sensitivity was sacrificed (q=1).  
In comparison, it can be seen that, in graphs B1, B2, B3, and B4, the cost was significantly 
lowered by accepting a slightly lower sensitivity (up to 0.1% reduction), thus a great 
reduction in cost can be achieved by sacrificing a sensitivity of 0.1%.  It should be noted, 
though, (see B1, B2, B3, and B4) that the cost was mostly reduced for higher FPR values.  
Thus, there was a good reason to find a way to reduce cost at low FPR values, because 
clinicians may want to choose a point to “operate” the test that has small FPR values. The 
cost can be lowered further by allowing a larger reduction of sensitivity, as long as such a 
reduction was considered appropriate. Graphs C1, C2, C3, and C4 show that, by sacrificing 
5% sensitivity, cost can be lowered for small FPR values. The cost of the BE strategy was 
severely lowered at small FPR values and then dropped to a cost of zero, eliminating the 
need for the second test. Also, a reduction can be seen when (AUC1=0.7, AUC2=0.7). 
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However, the same plots showed that cost can remain high for either the BN or BP 
strategy, though in different directions and depending on the FPR value. 
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Figure 5.3: The effect of q on the cost curves of the BE, BN, and BP strategies  
Reducing the percent of the accuracy (q) can lower cost in all strategies, however 
there were some exceptions. In Figures 5.4 A1, A2, A3, C1, C2, and C3, when b1=0.5 and 
b2=0.5 and with varying values of the AUC for test 1 and 2, the cost curves of the BP and 
BE strategies stayed close or the same even with up to 0.1% reduction and is reduced for a 
5% reduction in sensitivity. However, for the BN strategy, in graphs B1, B2, and B3 of 
Figure 5.4, the cost curves stayed much the same even with up to 5% reduction. 
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Figure 5.4 Exception to effect of q on the cost curves of each individual strategy with 
prevalence of 0.1 
For the same parameters above, one can examine the effect of prevalence on cost 
curves. In comparison to the graph above with low prevalence (e.g., 0.1), cost for the BP 
and BE strategies decreased when prevalence was high (0.7); while in contrast, cost 
increased for the BN strategy. This was true for identical or differing AUC values.  See 
Figure 5.5. 
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Figure 5.5 Exception to effect of q on the cost curves of each individual strategy with 
prevalence of 0.7. 
A similar result can be observed for the corresponding MCMROC curves graphed 
in Figure 5.6 that were associated with the cost curves in Figure 5.4.  
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Figure 5.6 Exception to the effect of q on the MCMROC curves of each individual strategy 
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It is recommended, therefore, if sensitivity is important to a researcher, to use a 
higher value of q rather than no reduction, such as q=0.999, as this retains the same MROC 
curve with the possibility of a reduced cost.  If the second test is painful or expensive for 
the patient, q=0.95 could reduce the cost significantly.  
5.6 Cost reduction 
One might want to determine how much cost was saved by accepting slightly lower 
sensitivity. Comparing the cost associated with the MROC curve versus the MCMROC 
curve through calculating the percent reduction in cost can help visualize the cost-
improvement created by accepting a slightly lower accuracy. The percent reduction in cost 
was calculated by 
( )CMROC  -  CMCMROCPercent Reduction   100%CMROC 
⎛ ⎞⎜ ⎟⎜ ⎟⎝ ⎠
= ×                                        (5.1) 
where CMROC was the cost associated with MROC curve and CMCMROC was the cost 
associated with MCMROC curve. Figure 5.7 compared cost corresponding to 0% reduction 
in sensitivity against 0.1% reduction in sensitivity (i.e. q=1.0 vs q=0.999). The BE strategy 
had a high percent reduction in cost for FPR > 0.20, and it achieved up to a 100% reduction 
in cost when FPR > 0.50, eliminating the need for a second test. The BP strategy had no 
cost reduction at low FPRs (e.g FPR < 0.35) and the percent reduction in cost increased for 
FPR > 0.35 but did not achieve 100% cost reduction. There was minimal change to cost for 
the BN strategy.  
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Figure 5.7: Cost reduction of 0% and 0.1% reduction in cost for the BE, BN, and BP 
strategies, respectively. 
Figure 5.8 compared 0% reduction in cost against 5% reduction in cost. In 
comparison with the other strategies, the BE strategy had a greater percent reduction in cost 
for FPR > 0, and it achieved up to a 100% reduction in cost when FPR > 0.25, eliminating 
the need for a second test. The BP strategy had no cost reduction at low FPRs (e.g FPR < 
0.25) and the percent reduction in cost increased for FPRs > 0.25, though it did not achieve 
100% reduction. There was minimal change to cost for the BN strategy.  Only the BE 
strategy achieved 100% cost reduction, meaning, no subjects required the second test.  
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Figure 5.8: Cost reduction of 0% reduction against 5% reduction in cost for the BE, BN, 
and BP strategies, respectively.  
5.7 The effect of q on the choice of optimal point 
As demonstrated in Figure 5.9 A2 and B2 when q=5%, the need for the second test was 
eliminated for the BE strategy for some FPR values.  The cost curves of the BN and BP 
strategies went in opposite directions, until they reach (0, 1) for the BP strategy and (1, 0) 
for the BN strategy.  The cost curve for the BE strategy was lowered significantly in all 
FPR regions. For example, when q=0.95, all points on the MCMROC curve were 
considered to be in the feasible region (discussed in Chapter 4) for the BE strategy under 
75% and 100% of the sample, meaning that there were more choices from which to find the 
optimal operating point.  In comparison, the choice of optimal points for the BN and BP 
strategies was limited by the fixed constraint on cost of testing (see Figure A1 and A2).  As 
the cost curve for the BN and BP strategies went up, there was more of an upward spread 
of points, meaning that Test 2 was required more frequently.  
A1                                          B1                                        
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A2                                          B2                                         
                   
Figure 5.9: the effect of cost constraint on determining OOP, q=0.999 and q=0.95, 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
Chapter 6  
6.1 Outline 
This chapter will apply the techniques developed in this research to collected data. The data 
application will be described using an introduction and data analysis section.  Data analysis 
will provide descriptive statistics on the original distributions by group (diseased, non-
diseased): N per group, means, standard deviations, minimums, maximums, and medians. 
Comparison between diseased and non-diseased individuals will be completed by the two-
sample T-test. Normality within group will be assessed, and if necessary, transformations 
using the Box-Cox transformation will be used to improve normality. Using means and 
standard deviations of the diseased and non-diseased populations, sensitivity, FPR (1-
specificity), and cost for each sequential strategy (BP, BN and BE) will be estimated. 
Graphical displays for the MROC, MCMROC and cost curves for each strategy will be 
generated and compared, including test thresholds. The optimal operating point for each 
strategy will be calculated using the Generalized Youden Index (GYI).   
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Application: Diabetes in Pima Indians 
6.2 Introduction 
Type 1 (insulin-dependent) diabetes occurs when the body’s immune system attacks the 
beta cells in the pancreas that produce insulin. Normally, insulin helps the sugar from 
ingested food absorb into body cells.  As no insulin is produced by the pancreas in people 
with Type 1 diabetes, these patients need daily insulin shots in order to control their blood 
sugar level. This form of diabetes is generally found during the younger age or teenage 
years, but may occur in adults under 30. Type 2 (non-insulin-dependent) occurs when fat 
and muscle cells are unable to properly use the body’s insulin.  This is also known as 
insulin resistance. Some Type 2 diabetics need insulin to control their blood sugar but 
many can keep their blood sugar at satisfactory levels by changes in diet, food choices, 
diabetes pills, or regular exercise, that help the body to use insulin more efficiently. This 
form generally occurs in adults older than 40 years, though it can occur in teenage years. 
The inheritance pattern in Type 2 diabetes is further complicated, as environmental factors, 
genetics, and lifestyle play a major role in the overall risk (Harris M., 1999; Bener A., Zirie 
M., and Al-Rikabi, 2005; Romao I. and Roth J., 2008).  
The Pima Indians of Arizona are known to have a high incidence of Type 2 diabetes 
and obesity. In this tribe, diabetes incidence has been reported to be as high as 40-50% in 
adults (Knowler et al, 1978). Data on Native American women of Pima heritage, aged 21 
and over was studied by Smith et al, 1988, and was made publicly available through the 
UCI Machine Learning data depository (Keogh, Merz and Blake, 1998). These data consist 
of diagnostic information for 768 women; 268 with diabetes, and 500 without diabetes.  
The outcome investigated was whether or not the patient showed symptoms of diabetes, 
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classified as showed by World Health Organization (WHO) criteria. The WHO criterion for 
classifying individuals as diabetic is a 2-hour postprandial plasma glucose ≥ 11.1mmol/l 
(WHO, 2003). This criteria considers both fasting and 2-hour blood samples, and classifies 
glucose tolerance as diabetes if (fasting glucose ≥7.0 or 2-h postprandial plasma glucose 
≥11.1 mmol/l). 
The original study collected many measurements with which to examine diabetes in 
this population.  For the purposes of the sequential testing in the research in this 
dissertation, two screening tests were considered: the first test combines anthropometric 
measurements of height and weight to produce a single measurement, the body mass index, 
BMI, kg/m2 (variable denoted by 1X ). BMI is the ratio of weight (in kilograms) to the 
square of height (in meters). The second test was a more costly blood test, the plasma 
glucose concentration in mg/dl (variable denoted by 2X  and hereafter referred to as 
glucose in this chapter). There were no missing values in these data but there were n=16 
recorded BMI or glucose with implausible results which were deleted (11 had a 0 BMI and 
5 had a 0 glucose value). Deletions of these cases resulted in a sample of 752 women (264 
with diabetes and 488 without diabetes) for analysis. 
6.3 Data Analysis  
Data were presented as mean ± SD for continuous variables (BMI and glucose) and as 
number and percentages (n and %) for diabetes status (Table 6.3.1). Among the 752 
women, 264 (35.11%) were diagnosed with Type II diabetes (BMI =35.37± 6.63 kg/m2 
with BMI ranging between 22.9 and 67.1 kg/m2, glucose = 142.49 ±29.64 mg/dL with 
glucose ranging between 78.0 and 199.0 mg/dL).  There were 488 (64.89%) women 
diagnosed as non-diabetic (BMI = 30.88 ± 6.57 kg/m2 with BMI ranging between 18.2 and 
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57.3 kg/m2, glucose = 110.83 ± 24.84 mg/dL with glucose ranged between 44.0 and 197.0 
mg/dL). 
Table 6.1: Summary of BMI and plasma glucose concentration by diabetes status   
       Quartiles 
Group n(%) Test SD Mean 25% 50% 75% 
264(35.11) BMI 6.63 35.37 30.83 34.25 38.65Diabetes 
  Glucose 29.64 142.49 119 140.5 167
488(64.89) BMI 6.57 30.88 25.6 30.1 35.38  Non-Diabetes 
 Glucose 24.84 110.83 93 107.5 125
The two-sample t-test demonstrated significant differences in BMI and glucose levels 
between those with and without diabetes, (p-value < 0.0001 for both BMI and glucose). 
Further, the empirical ROC curve of each individual test suggested that the two tests had 
discriminating ability superior to chance (see Figure 6.1), because tests of the hypothesis, 
H0: AUC=0.5, were found to be significant for each test (p-value <0.0001). As given in 
Table 6.2, the nonparametric AUC value for BMI is 0.684 (95% CI: 0.647, 0.722) and for 
glucose was 0.792 (95% CI: 0.759, 0.825). BMI did not appear to be as good a 
discriminator between those with and without diabetes as glucose because the CI around 
the AUC shows that BMI did not have higher AUC than glucose which can also be 
observed in Figure 6.1.  
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Table 6.2: AUC and confidence intervals (CI) of BMI and plasma glucose concentration. 
        Asymptotic 95% CI 
Test AUC Std. Error Sig. Lower Bound Upper Bound 
Glocose 0.792 0.017 <0.0001 0.759 0.825 
BMI 0.684 0.019 <0.0001 0.647 0.722 
 
 
Figure 6.1: Empirical ROC curves for predicting diabetes groups from BMI and plasma 
glucose concentration. 
The scatter plot in Figure 6.2 shows that women with diabetes had, in general, higher 
values of both BMI and glucose than those without diabetes. A Spearman correlation was 
used because the data were not normally distributed, as shown later in this section.  There 
were weak Spearman correlations between BMI and glucose in these data, (rho = 0.1) for 
the diabetes group and (rho = 0.1) for the non-diabetes group. Because these points 
overlapped, finding perfect separation between the values for those with and without 
diabetes was not possible.  
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Figure 6.2: Scatter plot of plasma glucose concentration and BMI by diabetes groups.  
 
The right panel of Figure 6.3 is the histogram of glucose by diabetes status and the left 
panel of Figure 6.3 is the histogram of BMI by diabetes status. These plots further 
demonstrated that women with diabetes tended to have higher BMI and higher glucose 
compared with those without diabetes. The BMI and glucose distributions in Figure 6.3 
appeared to be deviated from a normal distribution. This was confirmed by the skewness of 
0.65 for glucose and 0.46 for BMI, where skewness of zero indicates that the distribution 
was symmetric, a property of the normal distribution. Also the BMI and glucose for the 
diabetes group seemed a bit far from a normal distribution. This was confirmed by the 
skewness of 0.08 for glucose and 1.04 for BMI. One can formally test normality using 
Skewness/Kurtosis and Shapiro-Wilk tests (Tables 6.3 and 6.4). The p-value for these 
statistical tests was less than alpha, 0.05. This indicated the BMI and glucose were not 
normally distributed. The normal quantile plot, shown in Figure 6.4, suggests this.  The 
normal quantile, shown in black, slightly deviates from the normality boundary.  Therefore, 
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a transformation was needed so that the distributions for BMI and glucose can follow a 
binormal distribution.   
    
Figure 6.3: Histograms of BMI and plasma glucose concentration by diabetes groups 
                              Non-diabetic                                           Diabetic 
 
 
Figure 6.4: Normal Quantile plot of plasma glucose concentration and BMI by diabetes 
groups, respectively.  
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Table 6.3: Skewness/Kurtosis tests for Normality 
Group Test Pr(Skewness)1 Pr(Kurtosis)2 adj chi3 Prob>chi4 
Non-Diabetes Glucose 0.0000 0.0152 29.2700 0.0000 
 BMI 0.0001 0.9737 14.3700 0.0008 
Diabetes Glucose 0.6005 0.0000 31.9300 0.0000 
 BMI 0.0000 0.0001 39.3600 0.0000 
1 p-value to test (H0:skewness = 0); 2 p-value to test (H0: Kurtosis = 0)  3 adj chi is the chi-square test;   
4p-value for combining skewness and kurtosis; 
 
Table 6.4: Shapiro-Wilk W test for normal data 
Group Test W1 V Z2 Prob>z 
Non-Diabetes Glucose 0.9749 8.2730 5.0740 0.0000 
 BMI 0.9804 6.4620 4.4810 0.0000 
Diabetes  Glucose 0.9750 4.7660 3.6430 0.0001 
  BMI 0.9478 9.9420 5.3580 0.0000 
1 Shapiro–Wilk test;  2 z statistic 
Using the Box Cox transformation, the distributions were closer to normal.  For the 
diabetes distributions, the skewness was -0.198 for glucose and 0.41 for BMI.  For the non-
diabetic distributions, the skewness was 0.085 for glucose and -0.005 for BMI. The  
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histograms of transformed data seemed closer to the normal distribution (see Figure 6.5). 
The Box-Cox transformation equation that accomplished this was 
( )( )0.051X = BMI 1 0.05TRANS − for BMI and ( )( )0.2212X = glucose 1 0.221TRANS −  for glucose. 
Since glucose and BMI values were transformed, results were not directly interpretable.  
Thus, after analysis, it is useful to reverse this process to interpret results in the original 
units. The following were the equations used to transform the data back to the original: 
( ) 10.051BMI 0.05 X +1TRANS= ×  and ( ) 10.2212glucose 0.221 X +1TRANS= × . The ratio of disease and 
non-disease standard deviations (b), were estimated from the standard deviations of 
transformed data, for BMI 1 ˆ ˆN Db σ σ= = 0.25 0.21 1.2=  and for glucose 2b = 
0.63 0.63 1= .0.  Again, there were weak Pearson correlations between BMI and glucose in 
these data, (rho = 0.1) for the diabetes group and (rho = 0.1) for the non-diabetes group. 
Then sensitivity and FPR were estimated based on normal distribution CDFs by varying the 
threshold values for BMI and glucose. These were evaluated by varying BMI and glucose 
values in increments of 0.001. Selection of the ranges for threshold values was determined 
by examining data within 3 standard deviations of the diseased and non-diseased 
distributions. Specifically, the lower and upper intervals for the non-diseased and diseased 
populations were given by: 
 
 
Using the values in Table 6.5, this approach suggested a lower bound of 2.97 and an upper 
bound of 4.51 for BMI and a lower bound of 6.34 and an upper bound of 10.85 for glucose. 
Then threshold values for BMI and glucose were varied in increments of 0.001 to 
( ) ( )min 3* , 3* , max 3* , 3*N N D D N N D Dμ σ μ σ μ σ μ σ− − + +⎡ ⎤⎣ ⎦
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dichotomize the test results into those with or without diabetes. Sensitivity and FPR (1-
specificity) were then estimated based on the formulas assuming a normal distribution 
CDFs. 
Table 6.5: Summary of transformed data, BMI and glucose by diabetes groups 
       Quartiles 
Group  Test SD Mean 25% 50% 75% 
 BMI 0.21    3.88 3.7 3.87 4.0    Diabetes 
  Glucose 0.63 8.96 8.5 8.97 9.5 
 BMI 0.25     3.72 3.5 3.71 3.9   Non-Diabetes 
 Glucose 0.63  8.23 7.8 8.20 8.6 
6.4 MROC and cost curves 
Figure 6.5 demonstrates the MROC and cost curves for the diabetes data using BMI as the 
first test in the sequence and glucose as the second test.  All three sequential strategies (BP, 
BN, and BE) were examined.  The thresholds were used to dichotomize the test results into 
diseased and non-diseased. Based on the normal distribution CDFs, a sensitivity and 
specificity was estimated using these thresholds. The MROC curve was drawn by plotting 
maximum sensitivity with lowest cost at each FPR t≤ (e.g 1 specificity t− ≤ ). The cost 
curve was drawn by plotting lowest cost at each FPR t≤ . In terms of the performance, the 
BE and BN strategies had identical MROC curves, and were slightly higher than the BP 
strategy. In terms of cost, the BE and BN strategies were less costly than the BP strategy 
for FPR < 0.60; and the BE and BP strategies were less costly than the BN strategy for FPR 
> 0.60. It was apparent that the cost curve of the BE strategy follows that of both the BN 
and BP strategies over specific values of the FPR. Thus, the BE strategy had lower cost 
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over both low and high FPR values. If one were interested in a specific region of the 
MROC curve, such as FPRs < 0.60, one could choose the BE or BN strategy since the 
MROC curves were identical with similar cost curves for FPR< 0.60. For higher FPR 
values, one could choose the BE or BP strategy. 
                                  A                                                                  B 
 
Figure 6.5: MROC curves and cost curves for the three strategies  
6.5 BE produces results similar to the BN and BP strategies for some FPRs 
Figure 6.5 shows MROC curves and cost curves. It appears from the cost curves that the 
BE strategy produced results similar to the BN strategy when FPR 0.60 and was similar to 
the BP strategy when FPR>0.60, but it was not known for sure that their thresholds were 
equivalent until the threshold values were examined.  Figure 6.6 A shows that 2θ  from the 
BE strategy versus 1θ  from the BP strategy did not form an equivalent diagonal, but 1θ  
from the BE strategy versus 1θ  from the BP strategy was close to a diagonal line. This was 
not true for some larger thresholds, meaning that some of the BE strategy’s thresholds ( 1θ ) 
were close to the BP strategy’s thresholds ( 1θ ). Figure 6.6 B shows that 1θ  from the BE 
strategy was usually not equal to 1θ  from the BN strategy but 2θ  from the BE strategy 
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versus 1θ  from the BN strategy was close to a diagonal line for many of the thresholds. 
This was not true for smaller thresholds, meaning that the BE strategy’s thresholds 2θ  were 
close to BN’s thresholds 1θ . Graphs in Figure 6.6 A and B did not show the change of Test 
thresholds over FPR values.  The graph in Figure 6.6C shows when FPR < 0.60, the 
threshold 1θ  from the BE strategy approached+∞  (high values). When FPR > 0.60, the 
threshold 2θ  from the BE strategy approached−∞  (low values). This means that the BE 
strategy produced results similar to the BN and BP strategies at low and high FPR values, 
respectively. 
                        A                                             B                                          C 
 
Figure 6.6: Comparison of threshold values: 2θ  from the BE strategy similar to 1θ  from the 
BN strategy and 1θ  from the BE strategy similar to 1θ  from the BP 
6.6 The MCMROC and cost curves 
This section calculates the lowest cost while a negligible lower sensitivity (0.1% reduction) 
was accepted, and while accepting slightly lower sensitivity (5% reduction). Figure 6.6 
uses the values q=0.999, and q=0.95, respectively. In graphs A1, one can see that the 
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MCMROC curves with q=0.999 were identical when no sensitivity was sacrificed (q=1.0, 
see section 6.3). However, cost curves were slightly lower as compared to the cost curves 
with no sensitivity sacrificed. In graphs A2 and B2, when there was 5% reduction (q=0.95), 
the MCMROC curves were a bit lowered. In terms of cost, the BE and BN strategies were 
less costly than the BP strategy for FPR < 0.20; and the BE strategy was less costly than 
the BN strategy for FPR > 0.20.  
A1                                  B1 
 
A2                               B2 
 
Figure 6.7: MCMROC curves and cost curves for the three strategies  
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6.7 The effect of q on the MCMROC curves and cost curves 
To determine the effect of q, one can plot a separate graph for each of the BE, BN and BP 
strategy which have either the MROC/ MCMROC curves or the cost curves for the 3 q 
values of interest. Here, 0% reduction (equivalent to q=1) was represented in brown, up to 
0.1% reduction (equivalent to q=0.999) was represented in light blue, and up to 5% 
reduction (equivalent to q=0.95) was represented in red. All strategies reduced cost when 
allowed up to 5% reduction in sensitivity. Only the BE and BP strategies lowered the cost 
for large values of FPR when allowed up to 0.1% reduction in sensitivity. Figure 6.7 shows 
that q had an effect on the MCMROC curves cost curves of each individual strategy. 
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Figure 6.8: The effect of q on the MCMROC curves and cost curves of individual strategy 
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6.8 Optimality criterion  
From these data, clinicians would want to know what thresholds to use to diagnose new 
patients as having diabetes or not (the thresholds are often referred to as the “operating 
point” in the ROC literature). This section provides guidance in how to choose such a point 
that could be considered “optimal” As described in previous chapters, this optimal point 
will be a set of thresholds that provides a balance between specificity and sensitivity, 
subject to a restriction on the cost of sequential testing.  It was calculated using the 
Generalized Youden Index (GYI).   
Objective function         maxθ  { ( )TPR θ − *( ( ))}m FPR θ                                            
Subject to       0( )C Cθ ≤ , 
where [ ] ( ) ( )FP TN FN TP(1 ) / / C C ,m p p C C= − × − −⎡ ⎤⎣ ⎦  as defined in work by Metz (1978), 
was the slope of the combined diagnostic tests’ ROC curves (a straight line that passes 
through the ROC curves in the small FPR region, in a point called optimal point). p was the 
prevalence of disease, here for Pima Indian, the diabetes prevalence was 0.35, 
( ) ( )FP TN FN TP/ C CC C− −⎡ ⎤⎣ ⎦ was the cost/benefit (C/B) ratio of false-positive compared to false-
negative results. ( )C θ  is the cost of testing, which satisfies as much as fixed value, 0C , 
00 1C≤ ≤ . The following values of 0C  were considered here: 1 and 0.75. The 1 assumed 
that there was no cost constraint. A cost of less than 1 meant that not all of the subjects had 
to take the second test.  The 75% constraint meant that one would only consider thresholds 
which result in no more than 75% needing to take the 2nd test.   
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6.8.1 Determining optimal operating points to use in classifying results BMI and 
glucose test 
The next task was to find possible thresholds to use to classify the results of the BMI and 
glucose test.  This was done by varying the C/B ratios and the cost constraint. Table 6.6 
considers three values of C/B and slopes with different assumption for each, when 
C/B=0.05, indicated a slope of 0.1, which gives the lowest clinically significant value, as 
suggested by Metz. When C/B=0.538, which indicated a slope of 1, here the GYI becomes 
a Youden’s Index (YI). This also assumed that the cost of misclassifying non-diseased 
subjects was lower than the cost of misclassifying diseased subjects. The second C/B ratio 
considered was 1, which indicates a slope of 1.9. This ratio assumes that the cost of 
misclassifying non-diseased subjects was the same as the cost of misclassifying the 
diseased. The third C/B ratio considered was 1.538, which indicates a slope of 2.9.  This 
ratio assumes that the cost of misclassifying the non-diseased was greater than the cost of 
misclassifying diseased subjects.  
Table 6.6: C/B ratios and slopes  
C/B        slopes  
0.050 0.100 
0.538 1.000 
1.000 1.900 
1.538 2.900 
 
These slope values were suggested here because they were within the range of 0.1-3, used 
by Metz et al. in their study (1996). Figure 6.8 A shows cost curves for q=0.999 with a cost 
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no larger than 75%.  Using the BP strategy, in order to be able to satisfy the cost constraint, 
the optimal operating point must have FPRs > 0.49.  Both BN and BE strategies could have 
an optimal operating point with FPR < 0.20; In addition, the BE strategy could also 
produce an optimal operating point with FPR > 0.49. Figure 6.7 B shows cost curves for 
q=0.95 with the cost up to 75%; For BE all points on the MCMROC curve were in the 
feasible region for OOP.  In comparison, the choice of optimal points for the BN and BP 
strategies were affected by the cost of testing constraint. The optimal operation point for 
the BP strategy was restricted to those which produce FPRs > 0.28, while the optimal 
operating point for the BN strategy would have FPRs < 0.70. For cost up to 100%, all 
points on the MCMROC curve were considered to be in the feasible region. 
                                   A                                                                        B 
 
Figure 6.9: The effect of cost constraint on determining OOP, q=0.999 and q=0.95, 
respectively.  
As a reminder, BMI ranging between 18.2 and 57.3 kg/m2, and glucose ranged 
between 44.0 and 197.0 mg/dL. Table 6.7-6.10 list the optimal points found for each 
strategy using various C/B ratios (or slopes) for two values of q (q=0.95, 0.999), with and 
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without a cost restriction. ( 0 0.75,1.0C = )  In Table 6.7, where q=0.999 and 0 0.75C = , 
when the slope was 1, the optimal points found by BE and BN strategy seem reasonable 
because the FPRs were low (19% and 17% as compared to 49.5% for the BP strategy). The 
thresholds associated with the optimal operating point found by the BE strategy were 
1 56.4θ = and 2 27.6θ =  for BMI, and 3 125θ =  for glucose. This means that women whose 
BMIs were below 27.6 kg/m2 were considered non-diabetic, women whose BMIs were 
over 56.4 kg/m2 were considered as diabetic, women whose BMIs were between 27.6 and 
56.4 and whose glucose levels were above 125 mg/dL were considered diabetic and women 
whose BMIs were between 27.6 and 56.4 kg/m2 and whose glucose levels were below 125 
mg/dL were considered non-diabetic. There were many values in-between 2θ  and 1θ , which 
means more subjects took the second test. This created high cost but did not exceed 75%. It 
should be noted that the upper threshold of the BE strategy, 1 56.4
BEθ =  is so high that 
virtually no women will be diagnosed as diabetic based on BMI alone,  Additionally, it can 
be seen that 2θ  from the BE strategy was similar to 1θ  from BN.  This is because the 
curves for the BE strategy resembled those of the BN strategy for some FPR values. 
Similarly, this is true for the slopes of 1.9 and 2.9 with the same or slightly different 
optimal operating points for the BE and BN strategies. Because the optimal point for the 
BP strategy is restricted by the cost constraint (no larger than 75%) it does not change, for 
any value of slope of 1 or greater, while the optimal points found by the BN and BE 
strategies changed as C/B ratio or slope changes.  
The set of tables below show slope of 0.1 which was the lowest value that Metz 
considered to be clinically relevant. It can be seen that the same optimal operating points 
for the BE and BN strategies remain with cost no larger than 75% and 100% for each 
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q=0.95 and q=0.999.  Here 1θ  and 2θ  from the BE strategy and 1θ  from the BP strategy 
were essentially at the lower limit of the BMI values. This means that virtually everybody 
will be classified as positive on BMI. This makes cost low for these two strategies.  When 
the BN strategy has a low 1θ value but is not at the lower limit, there were few people who 
will be classified as negative on the first test. This was why cost was high for the BN 
strategy. 
Table 6.7: Optimal thresholds for each strategy when cost of testing was no larger than 
75% and q=0.999 
Slope C/B Strategy GYI        1θ  2θ   3θ   TPR FPR cost  
0.1 0.05 BE 0.911 25.06 21.03 106 0.993 0.885 0.103 
  BN 0.595 27.72  127 0.611 0.170 0.746 
  BP 0.910 23.83  121 0.994 0.905 0.089 
1 0.538 BE 0.449 56.40 27.60 125 0.639 0.190 0.749 
  BN 0.441 27.70  127 0.611 0.170 0.746 
  BP 0.379 36.60  116 0.874 0.495 0.747 
1.9 1 BE 0.301 56.30 27.60 132 0.552 0.135 0.749 
  BN 0.302 28.10  132 0.544 0.130 0.725 
  BP -0.046 36.60  116 0.874 0.495 0.747 
2.9 1.538 BE 0.203 57.40 28.60 142 0.418 0.075 0.698 
  BN 0.205 29.10 . 142 0.405 0.070 0.671 
    BP -0.540 36.60 . 116 0.874 0.495 0.747 
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Table 6.8 has similar information when q=0.95 and 0 0.75C = . When accepting 
slightly lower sensitivity (such as 5% reduction) at varying slope values, the optimal 
thresholds for the BE, BN, and BP strategies seemed reasonable in terms of the FPR 
values.  In general, the BE, BN, and BP strategies all had acceptable FPR values as 
compared to when q=0.999.  The optimal operating point for the BP strategy, however, 
remained associated with high cost, while the BN and BE strategies had, in comparison, 
optimal operating points associated with low cost. Since the MROC curves of the BN and 
BE strategies were similar, their optimal operating points were also similar.  Also, because 
the 1θ  threshold for the BE strategy is not as high for the various slopes, compared to the 
1θ  threshold for q=0.999, more women will be diagnosed as positive by BMI alone.    
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Table 6.8: Optimal thresholds for each strategy when cost of testing was no larger than 
75%, and q=0.95 
Slope C/B Strategy GYI  1θ  2θ   3θ   TPR FPR cost  
0.1 0.05 BE 0.909 20.63 20.32 147 0.998 0.965 0.004 
  BN 0.838 27.65 . 74 0.898 0.640 0.750 
  BP 0.909 21.15 . 175 0.997 0.955 0.030 
1 0.538 BE 0.428 39.00 28.60 124 0.682 0.255 0.538 
  BN 0.428 30.00 . 110 0.693 0.265 0.614 
  BP 0.401 36.60 . 138 0.691 0.290 0.749 
1.9 1 BE 0.275 46.70 30.60 130 0.507 0.125 0.553 
  BN 0.276 31.50 . 126 0.499 0.120 0.528 
  BP 0.152 36.60 . 138 0.691 0.290 0.749 
2.9 1.538 BE 0.184 51.10 31.60 140 0.369 0.065 0.510 
  BN 0.185 32.30 . 137 0.371 0.065 0.475 
    BP -0.137 36.60 . 138 0.691 0.290 0.749 
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Table 6.9 lists the optimal points found for each strategy using various C/B ratios 
and sensitivity reductions when there is no cost restriction, and q=0.999. These results can 
be thought about in comparison to the results when the cost of testing is no larger than 
75%. When the sensitivity was reduced by 0.1% with a slope greater than 1, the optimal 
points found by the BE and BN strategies seemed almost the same.  For the BP strategy, 
the results varied, since there was no cost restriction.  When the slope was greater than 0.1, 
the FPR values were lowered, but almost all patients had to have the second test. However, 
when the slope was 0.1, the FPR values were high for all strategies. The optimal point 
found by the BN and BE strategies changed but with similar optimal operating point for 
each slope value while the optimal point found by BP did change, as the C/B changed. This 
was because there were no restrictions on the cost of testing.    
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Table 6.9: Optimal thresholds for each strategy when no restrictions on cost of testing and 
q=0.999 
Slope C/B Strategy GYI  1θ  2θ   3θ   TPR FPR cost  
0.1 0.05 BE 0.911 25.06 21.03 106 0.993 0.885 0.103 
  BN 0.910 21.80 . 71 0.994 0.910 0.959 
  BP 0.910 23.83 . 121 0.994 0.905 0.089 
1 0.538 BE 0.463 52.60 26.70 118 0.733 0.270 0.792 
  BN 0.464 26.80 . 118 0.733 0.270 0.791 
  BP 0.437 52.20 . 123 0.722 0.285 0.994 
1.9 1 BE 0.301 56.30 27.60 132 0.552 0.135 0.749 
  BN 0.302 28.10 . 132 0.544 0.130 0.725 
  BP 0.270 56.60 . 138 0.521 0.135 0.998 
2.9 1.538 BE 0.203 57.40 28.60 142 0.418 0.075 0.698 
  BN 0.205 29.10 . 142 0.405 0.070 0.671 
    BP 0.174 57.50 . 150 0.374 0.070 0.999 
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Table 6.10 lists the optimal points found for each strategy using various C/B ratios 
when q=0.95 but there is no cost restriction.  When the sensitivity was reduced by 5% and a 
slope of 1 was used, the same 1θ , 2θ , and 3θ  for the BE holds for q=0.95 regardless of 
whether or not there was a cost constraint of 75% or no cost constraint. Similarly, the 
same 1θ  and 2θ  for the BN holds for q=0.95 regardless of the cost restriction. This was not 
true for the BP strategy. For the various slopes, when the optimal point for the BP strategy 
was not restricted by the cost constraint, the optimal point had a low FPR.  The threshold 
1θ  for the BP strategy was very high; few subjects were called positive on the first test 
(BMI), with most needing to be assessed by the second test which resulted in high cost. 
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Table 6.10: Optimal thresholds for each strategy when no restrictions on cost of testing and 
q=0.95 
Slope C/B Strategy MGYI  1θ  2θ   3θ   TPR FPR cost  
0.1 0.05 BE 0.909 20.63 20.32 147 0.998 0.965 0.004 
  BN 0.908 20.81 . 53 0.998 0.965 0.974 
  BP 0.909 21.15 . 175 0.997 0.955 0.030 
1 0.538 BE 0.428 39.00 28.60 124 0.682 0.255 0.538 
  BN 0.428 30.00 . 110 0.693 0.265 0.614 
  BP 0.402 37.40 . 138 0.672 0.270 0.780 
1.9 1 BE 0.275 46.70 30.60 130 0.507 0.125 0.553 
  BN 0.276 31.50 . 126 0.499 0.120 0.528 
  BP 0.245 44.10 . 145 0.478 0.125 0.946 
2.9 1.538 BE 0.184 51.10 31.60 140 0.369 0.065 0.510 
  BN 0.185 32.30 . 137 0.371 0.065 0.475 
    BP 0.156 48.30 . 154 0.342 0.065 0.982 
 
Since these results are derived from samples rather than being population based, it 
would be appropriate to assess the level of precision of the results. The use of bootstrap 
confidence intervals may be appropriate, however this takes considerable time and 
resources (see Chapter 7).   
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6.9 Summary 
In Figure 6.2, the points on the scatter plot overlap so that finding perfect separation 
between the values for those with and without diabetes was not possible with either a single 
test or the combination of the two. When the testing sequence did not require subjects to 
undergo the second test to have a diagnosis made, that meant that the subject did not have 
to undergo the blood work necessary for the glucose test.  Using up to 5% reduction in 
sensitivity greatly reduced the number of patients who were recommended to undergo the 
glucose test.  Sequential testing, with up to 5% reduction in sensitivity, is a valid way to 
lower cost.  It must be carefully noted though, that the sequential strategies may not result 
in true positive and specificities that are sufficiently high. 
The risks and consequences in falsely classified tests are many. A Pima Indian 
woman, falsely believing herself to be positive for diabetes, may undergo harmful, 
unnecessary insulin injections to combat a disease she does not have.  Conversely, a Pima 
Indian woman, falsely believing herself to be negative for disease, could avoid insulin 
injections that may be necessary for patient well-being. The sequalae of untreated diabetes 
are many and serious. 
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Chapter 7 
7.1 Discussion  
This research demonstrated the BE strategy as an alternative strategy to the BN and BP 
strategies. When sensitivity was not lowered in any way (q=1), it was shown 
mathematically that for a fixed FPR, the BE strategy’s accuracy would be at least as large 
as the BN strategy’s or the BP strategy’s accuracy, regardless of parameter settings (AUC 
values, standard deviations of the diseased and non-diseased populations, correlation, and 
prevalence). It was found that the BN and the BP strategy were greatly affected by the 
parameter settings. For example, when the ratio of the standard deviations of the diseased 
and non-diseased populations were less than 1 (meaning that the distribution for diseased 
subjects has twice the variability of the distribution of the non-diseased subjects), the BP 
strategy has as much accuracy as the BE strategy and higher than the BN strategy’s 
accuracy.  When the ratio of the standard deviations of the diseased and non-diseased 
populations was greater than 1 (meaning that the distribution of the non-diseased subjects 
has twice the variability of the distribution of the diseased subjects), the BN strategy had as 
much accuracy as the BE strategy and higher than the BP strategy’s accuracy.  Though the 
accuracy of the BN strategy or the BP strategy could equal that of the BE strategy, their 
variability based on the parameter settings makes the BE strategy the best strategy. 
The main focus of this research was to incorporate cost into the evaluation of each 
strategy’s performance. It can be seen that cost played an important role in showing real 
differences between the strategies.  It was shown that the BN strategy could lower the cost 
at low FPRs and that the BP strategy could lower cost at high FPR values. The BE strategy, 
however, lowered cost for both low and high FPR values.  Though for many situations the 
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BE strategy may produce results similar to the BN or the BP strategy for some FPR values, 
its cost was lower overall in both portions. Though for many situations the BE strategy 
produces results similar to the BN strategy or the BP strategy for some FPR values, its cost 
was lower overall in both portions. 
In Chapter 4, one may notice that cost may not be greatly reduced from 1. However, 
Chapter 5 showed that by allowing reduced accuracy by 5% or even 0.1%, cost was greatly 
reduced.  With a slight sacrifice of accuracy, the BE strategy’s cost was greatly decreased, 
as compared to the BN strategy and the BP strategy.  In contrast to the cost with no 
reduction in sensitivity, when the sensitivity was reduced by 0.1%, the cost was reduced 
significantly.  Some exceptions to this have already been acknowledged.  Therefore, a 0.1% 
reduction in sensitivity was recommended, as it could reduce the cost while retaining the 
same sensitivity.  If the second test is expensive or painful for the patient, a reduction of 
5% is recommended.    
           When the 3 strategies were applied to real data, the BE strategy could again be 
described as the best strategy, in terms of accuracy and cost. The diabetes data shown in 
Chapter 6 provided a real world examination of the BE, BN, and BP strategies.  Just as in 
the previous chapters, it was found that the BN and BE strategies were the most 
consistently accurate and least expensive choice. Also the optimal rules found by the BE 
and BN strategies seemed more reasonable than those found by the BP strategy because the 
BE and BN strategies have a lower FPRs. The findings here were recommended for the 
Pima Indian group only.   
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7.2 Limitations 
If a researcher was interested in, for example, the smaller values of FPR, they might choose 
the BN strategy, which may be as low in cost as the BE strategy. The BN strategy, in this 
case, could still be a valid choice, and this researcher does not advise against its use in 
certain circumstances. Another challenge in using the BE strategy was the extensive 
computation required to produce results.  The BN and BP strategies take significantly less 
time than the BE strategy.  If time was an issue to a researcher, they might want to avoid 
using the BE strategy and go with the other strategy with the lower cost.  Furthermore, the 
approach discussed in Chapters 4-6 assumed the tests were normally distributed.  In real 
application, diagnostic tests may not always be distributed normally. This is not an issue if 
the data can be transformed to normality. However, it may not always be possible to find 
appropriate transformations. This may appear as a limitation, but it points the way for 
future work.   
        Another limitation to be considered is that this research only examined the effect of 
certain parameters of AUC values and the diseased and non-diseased standard deviations.  
Other parameters could be considered by future researchers 
        The method used in sequencing the tests is another issue that could change the results 
of this study.  The tests could be sequenced in a variety of different ways.  They could be 
sequenced by cost, by discomfort to patient, or by accuracy (as was done in this research).  
In Chapter 6, the goal was to reduce the number of patients who required Test 2 (glucose), 
which was more painful (blood work) and expensive (processing). A different sequence of 
tests could be considered in future work. 
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7.3 Directions for future research  
The research detailed here concerned combining two continuous tests, but could be 
extended to more than two tests, such as three sequential tests.  Research could be 
conducted using three tests, or more.  In doing that, the strategies could be extended.     
A further avenue for future research is to develop methods to use if it is not possible 
to find a transformation which will make the data follow a normal distribution With 
parametric methods, for example, the assumption that the tests are normally distributed 
need not be made.  In this case, empirical ROC curve would be produced by using the 
observed data.   
This research used q max[TPR( )]θ×   to determine the acceptable accuracy, but 
max[TPR( )]θ -ε  could also be used in which max[TPR( )]θ , is the maximum sensitivity for 
FPR t≤ .  Future researchers could explore the effects of using max[TPR( )]θ -ε .  
Finally, because these techniques were applied to collected data, some estimate of 
precision of costs or thresholds should be made.. Assessing the precision of the optimal 
operating point is an issue that could be considered as future research topic by using  
techniques such as bootstrapping. However, this takes considerable time and resources.  
For example, the diabetes data used in Chapter 6 used a threshold increment of 0.001 (see 
Table 7.1).  The BN strategy, with a threshold increment of 0.001, produced 6,951,451 
thresholds that needed to be evaluated.  Running two-thousand bootstrap samples of this 
size would require 90,000 minutes, or 62.5 days, to process bootstrapping results, not 
including the programming time.  The other strategies also take extensive time, especially 
BE.  It is important to note here that BE requires far more time to process than the other 
strategies because it has 3 rather than 2 thresholds to vary. Assuming a threshold increment 
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of 0.001, BE produced 137,400,549 thresholds that needed to be evaluated.  Processing 
these results would require the proper equipment and an ample amount of time. However, 
the results seen from this could be useful for future research.      
 
Table 7.1:  Estimated time needed to evaluate the three strategies 
Strategy Time1  
 
Thresholds 
increment 
Number of  
thresholds 2  
Number of 
days 3 
BN 45min   0.001 6,951,451 62.5 
BP 36min 0.001 6,951,451 50 
BE 137min
  
0.001 137,400,549
  
190.3  
1 Time needed to run each strategy to produce one MCMROC curve and cost curve 
2 Number of thresholds evaluated to produce one MCMROC curve and cost curve 
3 Number of days needed to run 2000 bootstrap samples to produce 2000 MCMROC curves and cost curves 
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Appendix A 
 
Graphs 
MROC curves and cost curves  
The plot in left panel shows MROC curves, and the two plots in right panel show the cost 
associated with MROC curves when disease prevalence is low (prevalence = 0.1) and when 
disease prevalence is high (prevalence = 0.7), respectively. 
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Figure A1.1a: (b1=1, b2=1) 
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Figure A1.1b: (b1=1, b2=2) 
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Figure A1.1c: (b1=1, b2=0.5) 
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Figure A1.1d: (b1=2, b2=1) 
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Figure A1.1e: (b1=2, b2=2) 
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Figure A1.1f: (b1=2, b2=0.5) 
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Figure A1.1g: (b1=0.5, b2=1) 
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Figure A1.1h: (b1=0.5, b2=2) 
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Figure A1.1i: (b1=0.5, b2=0.5) 
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A1.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure A1.2a: (b1=1, b2=1) 
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Figure A1.2b: (b1=1, b2=2) 
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Figure A1.2c: (b1=1, b2=0.5) 
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Figure A1.2d: (b1=2, b2=1) 
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Figure A1.2e: (b1=2, b2=2) 
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Figure A1.2f: (b1=2, b2=0.5) 
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Figure A1.2g: (b1=0.5, b2=1) 
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Figure A1.2h: (b1=0.5, b2=2) 
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Figure A1.2i: (b1=0.5, b2=0.5) 
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A1.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure A1.3a: (b1=1, b2=1) 
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Figure A1.3b: (b1=1, b2=2) 
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Figure A1.3c: (b1=1, b2=0.5) 
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Figure A1.3d: (b1=2, b2=1) 
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Figure A1.3e: (b1=2, b2=2) 
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Figure A1.3f: (b1=2, b2=0.5) 
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Figure A1.3g: (b1=0.5, b2=1) 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MROC Curves: Area(0.70,0.70)
b1=0.5,b2=2,rD=0,rN=0,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.70)
b1=0.5,b2=2,rD=0,rN=0,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.70)
b1=0.5,b2=2,rD=0,rN=0,Prevalence=0.7
strategy BE BN BP  
Figure A1.3h: (b1=0.5, b2=2) 
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Figure A1.3i: (b1=0.5, b2=0.5) 
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A2  Dependent of the tests ( 0.3, 0.3)D Nρ ρ= =  
A2.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure A2.1a: (b1=1, b2=1) 
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Figure A2.1b: (b1=1, b2=2) 
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Figure A2.1c: (b1=1, b2=0.5) 
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Figure A2.1d: (b1=2, b2=1) 
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Figure A2.1e: (b1=2, b2=2) 
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Figure A2.1f: (b1=2, b2=0.5) 
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Figure A2.1g: (b1=0.5, b2=1) 
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Figure A2.1h: (b1=0.5, b2=2) 
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Figure A2.1i: (b1=0.5, b2=0.5) 
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A2.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure A2.2a: (b1=1, b2=1) 
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Figure A2.2b: (b1=1, b2=2) 
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Figure A2.2c: (b1=1, b2=0.5) 
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Figure A2.2d: (b1=2, b2=1) 
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Figure A2.2e: (b1=2, b2=2) 
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Figure A2.2f: (b1=2, b2=0.5) 
 
156 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MROC Curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.3,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.3,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.3,Prevalence=0.7
strategy BE BN BP  
Figure A2.2g: (b1=0.5, b2=1) 
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Figure A2.2h: (b1=0.5, b2=2) 
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Figure A2.2i: (b1=0.5, b2=0.5) 
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A2.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure A2.3a: (b1=1, b2=1) 
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Figure A2.3b: (b1=1, b2=2) 
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Figure A2.3c: (b1=1, b2=0.5) 
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Figure A2.3d: (b1=2, b2=1) 
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Figure A2.3e: (b1=2, b2=2) 
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Figure A2.3f: (b1=2, b2=0.5) 
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Figure A2.3g: (b1=0.5, b2=1) 
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Figure A2.3h: (b1=0.5, b2=2) 
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Figure A2.3i: (b1=0.5, b2=0.5) 
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A3 Dependent of the tests ( 0.3, 0.7)D Nρ ρ= =  
A3.1 AUC1 = 0.90, AUC2 = 0.90 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MROC Curves: Area(0.90,0.90)
b1=1,b2=1,rD=0.3,rN=0.7,Prevalence=0.1
strategy BE BN BP  
Figure A3.1a: (b1=1, b2=1) 
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Figure A3.1b: (b1=1, b2=2) 
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Figure A3.1c: (b1=1, b2=0.5) 
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Figure A3.1d: (b1=2, b2=1) 
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Figure A3.1e: (b1=2, b2=2) 
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Figure A3.1f: (b1=2, b2=0.5) 
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Figure A3.1g: (b1=0.5, b2=1) 
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Figure A3.1h: (b1=0.5, b2=2) 
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Figure A3.1i: (b1=0.5, b2=0.5) 
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A3.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure A3.2a: (b1=1, b2=1) 
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Figure A3.2b: (b1=1, b2=2) 
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Figure A3.2c: (b1=1, b2=0.5) 
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Figure A3.2d: (b1=2, b2=1) 
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Figure A3.2e: (b1=2, b2=2) 
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Figure A3.2f: (b1=2, b2=0.5) 
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Figure A3.2g: (b1=0.5, b2=1) 
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Figure A3.2h: (b1=0.5, b2=2) 
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Figure A3.2i: (b1=0.5, b2=0.5) 
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A3.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure A3.3a: (b1=1, b2=1) 
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Figure A3.3b: (b1=1, b2=2) 
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Figure A3.3c: (b1=1, b2=0.5) 
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Figure A3.3d: (b1=2, b2=1) 
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Figure A3.3e: (b1=2, b2=2) 
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Figure A3.3f: (b1=2, b2=0.5) 
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Figure A3.3g: (b1=0.5, b2=1) 
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Figure A3.3h: (b1=0.5, b2=2) 
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Figure A3.3i: (b1=0.5, b2=0.5) 
 
 
169 
 
A4 Dependent of the tests ( 0.7, 0.3)D Nρ ρ= =  
A4.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure A4.1a: (b1=1, b2=1) 
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Figure A4.1b: (b1=1, b2=2) 
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Figure A4.1c: (b1=1, b2=0.5) 
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Figure A4.1d: (b1=2, b2=1) 
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Figure A4.1e: (b1=2, b2=2) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MROC Curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.3,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.3,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.3,Prevalence=0.7
strategy BE BN BP  
Figure A4.1f: (b1=2, b2=0.5) 
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Figure A4.1g: (b1=0.5, b2=1) 
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Figure A4.1h: (b1=0.5, b2=2) 
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Figure A4.1i: (b1=0.5, b2=0.5) 
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A4.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure A4.2a: (b1=1, b2=1) 
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Figure A4.2b: (b1=1, b2=2) 
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Figure A4.2c: (b1=1, b2=0.5) 
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Figure A4.2d: (b1=2, b2=1) 
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Figure A4.2e: (b1=2, b2=2) 
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Figure A4.2f: (b1=2, b2=0.5) 
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Figure A4.2g: (b1=0.5, b2=1) 
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Figure A4.2h: (b1=0.5, b2=2) 
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Figure A4.2i: (b1=0.5, b2=0.5) 
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A4.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure A4.3a: (b1=1, b2=1) 
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Figure A4.3b: (b1=1, b2=2) 
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Figure A4.3c: (b1=1, b2=0.5) 
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Figure A4.3d: (b1=2, b2=1) 
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Figure A4.3e: (b1=2, b2=2) 
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Figure A4.3f: (b1=2, b2=0.5) 
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Figure A4.3g: (b1=0.5, b2=1) 
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Figure A4.3h: (b1=0.5, b2=2) 
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Figure A4.3i: (b1=0.5, b2=0.5) 
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A5 Dependent of the tests ( 0.7, 0.7)D Nρ ρ= =  
A5.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure A5.1a: (b1=1, b2=1) 
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Figure A5.1b: (b1=1, b2=2) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MROC Curves: Area(0.90,0.90)
b1=1,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=1,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.1
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=1,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.7
strategy BE BN BP  
Figure A5.1c: (b1=1, b2=0.5) 
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Figure A5.1d: (b1=2, b2=1) 
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Figure A5.1e: (b1=2, b2=2) 
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Figure A5.1f: (b1=2, b2=0.5) 
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Figure A5.1g: (b1=0.5, b2=1) 
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Figure A5.1h: (b1=0.5, b2=2) 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MROC Curves: Area(0.90,0.90)
b1=0.5,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.1
strategy BE BN BP  
Figure A5.1i: (b1=0.5, b2=0.5) 
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A5.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure A5.2a: (b1=1, b2=1) 
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Figure A5.2b: (b1=1, b2=2) 
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Figure A5.2c: (b1=1, b2=0.5) 
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Figure A5.2d: (b1=2, b2=1) 
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Figure A5.2e: (b1=2, b2=2) 
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Figure A5.2f: (b1=2, b2=0.5) 
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Figure A5.2g: (b1=0.5, b2=1) 
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Figure A5.2h: (b1=0.5, b2=2) 
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Figure A5.2i: (b1=0.5, b2=0.5) 
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A5.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure A5.3a: (b1=1, b2=1) 
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Figure A5.3b: (b1=1, b2=2) 
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Figure A5.3c: (b1=1, b2=0.5) 
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Figure A5.3d: (b1=2, b2=1) 
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Figure A5.3e: (b1=2, b2=2) 
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Figure A5.3f: (b1=2, b2=0.5) 
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Figure A5.3g: (b1=0.5, b2=1) 
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Figure A5.3h: (b1=0.5, b2=2) 
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Figure A5.3i: (b1=0.5, b2=0.5) 
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Appendix B 
 
 
Graphs (q=0.999) 
 
The two plots in the top show MCMROC curves and cost curves when disease prevalence 
is low (prevalence = 0.1) and below show MCMROC curves and cost curves when disease 
prevalence is high (prevalence = 0.7). 
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B1 Independent of the tests , B1.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure B1.1a: (b1=1, b2=1) 
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Figure B1.1b: (b1=1, b2=2) 
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Figure B1.1c: (b1=1, b2=0.5) 
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Figure B1.1d: (b1=2, b2=1) 
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Figure B1.1e: (b1=2, b2=2) 
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Figure B1.1f: (b1=2, b2=0.5) 
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Figure B1.1g: (b1=0.5, b2=1) 
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Figure B1.1h: (b1=0.5, b2=2) 
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Figure B1.1i: (b1=0.5, b2=0.5) 
 
 
 
 
194 
 
.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure B1.2a: (b1=1, b2=1) 
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Figure B1.2b: (b1=1, b2=2) 
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Figure B1.2c: (b1=1, b2=0.5) 
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Figure B1.2d: (b1=2, b2=1) 
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Figure B1.2e: (b1=2, b2=2) 
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Figure B1.2f: (b1=2, b2=0.5) 
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Figure B1.2g: (b1=0.5, b2=1) 
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Figure B1.2h: (b1=0.5, b2=2) 
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Figure B1.2i: (b1=0.5, b2=0.5) 
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B1.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure B1.3a: (b1=1, b2=1) 
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Figure B1.3b: (b1=1, b2=2) 
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Figure B1.3c: (b1=1, b2=0.5) 
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Figure B1.3d: (b1=2, b2=1) 
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Figure B1.3e: (b1=2, b2=2) 
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Figure B1.3f: (b1=2, b2=0.5) 
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Figure B1.3g: (b1=0.5, b2=1) 
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Figure B1.3h: (b1=0.5, b2=2) 
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Figure B1.3i: (b1=0.5, b2=0.5) 
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B2 Dependent of the tests ( 0.3, 0.3)D Nρ ρ= =  
B2.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure B2.1a: (b1=1, b2=1) 
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Figure B2.1b: (b1=1, b2=2) 
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Figure B2.1c: (b1=1, b2=0.5) 
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Figure B2.1d: (b1=2, b2=1) 
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Figure B2.1e: (b1=2, b2=2) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.3,rN=0.3,Prevalence=0.1,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.3,rN=0.3,Prevalence=0.1,q=0.999
strategy BE BN BP  
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.3,rN=0.3,Prevalence=0.7,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=2,b2=0.5,rD=0.3,rN=0.3,Prevalence=0.7,q=0.999
strategy BE BN BP  
Figure B2.1f: (b1=2, b2=0.5) 
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Figure B2.1g: (b1=0.5, b2=1) 
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Figure B2.1h: (b1=0.5, b2=2) 
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Figure B2.1i: (b1=0.5, b2=0.5) 
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B2.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure B2.2a: (b1=1, b2=1) 
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Figure B2.2b: (b1=1, b2=2) 
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Figure B2.2c: (b1=1, b2=0.5) 
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Figure B2.2d: (b1=2, b2=1) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=2,b2=2,rD=0.3,rN=0.3,Prevalence=0.1,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=2,b2=2,rD=0.3,rN=0.3,Prevalence=0.1,q=0.999
strategy BE BN BP  
215 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=2,b2=2,rD=0.3,rN=0.3,Prevalence=0.7,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=2,b2=2,rD=0.3,rN=0.3,Prevalence=0.7,q=0.999
strategy BE BN BP  
Figure B2.2e: (b1=2, b2=2) 
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Figure B2.2f: (b1=2, b2=0.5) 
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Figure B2.2g: (b1=0.5, b2=1) 
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Figure B2.2h: (b1=0.5, b2=2) 
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Figure B2.2i: (b1=0.5, b2=0.5) 
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B2.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure B2.3a: (b1=1, b2=1) 
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Figure B2.3b: (b1=1, b2=2) 
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Figure B2.3c: (b1=1, b2=0.5) 
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Figure B2.3d: (b1=2, b2=1) 
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Figure B2.3e: (b1=2, b2=2) 
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Figure B2.3f: (b1=2, b2=0.5) 
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Figure B2.3g: (b1=0.5, b2=1) 
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Figure B2.3h: (b1=0.5, b2=2) 
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Figure B2.3i: (b1=0.5, b2=0.5) 
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B3 Dependent of the tests ( 0.3, 0.7)D Nρ ρ= =  
B3.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure B3.1a: (b1=1, b2=1) 
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Figure B3.1b: (b1=1, b2=2) 
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Figure B3.1c: (b1=1, b2=0.5) 
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Figure B3.1d: (b1=2, b2=1) 
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Figure B3.1e: (b1=2, b2=2) 
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Figure B3.1f: (b1=2, b2=0.5) 
 
228 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.90,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.7,Prevalence=0.1,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.7,Prevalence=0.1,q=0.999
strategy BE BN BP  
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.90,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.7,Prevalence=0.7,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=0.5,b2=1,rD=0.3,rN=0.7,Prevalence=0.7,q=0.999
strategy BE BN BP  
Figure B3.1g: (b1=0.5, b2=1)  
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Figure B3.1h: (b1=0.5, b2=2) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.90,0.90)
b1=0.5,b2=0.5,rD=0.3,rN=0.7,Prevalence=0.1,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=0.5,b2=0.5,rD=0.3,rN=0.7,Prevalence=0.1,q=0.999
strategy BE BN BP  
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.90,0.90)
b1=0.5,b2=0.5,rD=0.3,rN=0.7,Prevalence=0.7,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.90,0.90)
b1=0.5,b2=0.5,rD=0.3,rN=0.7,Prevalence=0.7,q=0.999
strategy BE BN BP  
Figure B3.1i: (b1=0.5, b2=0.5) 
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B3.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure B3.2a: (b1=1, b2=1) 
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Figure B3.2b: (b1=1, b2=2) 
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Figure B3.2c: (b1=1, b2=0.5) 
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Figure B3.2d: (b1=2, b2=1) 
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Figure B3.2e: (b1=2, b2=2) 
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Figure B3.2f: (b1=2, b2=0.5) 
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Figure B3.2g: (b1=0.5, b2=1) 
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Figure B3.2h: (b1=0.5, b2=2) 
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Figure B3.2i: (b1=0.5, b2=0.5) 
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B3.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure B3.3a: (b1=1, b2=1) 
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Figure B3.3b: (b1=1, b2=2) 
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Figure B3.3c: (b1=1, b2=0.5) 
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Figure B3.3d: (b1=2, b2=1) 
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Figure B3.3e: (b1=2, b2=2) 
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Figure B3.3f: (b1=2, b2=0.5) 
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Figure B3.3g: (b1=0.5, b2=1) 
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Figure B3.3h: (b1=0.5, b2=2) 
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Figure B3.3i: (b1=0.5, b2=0.5) 
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B4 Dependent of the tests ( 0.7, 0.3)D Nρ ρ= =  
B4.1 AUC1 = 0.90, AUC2 = 0.90 
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Figure B4.1a: (b1=1, b2=1) 
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Figure B4.1b: (b1=1, b2=2) 
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Figure B4.1c: (b1=1, b2=0.5) 
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Figure B4.1d: (b1=2, b2=1) 
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Figure B4.1e: (b1=2, b2=2) 
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Figure B4.1f: (b1=2, b2=0.5) 
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Figure B4.1g: (b1=0.5, b2=1)  
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Figure B4.1h: (b1=0.5, b2=2) 
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Figure B4.1i: (b1=0.5, b2=0.5) 
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B4.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure B4.2a: (b1=1, b2=1) 
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Figure B4.2b: (b1=1, b2=2) 
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Figure B4.2c: (b1=1, b2=0.5) 
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Figure B4.2d: (b1=2, b2=1) 
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Figure B4.2e: (b1=2, b2=2) 
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Figure B4.2f: (b1=2, b2=0.5) 
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Figure B4.2g: (b1=0.5, b2=1) 
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Figure B4.2h: (b1=0.5, b2=2) 
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Figure B4.2i: (b1=0.5, b2=0.5) 
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B4.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure B4.3a: (b1=1, b2=1) 
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Figure B4.3b: (b1=1, b2=2) 
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Figure B4.3c: (b1=1, b2=0.5) 
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Figure B4.3d: (b1=2, b2=1) 
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Figure B4.3e: (b1=2, b2=2) 
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Figure B4.3f: (b1=2, b2=0.5) 
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Figure B4.3g: (b1=0.5, b2=1) 
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Figure B4.3h: (b1=0.5, b2=2) 
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Figure B4.3i: (b1=0.5, b2=0.5) 
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B5  Dependent of the tests ( 0.7, 0.7)D Nρ ρ= =  
B5 .1 AUC1 = 0.90, AUC2 = 0.90 
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Figure B5 .1a: (b1=1, b2=1) 
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Figure B5 .1b: (b1=1, b2=2) 
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Figure B5 .1c: (b1=1, b2=0.5) 
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Figure B5 .1d: (b1=2, b2=1) 
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Figure B5 .1e: (b1=2, b2=2) 
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Figure B5 .1f: (b1=2, b2=0.5) 
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Figure B5 .1g: (b1=0.5, b2=1)  
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Figure B5 .1h: (b1=0.5, b2=2) 
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Figure B5 .1i: (b1=0.5, b2=0.5) 
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B5 .2 AUC1 = 0.70, AUC2 = 0.90 
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Figure B5 .2a: (b1=1, b2=1) 
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Figure B5 .2b: (b1=1, b2=2) 
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Figure B5 .2c: (b1=1, b2=0.5) 
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Figure B5 .2d: (b1=2, b2=1) 
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Figure B5 .2e: (b1=2, b2=2) 
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Figure B5 .2f: (b1=2, b2=0.5) 
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Figure B5 .2g: (b1=0.5, b2=1) 
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Figure B5 .2h: (b1=0.5, b2=2) 
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Figure B5 .2i: (b1=0.5, b2=0.5) 
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B5 .3 AUC1 = 0.70, AUC2 = 0.70 
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Figure B5 .3a: (b1=1, b2=1) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.70)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.1,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.70)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.1,q=0.999
strategy BE BN BP  
273 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.70)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.7,q=0.999
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.70)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.7,q=0.999
strategy BE BN BP  
Figure B5 .3b: (b1=1, b2=2) 
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Figure B5 .3c: (b1=1, b2=0.5) 
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Figure B5 .3d: (b1=2, b2=1) 
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Figure B5 .3e: (b1=2, b2=2) 
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Figure B5 .3f: (b1=2, b2=0.5) 
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Figure B5 .3g: (b1=0.5, b2=1) 
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Figure B5 .3h: (b1=0.5, b2=2) 
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Figure B5 .3i: (b1=0.5, b2=0.5) 
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Appendix C 
 
Graphs (q=0.95) 
 
The two plots in the top show MCMROC curves and cost curves when disease prevalence 
is low (prevalence = 0.1) and below show MCMROC curves and cost curves when disease 
prevalence is high (prevalence = 0.7). 
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Figure C1.1a: (b1=1, b2=1) 
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Figure C1.1b: (b1=1, b2=2) 
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Figure C1.1c: (b1=1, b2=0.5) 
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Figure C1.1d: (b1=2, b2=1) 
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Figure C1.1e: (b1=2, b2=2) 
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Figure C1.1f: (b1=2, b2=0.5) 
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Figure C1.1g: (b1=0.5, b2=1) 
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Figure C1.1h: (b1=0.5, b2=2) 
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Figure C1.1i: (b1=0.5, b2=0.5) 
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C1.2 AUC1 = 0.70, AUC2 = 0.90 
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Figure C1.2a: (b1=1, b2=1) 
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Figure C1.2b: (b1=1, b2=2) 
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Figure C1.2c: (b1=1, b2=0.5) 
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Figure C1.2d: (b1=2, b2=1) 
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Figure C1.2e: (b1=2, b2=2) 
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Figure C1.2f: (b1=2, b2=0.5) 
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Figure C1.2g: (b1=0.5, b2=1) 
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Figure C1.2h: (b1=0.5, b2=2) 
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Figure C1.2i: (b1=0.5, b2=0.5) 
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C1.3 AUC1 = 0.70, AUC2 = 0.70 
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Figure C1.3a: (b1=1, b2=1) 
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Figure C1.3b: (b1=1, b2=2) 
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Figure C1.3c: (b1=1, b2=0.5) 
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Figure C1.3d: (b1=2, b2=1) 
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Figure C1.3e: (b1=2, b2=2) 
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Figure C1.3f: (b1=2, b2=0.5) 
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Figure C1.3g: (b1=0.5, b2=1) 
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Figure C1.3h: (b1=0.5, b2=2) 
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Figure C1.3i: (b1=0.5, b2=0.5) 
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C2 Dependent of the tests ( 0.3, 0.3)D Nρ ρ= =  
C2. 1 AUC1 = 0.90, AUC2 = 0.90 
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Figure C2. 1a: (b1=1, b2=1) 
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Figure C2. 1b: (b1=1, b2=2) 
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Figure C2. 1c: (b1=1, b2=0.5) 
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Figure C2. 1d: (b1=2, b2=1) 
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Figure C2. 1e: (b1=2, b2=2) 
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Figure C2. 1f: (b1=2, b2=0.5) 
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Figure C2. 1g: (b1=0.5, b2=1) 
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Figure C2. 1h: (b1=0.5, b2=2) 
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Figure C2. 1i: (b1=0.5, b2=0.5) 
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C2. 2 AUC1 = 0.70, AUC2 = 0.90 
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Figure C2. 2a: (b1=1, b2=1) 
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Figure C2. 2b: (b1=1, b2=2) 
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Figure C2. 2c: (b1=1, b2=0.5) 
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Figure C2. 2d: (b1=2, b2=1) 
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Figure C2. 2e: (b1=2, b2=2) 
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Figure C2. 2f: (b1=2, b2=0.5) 
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Figure C2. 2g: (b1=0.5, b2=1) 
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Figure C2. 2h: (b1=0.5, b2=2) 
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Figure C2. 2i: (b1=0.5, b2=0.5) 
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C2. 3 AUC1 = 0.70, AUC2 = 0.70 
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Figure C2. 3a: (b1=1, b2=1) 
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Figure C2. 3b: (b1=1, b2=2) 
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Figure C2. 3c: (b1=1, b2=0.5) 
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Figure C2. 3d: (b1=2, b2=1) 
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Figure C2. 3e: (b1=2, b2=2) 
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Figure C2. 3f: (b1=2, b2=0.5) 
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Figure C2. 3g: (b1=0.5, b2=1) 
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Figure C2. 3h: (b1=0.5, b2=2) 
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Figure C2. 3i: (b1=0.5, b2=0.5) 
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C3 Dependent of the tests ( 0.3, 0.7)D Nρ ρ= =  
C3. 1 AUC1 = 0.90, AUC2 = 0.90 
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Figure C3. 1a: (b1=1, b2=1) 
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Figure C3. 1b: (b1=1, b2=2) 
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Figure C3. 1c: (b1=1, b2=0.5) 
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Figure C3. 1d: (b1=2, b2=1) 
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Figure C3. 1e: (b1=2, b2=2) 
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Figure C3. 1f: (b1=2, b2=0.5) 
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Figure C3. 1g: (b1=0.5, b2=1) 
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Figure C3. 1h: (b1=0.5, b2=2) 
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Figure C3. 1i: (b1=0.5, b2=0.5) 
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C3. 2 AUC1 = 0.70, AUC2 = 0.90 
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Figure C3. 2a: (b1=1, b2=1) 
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Figure C3. 2b: (b1=1, b2=2) 
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Figure C3. 2c: (b1=1, b2=0.5) 
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Figure C3. 2d: (b1=2, b2=1) 
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Figure C3. 2e: (b1=2, b2=2) 
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Figure C3. 2f: (b1=2, b2=0.5) 
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Figure C3. 2g: (b1=0.5, b2=1) 
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Figure C3. 2h: (b1=0.5, b2=2) 
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Figure C3. 2i: (b1=0.5, b2=0.5) 
 
 
 
 
327 
 
 
C3. 3 AUC1 = 0.70, AUC2 = 0.70 
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Figure C3. 3a: (b1=1, b2=1) 
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Figure C3. 3b: (b1=1, b2=2) 
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Figure C3. 3c: (b1=1, b2=0.5) 
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Figure C3. 3d: (b1=2, b2=1) 
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Figure C3. 3e: (b1=2, b2=2) 
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Figure C3. 3f: (b1=2, b2=0.5) 
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Figure C3. 3g: (b1=0.5, b2=1) 
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Figure C3. 3h: (b1=0.5, b2=2) 
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Figure C3. 3i: (b1=0.5, b2=0.5) 
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C4 Dependent of the tests ( 0.7, 0.3)D Nρ ρ= =  
C4. 1 AUC1 = 0.90, AUC2 = 0.90 
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Figure C4. 1a: (b1=1, b2=1) 
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Figure C4. 1b: (b1=1, b2=2) 
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Figure C4. 1c: (b1=1, b2=0.5) 
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Figure C4. 1d: (b1=2, b2=1) 
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Figure C4. 1e: (b1=2, b2=2) 
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Figure C4. 1f: (b1=2, b2=0.5) 
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Figure C4. 1g: (b1=0.5, b2=1) 
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Figure C4. 1h: (b1=0.5, b2=2) 
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Figure C4. 1i: (b1=0.5, b2=0.5) 
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C4. 2 AUC1 = 0.70, AUC2 = 0.90 
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Figure C4. 2a: (b1=1, b2=1) 
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Figure C4. 2b: (b1=1, b2=2) 
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Figure C4. 2c: (b1=1, b2=0.5) 
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Figure C4. 2d: (b1=2, b2=1) 
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Figure C4. 2e: (b1=2, b2=2) 
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Figure C4. 2f: (b1=2, b2=0.5) 
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Figure C4. 2g: (b1=0.5, b2=1) 
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Figure C4. 2h: (b1=0.5, b2=2) 
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Figure C4. 2i: (b1=0.5, b2=0.5) 
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C4. 3 AUC1 = 0.70, AUC2 = 0.70 
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Figure C4. 3a: (b1=1, b2=1) 
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Figure C4. 3b: (b1=1, b2=2) 
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Figure C4. 3c: (b1=1, b2=0.5) 
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Figure C4. 3d: (b1=2, b2=1) 
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Figure C4. 3e: (b1=2, b2=2) 
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Figure C4. 3f: (b1=2, b2=0.5) 
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Figure C4. 3g: (b1=0.5, b2=1) 
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Figure C4. 3h: (b1=0.5, b2=2) 
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Figure C4. 3i: (b1=0.5, b2=0.5) 
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C5 Dependent of the tests ( 0.7, 0.7)D Nρ ρ= =  
C5. 1 AUC1 = 0.90, AUC2 = 0.90 
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Figure C5. 1a: (b1=1, b2=1) 
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Figure C5. 1b: (b1=1, b2=2) 
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Figure C5. 1c: (b1=1, b2=0.5) 
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Figure C5. 1d: (b1=2, b2=1) 
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Figure C5. 1e: (b1=2, b2=2) 
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Figure C5. 1f: (b1=2, b2=0.5) 
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Figure C5. 1g: (b1=0.5, b2=1) 
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Figure C5. 1h: (b1=0.5, b2=2) 
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Figure C5. 1i: (b1=0.5, b2=0.5) 
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. 2 AUC1 = 0.70, AUC2 = 0.90 
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Figure C5. 2a: (b1=1, b2=1) 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.1,q=0.95
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.1,q=0.95
strategy BE BN BP  
358 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.7,q=0.95
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=1,b2=2,rD=0.7,rN=0.7,Prevalence=0.7,q=0.95
strategy BE BN BP  
Figure C5. 2b: (b1=1, b2=2) 
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Figure C5. 2c: (b1=1, b2=0.5) 
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Figure C5. 2d: (b1=2, b2=1) 
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Figure C5. 2e: (b1=2, b2=2) 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.1,q=0.95
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.1,q=0.95
strategy BE BN BP  
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.7,q=0.95
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=2,b2=0.5,rD=0.7,rN=0.7,Prevalence=0.7,q=0.95
strategy BE BN BP  
Figure C5. 2f: (b1=2, b2=0.5) 
 
361 
 
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.7,rN=0.7,Prevalence=0.1,q=0.95
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.7,rN=0.7,Prevalence=0.1,q=0.95
strategy BE BN BP  
Sensitivity
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
MCMROC Curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.7,rN=0.7,Prevalence=0.7,q=0.95
strategy BE BN BP
cost
0.0
0.2
0.4
0.6
0.8
1.0
FPR
0.0 0.2 0.4 0.6 0.8 1.0
Cost curves: Area(0.70,0.90)
b1=0.5,b2=1,rD=0.7,rN=0.7,Prevalence=0.7,q=0.95
strategy BE BN BP  
Figure C5. 2g: (b1=0.5, b2=1) 
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Figure C5. 2h: (b1=0.5, b2=2) 
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Figure C5. 2i: (b1=0.5, b2=0.5) 
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C5. 3 AUC1 = 0.70, AUC2 = 0.70 
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Figure C5. 3a: (b1=1, b2=1) 
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Figure C5. 3b: (b1=1, b2=2) 
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Figure C5. 3c: (b1=1, b2=0.5) 
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Figure C5. 3d: (b1=2, b2=1) 
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Figure C5. 3e: (b1=2, b2=2) 
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Figure C5. 3f: (b1=2, b2=0.5) 
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Figure C5. 3g: (b1=0.5, b2=1) 
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Figure C5. 3h: (b1=0.5, b2=2) 
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Figure C5. 3i: (b1=0.5, b2=0.5) 
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D1: Define permanent SAS formats  
 
libname FORMAT 'C:\project'; 
run; 
proc format LIBRARY = FORMAT ;  
value lessthan (multilabel) 
0-0.005 = '<=0.005' 
0-0.01 = '<=0.01' 
0-0.015 = '<=0.015' 
0-0.02 = '<=0.02' 
0-0.025 = '<=0.025' 
0-0.03 = '<=0.03' 
0-0.035 = '<=0.035' 
0-0.04 = '<=0.04' 
0-0.045 = '<=0.045' 
0-0.05 = '<=0.05' 
0-0.055 = '<=0.055' 
0-0.06 = '<=0.06' 
0-0.065 = '<=0.065' 
0-0.07 = '<=0.07' 
0-0.075 = '<=0.075' 
0-0.08 = '<=0.08' 
0-0.085 = '<=0.085' 
0-0.09 = '<=0.09' 
0-0.095 = '<=0.095' 
0-0.10 = '<=0.1' 
0-0.105 = '<=0.105' 
0-0.11 = '<=0.11' 
0-0.115 = '<=0.115' 
0-0.12 = '<=0.12' 
0-0.125 = '<=0.125' 
0-0.13 = '<=0.13' 
0-0.135 = '<=0.135' 
0-0.14 = '<=0.14' 
0-0.145 = '<=0.145' 
0-0.15 = '<=0.15' 
0-0.155 = '<=0.155' 
0-0.16 = '<=0.16' 
0-0.165 = '<=0.165' 
0-0.17 = '<=0.17' 
0-0.175 = '<=0.175' 
0-0.18 = '<=0.18' 
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0-0.185 = '<=0.185' 
0-0.19 = '<=0.19' 
0-0.195 = '<=0.195' 
0-0.2       = '<=0.2' 
0-0.205 = '<=0.205' 
0-0.21 = '<=0.21' 
0-0.215 = '<=0.215' 
0-0.22 = '<=0.22' 
0-0.225 = '<=0.225' 
0-0.23 = '<=0.23' 
0-0.235 = '<=0.235' 
0-0.24 = '<=0.24' 
0-0.245 = '<=0.245' 
0-0.25 = '<=0.25' 
0-0.255 = '<=0.255' 
0-0.26 = '<=0.26' 
0-0.265 = '<=0.265' 
0-0.27 = '<=0.27' 
0-0.275 = '<=0.275' 
0-0.28 = '<=0.28' 
0-0.285 = '<=0.285' 
0-0.29 = '<=0.29' 
0-0.295 = '<=0.295' 
0-0.30 = '<=0.3' 
0-0.305 = '<=0.305' 
0-0.31 = '<=0.31' 
0-0.315 = '<=0.315' 
0-0.32 = '<=0.32' 
0-0.325 = '<=0.325' 
0-0.33 = '<=0.33' 
0-0.335 = '<=0.335' 
0-0.34 = '<=0.34' 
0-0.345 = '<=0.345' 
0-0.35 = '<=0.35' 
0-0.355 = '<=0.355' 
0-0.36 = '<=0.36' 
0-0.365 = '<=0.365' 
0-0.37 = '<=0.37' 
0-0.375 = '<=0.375' 
0-0.38 = '<=0.38' 
0-0.385 = '<=0.385' 
0-0.39 = '<=0.39' 
0-0.395 = '<=0.395' 
0-0.40 = '<=0.4' 
0-0.405 = '<=0.405' 
0-0.41 = '<=0.41' 
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0-0.415 = '<=0.415' 
0-0.42 = '<=0.42' 
0-0.425 = '<=0.425' 
0-0.43 = '<=0.43' 
0-0.435 = '<=0.435' 
0-0.44 = '<=0.44' 
0-0.445 = '<=0.445' 
0-0.45 = '<=0.45' 
0-0.455 = '<=0.455' 
0-0.46 = '<=0.46' 
0-0.465 = '<=0.465' 
0-0.47 = '<=0.47' 
0-0.475 = '<=0.475' 
0-0.48 = '<=0.48' 
0-0.485 = '<=0.485' 
0-0.49 = '<=0.49' 
0-0.495 = '<=0.495' 
0-0.50 = '<=0.50' 
0-0.505 = '<=0.505' 
0-0.51 = '<=0.51' 
0-0.515 = '<=0.515' 
0-0.52 = '<=0.52' 
0-0.525 = '<=0.525' 
0-0.53 = '<=0.53' 
0-0.535 = '<=0.535' 
0-0.54 = '<=0.54' 
0-0.545 = '<=0.545' 
0-0.55 = '<=0.55' 
0-0.555 = '<=0.555' 
0-0.56 = '<=0.56' 
0-0.565 = '<=0.565' 
0-0.57 = '<=0.57' 
0-0.575 = '<=0.575' 
0-0.58 = '<=0.58' 
0-0.585 = '<=0.585' 
0-0.59 = '<=0.59' 
0-0.595 = '<=0.595' 
0-0.60 = '<=0.6' 
0-0.605 = '<=0.605' 
0-0.61 = '<=0.61' 
0-0.615 = '<=0.615' 
0-0.62 = '<=0.62' 
0-0.625 = '<=0.625' 
0-0.63 = '<=0.63' 
0-0.635 = '<=0.635' 
0-0.64 = '<=0.64' 
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0-0.645 = '<=0.645' 
0-0.65 = '<=0.65' 
0-0.655 = '<=0.655' 
0-0.66 = '<=0.66' 
0-0.665 = '<=0.665' 
0-0.67 = '<=0.67' 
0-0.675 = '<=0.675' 
0-0.68 = '<=0.68' 
0-0.685 = '<=0.685' 
0-0.69 = '<=0.69' 
0-0.695 = '<=0.695' 
0-0.70 = '<=0.7' 
0-0.705 = '<=0.705' 
0-0.71 = '<=0.71' 
0-0.715 = '<=0.715' 
0-0.72 = '<=0.72' 
0-0.725 = '<=0.725' 
0-0.73 = '<=0.73' 
0-0.735 = '<=0.735' 
0-0.74 = '<=0.74' 
0-0.745 = '<=0.745' 
0-0.75 = '<=0.75' 
0-0.755 = '<=0.755' 
0-0.76 = '<=0.76' 
0-0.765 = '<=0.765' 
0-0.77 = '<=0.77' 
0-0.775 = '<=0.775' 
0-0.78 = '<=0.78' 
0-0.785 = '<=0.785' 
0-0.79 = '<=0.79' 
0-0.795 = '<=0.795' 
0-0.80 = '<=0.8' 
0-0.805 = '<=0.805' 
0-0.81 = '<=0.81' 
0-0.815 = '<=0.815' 
0-0.82 = '<=0.82' 
0-0.825 = '<=0.825' 
0-0.83 = '<=0.83' 
0-0.835 = '<=0.835' 
0-0.84 = '<=0.84' 
0-0.845 = '<=0.845' 
0-0.85 = '<=0.85' 
0-0.855 = '<=0.855' 
0-0.86 = '<=0.86' 
0-0.865 = '<=0.865' 
0-0.87 = '<=0.87' 
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0-0.875 = '<=0.875' 
0-0.88 = '<=0.88' 
0-0.885 = '<=0.885' 
0-0.89 = '<=0.89' 
0-0.895 = '<=0.895' 
0-0.900 =  '<=0.9' 
0-0.905 = '<=0.905' 
0-0.91 = '<=0.91' 
0-0.915 = '<=0.915' 
0-0.92 = '<=0.92' 
0-0.925 = '<=0.925' 
0-0.93 = '<=0.93' 
0-0.935 = '<=0.935' 
0-0.94 = '<=0.94' 
0-0.945 = '<=0.945' 
0-0.95 = '<=0.95' 
0-0.955 = '<=0.955' 
0-0.96 = '<=0.96' 
0-0.965 = '<=0.965' 
0-0.97 = '<=0.97' 
0-0.975 = '<=0.975' 
0-0.98 = '<=0.98' 
0-0.985 = '<=0.985' 
0-0.99 = '<=0.99' 
0-0.995 = '<=0.995' 
0-1.00 = '<=1';run; 
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D2: Generating MROC/MCMROC and cost curves 
 
libname bios 'C:\ project \r0r0\90_90\b1b1';run; 
LIBNAME FRMT 'C:\ project';run; 
OPTIONS FMTSEARCH=(FRMT);run; 
********************************************BP*****; 
data rocBP; 
do c1=-3 to 4.81 by 0.04; 
do c2=-3 to 4.81 by 0.04; 
Sensitivity = 1-probbnrm((c1-1.81)/1,(c2-1.81)/1, 0); 
FP = 1-probbnrm((c1-0)/1,(c2-0)/1, 0); 
FPR = ceil(FP*200)/200 + (FP=0); 
costp01 = (probnorm((c1-1.81)/1 ))* 0.1 + (probnorm((c1-0)/1 ))*(1-0.1) ; 
costp07 = (probnorm((c1-1.81)/1 ))* 0.7 + (probnorm((c1-0)/1 ))*(1-0.7) ; 
output; 
end; 
end; 
run;quit; 
proc sort data=rocBP; by FP;run; 
proc means data=rocBP max noprint nway;   
var Sensitivity; class FP ;  
output out=mrocBP (drop=_type_ _freq_ FP) 
    max=MTPR 
    maxid(Sensitivity(c1))=c1  
       maxid(Sensitivity(c2))=c2 
       maxid(Sensitivity(Sensitivity))=Sensitivity 
       maxid(Sensitivity(costp01))=costp01 
       maxid(Sensitivity(costp07))=costp07; 
format FP lessthan.; 
run; 
data mrocBP;set mrocBP;FPR=_n_/200;run;  
/*********************** MCMROC*******************/ 
proc sort data=rocBP; by FPR;run; 
proc sort data=mrocBP; by FPR ;run; 
data mrocBPq; 
merge rocBP mrocBP; 
by FPR; 
run; 
**************q=1 PREV=0.1**************************; 
data mrocBPq1;  
set mrocBPq ; 
TPRmaxq = 1 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
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proc sort data=mrocBPq1; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBPq1  min noprint nway;   
var costp01; class FP ;   
output out=mincq1BPp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; ******************q=1 PREV=0.7**************************; 
proc sort data=mrocBPq1; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBPq1  min noprint nway;   
var costp07; class FP ;   
output out=mincq1BPp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
*****************q=0.95 PREV=0.1******; 
data mrocBPq95;  
set mrocBPq ; 
TPRmaxq = 0.95 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
proc sort data=mrocBPq95; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBPq95  min noprint nway;   
var costp01; class FP ;   
output out=mincq95BPp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
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run; 
**********************************************q=1 PREV=0.7***; 
proc sort data=mrocBPq95; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBPq95  min noprint nway;   
var costp07; class FP ;   
output out=mincq95BPp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
********************************************BN*****; 
data rocBN; 
do c1=-3 to 4.81 by 0.04; 
do c2=-3 to 4.81 by 0.04; 
Sensitivity = 1-cdf('NORMAL',(c1-1.81)/1 ,0,1)-cdf('NORMAL',(c2-1.81)/1 ,0,1) + 
probbnrm((c1-1.81)/1,(c2-1.81)/1, 0); 
FP = 1-cdf('NORMAL',(c1-0)/1 ,0,1)-cdf('NORMAL',(c2-0)/1 ,0,1) + probbnrm((c1-
0)/1,(c2-0)/1, 0); 
FPR = ceil(FP*200)/200 + (FP=0); 
costp01 = (1-probnorm((c1-1.81)/1 )) * 0.1 +  (1-probnorm((c1-0)/1 ))*(1-0.1) ; 
costp07 = (1-probnorm((c1-1.81)/1 )) * 0.7 +  (1-probnorm((c1-0)/1 ))*(1-0.7) ; 
output; 
end; 
end; 
run; 
proc sort data=rocBN; by FP;run; 
proc means data=rocBN max noprint nway;   
var Sensitivity; class FP / mlf;  
output out=mrocBN (drop=_type_ _freq_ FP) 
    max=MTPR 
    maxid(Sensitivity(c1))=c1  
       maxid(Sensitivity(c2))=c2 
       maxid(Sensitivity(Sensitivity))=Sensitivity 
       maxid(Sensitivity(costp01))=costp01 
       maxid(Sensitivity(costp07))=costp07; 
format FP lessthan.; 
run; 
data mrocBN;set mrocBN;FPR=_n_/200;run;  
/**************************************** MCMROC****/ 
proc sort data=rocBN; by FPR;run; 
proc sort data=mrocBN; by FPR ;run; 
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data mrocBNq; 
merge rocBN mrocBN; 
by FPR; 
run; 
**********************************************q=1 PREV=0.1***; 
data mrocBNq1;  
set mrocBNq ; 
TPRmaxq = 1 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
proc sort data=mrocBNq1; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBNq1  min noprint nway;   
var costp01; class FP ;   
output out=mincq1BNp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************************************q=1 PREV=0.7*****; 
proc sort data=mrocBNq1; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBNq1  min noprint nway;   
var costp07; class FP ;   
output out=mincq1BNp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************************************q=0.95 PREV=0.1*****; 
data mrocBNq95;  
set mrocBNq ; 
TPRmaxq = 0.95 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
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run; 
proc sort data=mrocBNq95; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBNq95  min noprint nway;   
var costp01; class FP ;   
output out=mincq95BNp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
********************q=1 PREV=0.7**********************; 
proc sort data=mrocBNq95; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBNq95  min noprint nway;   
var costp07; class FP ;   
output out=mincq95BNp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
 
******BE*************************************************************; 
data rocBE; 
do c1=-3 to 4.81 by 0.04; 
do c2=-3 to c1 by 0.04; 
do c3=-3 to 4.81 by 0.04; 
Sensitivity = 1-cdf('NORMAL',(c2-1.81)/1 ,0,1) + probbnrm((c2-1.81)/1,(c3-1.81)/1, 0) - 
probbnrm((c1-1.81)/1,(c3-1.81)/1, 0); 
FP = 1-cdf('NORMAL',(c2-0)/1 ,0,1) + probbnrm((c2-0)/1,(c3-0)/1, 0) - probbnrm((c1-
0)/1,(c3-0)/1, 0); 
FPR = ceil(FP*200)/200 + (FP=0); 
costp01 =(probnorm((c1-1.81)/1 )-probnorm((c2-1.81)/1 ))*0.1 + (probnorm((c1-0)/1 )-
probnorm((c2-0)/1 ))*(1-0.1) ; 
costp07 =(probnorm((c1-1.81)/1 )-probnorm((c2-1.81)/1 ))*0.7 + (probnorm((c1-0)/1 )-
probnorm((c2-0)/1 ))*(1-0.7) ; 
output; 
end; 
end; 
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end; 
run; 
proc sort data=rocBE; by FP;run; 
proc means data=rocBE max noprint nway;   
var Sensitivity; class FP / mlf;  
output out=mrocBE (drop=_type_ _freq_ FP) 
    max=MTPR 
    maxid(Sensitivity(c1))=c1  
       maxid(Sensitivity(c2))=c2 
    maxid(Sensitivity(c3))=c3 
       maxid(Sensitivity(Sensitivity))=Sensitivity 
       maxid(Sensitivity(costp01))=costp01 
       maxid(Sensitivity(costp07))=costp07; 
format FP lessthan.; 
run; 
data mrocBE;set mrocBE;FPR=_n_/200;run;  
/**************************************** MCMROC*****/ 
proc sort data=rocBE; by FPR;run; 
proc sort data=mrocBE; by FPR ;run; 
data mrocBEq; 
merge rocBE mrocBE; 
by FPR; 
run; 
**********************************************q=1 PREV=0.1*********; 
data mrocBEq1;  
set mrocBEq ; 
TPRmaxq = 1 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
proc sort data=mrocBEq1; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBEq1  min noprint nway;   
var costp01; class FP ;   
output out=mincq1BEp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(c3))=c3 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
*******************q=1 PREV=0.7***********************************; 
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proc sort data=mrocBEq1; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBEq1  min noprint nway;   
var costp07; class FP ;   
output out=mincq1BEp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
 minid(costp01(c3))=c3 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
************q=0.95 PREV=0.1********************************; 
data mrocBEq95;  
set mrocBEq ; 
TPRmaxq = 0.95 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
proc sort data=mrocBEq95; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBEq95  min noprint nway;   
var costp01; class FP ;   
output out=mincq95BEp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
 minid(costp01(c3))=c3 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
*******************q=1 PREV=0.7****************************************; 
proc sort data=mrocBEq95; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBEq95  min noprint nway;   
var costp07; class FP ;   
output out=mincq95BEp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
 minid(costp01(c3))=c3 
      minid(costp07(FPR))=FPR 
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      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************************************q=0.999 *****; 
data mrocBPq999;  
set mrocBPq ; 
TPRmaxq = 0.999 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
proc sort data=mrocBPq999; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBPq999  min noprint nway;   
var costp01; class FP ;   
output out=mincq999BPp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
***********q=1 PREV=0.7**************; 
proc sort data=mrocBPq999; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBPq999  min noprint nway;   
var costp07; class FP ;   
output out=mincq999BPp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************q=0.999 PREV=0.1************************; 
data mrocBNq999;  
set mrocBNq ; 
TPRmaxq = 0.999 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
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if q=0 then delete; 
run; 
proc sort data=mrocBNq999; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBNq999  min noprint nway;   
var costp01; class FP ;   
output out=mincq999BNp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
      minid(costp01(FPR))=FPR 
      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************************************q=1 PREV=0.7***; 
proc sort data=mrocBNq999; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBNq999  min noprint nway;   
var costp07; class FP ;   
output out=mincq999BNp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************************************q=0.999 PREV=0.1**; 
data mrocBEq999;  
set mrocBEq ; 
TPRmaxq = 0.999 * MTPR ; 
if Sensitivity >= TPRmaxq then q=1; 
else q=0; 
if q=0 then delete; 
run; 
proc sort data=mrocBEq999; by FPR costp01 descending Sensitivity ;run; 
proc means data=mrocBEq999  min noprint nway;   
var costp01; class FP ;   
output out=mincq999BEp01 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp01(c1))=c1  
      minid(costp01(c2))=c2 
 minid(costp01(c3))=c3 
      minid(costp01(FPR))=FPR 
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      minid(costp01(MTPR))=MTPR 
      minid(costp01(TPRmaxq))=TPRmaxq 
      minid(costp01(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
**********************************************q=1 PREV=0.7***; 
proc sort data=mrocBEq999; by FPR costp07 descending Sensitivity ;run; 
proc means data=mrocBEq999  min noprint nway;   
var costp07; class FP ;   
output out=mincq999BEp07 (drop=_type_ _freq_ FP) 
      min=cost  
      minid(costp07(c1))=c1  
      minid(costp07(c2))=c2 
   minid(costp01(c3))=c3 
      minid(costp07(FPR))=FPR 
      minid(costp07(MTPR))=MTPR 
      minid(costp07(TPRmaxq))=TPRmaxq 
      minid(costp07(Sensitivity))=Sensitivity; 
format FP lessthan.; 
run; 
********************q=1,Prevalence=0.1,MROC curves **************; 
data mincq1BEp01; set mincq1BEp01;strategy='BE';run;  
data mincq1BNp01; set mincq1BNp01;strategy='BN';run;  
data mincq1BPp01; set mincq1BPp01;strategy='BP';run;  
data bios.mcmrocq1p01; 
set mincq1BEp01 mincq1BNp01 mincq1BPp01; 
run; 
data mincq1BEp07; set mincq1BEp07;strategy='BE';run;  
data mincq1BNp07; set mincq1BNp07;strategy='BN';run;  
data mincq1BPp07; set mincq1BPp07;strategy='BP';run;  
data bios.mcmrocq1p07; 
set mincq1BEp07 mincq1BNp07 mincq1BPp07; 
run; 
data mincq95BEp01; set mincq95BEp01;strategy='BE';run;  
data mincq95BNp01; set mincq95BNp01;strategy='BN';run;  
data mincq95BPp01; set mincq95BPp01;strategy='BP';run;  
data bios.mcmrocq95p01; 
set mincq95BEp01 mincq95BNp01 mincq95BPp01; 
run; 
data mincq95BEp07; set mincq95BEp07;strategy='BE';run;  
data mincq95BNp07; set mincq95BNp07;strategy='BN';run;  
data mincq95BPp07; set mincq95BPp07;strategy='BP';run;  
data bios.mcmrocq95p07; 
set mincq95BEp07 mincq95BNp07 mincq95BPp07; 
run; 
data mincq999BEp01; set mincq999BEp01;strategy='BE';run;  
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data mincq999BNp01; set mincq999BNp01;strategy='BN';run;  
data mincq999BPp01; set mincq999BPp01;strategy='BP';run;  
data bios.mcmrocq999p01; 
set mincq999BEp01 mincq999BNp01 mincq999BPp01; 
run; 
data mincq999BEp07; set mincq999BEp07;strategy='BE';run;  
data mincq999BNp07; set mincq999BNp07;strategy='BN';run;  
data mincq999BPp07; set mincq999BPp07;strategy='BP';run;  
data bios.mcmrocq999p07; 
set mincq999BEp07 mincq999BNp07 mincq999BPp07; 
run; 
ODS rtf FILE = 'C:\sim\r0r0\90_90\b1b1\q1q95final.rtf'  style=journal2; 
goptions reset=all vsize=2.5 hsize=1.9 htitle=.8 htext=.4; 
axis1 w=1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 w=1 order=(0 to 1 by 
0.2) major=(h=.2) minor =(n=1); 
SYMBOL1 v=none COLOR=green INTERPOL=join LINE=1 h=1 w=2; 
SYMBOL2 v=none COLOR=blue INTERPOL=join LINE=35 h=1 w=2; 
SYMBOL3 v=none COLOR=red INTERPOL=join LINE=2 h=1 w=2; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(1.2,.5) ; 
proc gplot data=bios.mcmrocq1p01; 
plot Sensitivity * FPR = strategy / vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'MROC Curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.1'; 
run; 
goptions reset=global vsize=2.5 hsize=1.7 htitle=.8 htext=.4; 
axis1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 order=(0 to 1 by 0.2) 
major=(h=.2) minor =(n=1); 
SYMBOL1 c=black v=: COLOR=green h=.2 w=.2; 
SYMBOL2 c=black v=triangle COLOR=blue h=.1 w=.1; 
SYMBOL3 c=black v=square COLOR=red h=.1 w=.1; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(.8,.5) ; 
proc gplot data=bios.mcmrocq1p01; 
plot cost * FPR = strategy/ vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'Cost curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.1'; 
run; 
/**********************************Prevalence=0.7***************/ 
goptions reset=all vsize=2.5 hsize=1.9 htitle=.8 htext=.4; 
axis1 w=1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 w=1 order=(0 to 1 by 
0.2) major=(h=.2) minor =(n=1); 
SYMBOL1 v=none COLOR=green INTERPOL=join LINE=1 h=1 w=2; 
SYMBOL2 v=none COLOR=blue INTERPOL=join LINE=35 h=1 w=2; 
SYMBOL3 v=none COLOR=red INTERPOL=join LINE=2 h=1 w=2; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(1.2,.5) ; 
proc gplot data=bios.mcmrocq1p07; 
plot Sensitivity * FPR = strategy / vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
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title1 'MROC Curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.7'; 
run; 
goptions reset=global vsize=2.5 hsize=1.7 htitle=.8 htext=.4; 
axis1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 order=(0 to 1 by 0.2) 
major=(h=.2) minor =(n=1); 
SYMBOL1 c=black v=: COLOR=green h=.2 w=.2; 
SYMBOL2 c=black v=triangle COLOR=blue h=.1 w=.1; 
SYMBOL3 c=black v=square COLOR=red h=.1 w=.1; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(.8,.5) ; 
proc gplot data=bios.mcmrocq1p07; 
plot cost * FPR = strategy/ vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'Cost curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.7'; 
run; 
******************q=0.999,Prevalence=0.1, MCMROC curves ****; 
goptions reset=all vsize=2.5 hsize=1.9 htitle=.8 htext=.4; 
axis1 w=1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 w=1 order=(0 to 1 by 
0.2) major=(h=.2) minor =(n=1); 
SYMBOL1 v=none COLOR=green INTERPOL=join LINE=1 h=1 w=2; 
SYMBOL2 v=none COLOR=blue INTERPOL=join LINE=35 h=1 w=2; 
SYMBOL3 v=none COLOR=red INTERPOL=join LINE=2 h=1 w=2; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(1.2,.5) ; 
proc gplot data=bios.mcmrocq999p01; 
plot Sensitivity * FPR = strategy / vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'MCMROC Curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.1,q=0.999'; 
run; 
goptions reset=global vsize=2.5 hsize=1.7 htitle=.8 htext=.4; 
axis1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 order=(0 to 1 by 0.2) 
major=(h=.2) minor =(n=1); 
SYMBOL1 c=black v=: COLOR=green h=.2 w=.2; 
SYMBOL2 c=black v=triangle COLOR=blue h=.1 w=.1; 
SYMBOL3 c=black v=square COLOR=red h=.1 w=.1; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(.8,.5) ; 
proc gplot data=bios.mcmrocq999p01; 
plot cost * FPR = strategy/ vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'Cost curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.1,q=0.999'; 
run; 
/******************************************Prevalence=0.7***/ 
goptions reset=all vsize=2.5 hsize=1.9 htitle=.8 htext=.4; 
axis1 w=1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 w=1 order=(0 to 1 by 
0.2) major=(h=.2) minor =(n=1); 
SYMBOL1 v=none COLOR=green INTERPOL=join LINE=1 h=1 w=2; 
SYMBOL2 v=none COLOR=blue INTERPOL=join LINE=35 h=1 w=2; 
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SYMBOL3 v=none COLOR=red INTERPOL=join LINE=2 h=1 w=2; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(1.2,.5) ; 
proc gplot data=bios.mcmrocq999p07; 
plot Sensitivity * FPR = strategy / vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'MCMROC Curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.7,q=0.999'; 
run; 
goptions reset=global vsize=2.5 hsize=1.7 htitle=.8 htext=.4; 
axis1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 order=(0 to 1 by 0.2) 
major=(h=.2) minor =(n=1); 
SYMBOL1 c=black v=: COLOR=green h=.2 w=.2; 
SYMBOL2 c=black v=triangle COLOR=blue h=.1 w=.1; 
SYMBOL3 c=black v=square COLOR=red h=.1 w=.1; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(.8,.5) ; 
proc gplot data=bios.mcmrocq999p07; 
plot cost * FPR = strategy/ vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'Cost curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.7,q=0.999'; 
run; 
***********************q=0.95,Prevalence=0.1, MCMROC curves ****; 
goptions reset=all vsize=2.5 hsize=1.9 htitle=.8 htext=.4; 
axis1 w=1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 w=1 order=(0 to 1 by 
0.2) major=(h=.2) minor =(n=1); 
SYMBOL1 v=none COLOR=green INTERPOL=join LINE=1 h=1 w=2; 
SYMBOL2 v=none COLOR=blue INTERPOL=join LINE=35 h=1 w=2; 
SYMBOL3 v=none COLOR=red INTERPOL=join LINE=2 h=1 w=2; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(1.2,.5) ; 
proc gplot data=bios.mcmrocq95p01; 
plot Sensitivity * FPR = strategy / vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'MCMROC Curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.1,q=0.95'; 
run; 
goptions reset=global vsize=2.5 hsize=1.7 htitle=.8 htext=.4; 
axis1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 order=(0 to 1 by 0.2) 
major=(h=.2) minor =(n=1); 
SYMBOL1 c=black v=: COLOR=green h=.2 w=.2; 
SYMBOL2 c=black v=triangle COLOR=blue h=.1 w=.1; 
SYMBOL3 c=black v=square COLOR=red h=.1 w=.1; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(.8,.5) ; 
proc gplot data=bios.mcmrocq95p01; 
plot cost * FPR = strategy/ vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'Cost curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.1,q=0.95'; 
run; 
/******************************************Prevalence=0.7*/ 
goptions reset=all vsize=2.5 hsize=1.9 htitle=.8 htext=.4; 
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axis1 w=1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 w=1 order=(0 to 1 by 
0.2) major=(h=.2) minor =(n=1); 
SYMBOL1 v=none COLOR=green INTERPOL=join LINE=1 h=1 w=2; 
SYMBOL2 v=none COLOR=blue INTERPOL=join LINE=35 h=1 w=2; 
SYMBOL3 v=none COLOR=red INTERPOL=join LINE=2 h=1 w=2; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(1.2,.5) ; 
proc gplot data=bios.mcmrocq95p07; 
plot Sensitivity * FPR = strategy / vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'MCMROC Curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.7,q=0.95'; 
run; 
goptions reset=global vsize=2.5 hsize=1.7 htitle=.8 htext=.4; 
axis1 order=(0 to 1 by 0.2) major=(h=.2) minor =(n=1); axis2 order=(0 to 1 by 0.2) 
major=(h=.2) minor =(n=1); 
SYMBOL1 c=black v=: COLOR=green h=.2 w=.2; 
SYMBOL2 c=black v=triangle COLOR=blue h=.1 w=.1; 
SYMBOL3 c=black v=square COLOR=red h=.1 w=.1; 
LEGEND1 position= (BOTTOM CENTER OUTSIDE)  shape=symbol(.8,.5) ; 
proc gplot data=bios.mcmrocq95p07; 
plot cost * FPR = strategy/ vaxis=axis1 haxis=axis2 LEGEND = LEGEND1; 
title1 'Cost curves: Area(0.90,0.90)'; 
title2 'b1=1,b2=1,rD=0,rN=0,Prevalence=0.7,q=0.95'; 
run;quit; 
ods rtf close; 
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D3: Optimal Operating points 
 
libname bios 'C:\project\r0r0\90_90\b1b1';run; 
LIBNAME FRMT 'C:\ project';run; 
OPTIONS FMTSEARCH=(FRMT);run; 
/*********************** Generalized Youden index  **/ 
/****************** REV=0.1, cb=0.01, slope=0.1 ,q=1***/ 
data Optimalq1p01cb01p1; 
set bios.mcmrocq1p01; 
GYI = Sensitivity - ((1-0.1)/(0.1))*0.01*FPR; 
run; 
data Optimalq1p01cb01p1; 
set Optimalq1p01cb01p1; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p01cb01p1;by strategy; 
run; 
proc means data=Optimalq1p01cb01p1 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p01cb01p1 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/**************************************** REV=0.1, cb=0.11,slope=1 
,q=1*********************************************************************
*******/ 
data Optimalq1p01cb11p1; 
set bios.mcmrocq1p01; 
GYI = Sensitivity - ((1-0.1)/(0.1))*0.11*FPR; 
run; 
data Optimalq1p01cb11p1; 
set Optimalq1p01cb11p1; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p01cb11p1;by strategy; 
run; 
proc means data=Optimalq1p01cb11p1 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p01cb11p1 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
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    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/**************************************** REV=0.1, cb=0.33,slope=3 
,q=1*********************************************************************
*******/ 
data Optimalq1p01cb33p1; 
set bios.mcmrocq1p01; 
GYI = Sensitivity - ((1-0.1)/(0.1))*0.33*FPR; 
run; 
data Optimalq1p01cb33p1; 
set Optimalq1p01cb33p1; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p01cb33p1;by strategy; 
run; 
proc means data=Optimalq1p01cb33p1 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p01cb33p1 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/**************************************** REV=0.1, cb=1,slope=9 
,q=1*********************************************************************
*******/ 
data Optimalq1p01cb10p1; 
set bios.mcmrocq1p01; 
GYI = Sensitivity - ((1-0.1)/(0.1))*1*FPR; 
run; 
data Optimalq1p01cb10p1; 
set Optimalq1p01cb10p1; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p01cb10p1;by strategy; 
run; 
proc means data=Optimalq1p01cb10p1 max noprint; 
var GYI; 
by strategy; 
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output out=MGYIcq1p01cb10p1 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/**************************************** REV=0.1*/ 
ods rtf file="C:\sim\r0r0\90_90\b1b1\final GYI\75\MGYIcost75bp1.rtf" ; 
ods rtf ; 
proc print data = MGYIcq1p01cb01p1; run; 
ods rtf ; 
proc print data = MGYIcq1p01cb11p1; run; 
ods rtf ; 
proc print data = MGYIcq1p01cb33p1; run; 
ods rtf ; 
proc print data = MGYIcq1p01cb10p1; run; 
ods rtf close; 
/*********************************** Generalized Youden index  ***/ 
/******************* REV=0.1, cb=0.23,slope=0.1 ,q=1**/ 
data Optimalq1p07cb23p7; 
set bios.mcmrocq1p07; 
GYI = Sensitivity - ((1-0.7)/(0.7))*0.23*FPR; 
run; 
data Optimalq1p07cb23p7; 
set Optimalq1p07cb23p7; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p07cb23p7;by strategy; 
run; 
proc means data=Optimalq1p07cb23p7 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p07cb23p7 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/******************************* REV=0.1, cb=1,slope=0.43 ,q=1**/ 
data Optimalq1p07cb1p7; 
set bios.mcmrocq1p07; 
GYI = Sensitivity - ((1-0.7)/(0.7))*1*FPR; 
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run; 
data Optimalq1p07cb1p7; 
set Optimalq1p07cb1p7; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p07cb1p7;by strategy; 
run; 
proc means data=Optimalq1p07cb1p7 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p07cb1p7 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/******************* REV=0.1, cb=2.33,slope=1 ,q=1***/ 
data Optimalq1p07cb233p7; 
set bios.mcmrocq1p07; 
GYI = Sensitivity - ((1-0.7)/(0.7))*2.33*FPR; 
run; 
data Optimalq1p07cb233p7; 
set Optimalq1p07cb233p7; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p07cb233p7;by strategy; 
run; 
proc means data=Optimalq1p07cb233p7 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p07cb233p7 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/**************************************** REV=0.1, cb=7,slope=3 ,q=1**/ 
data Optimalq1p07cb70p7; 
set bios.mcmrocq1p07; 
GYI = Sensitivity - ((1-0.7)/(0.7))*7*FPR; 
run; 
data Optimalq1p07cb70p7; 
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set Optimalq1p07cb70p7; 
where cost <= 0.75; 
run; 
proc sort data= Optimalq1p07cb70p7;by strategy; 
run; 
proc means data=Optimalq1p07cb70p7 max noprint; 
var GYI; 
by strategy; 
output out=MGYIcq1p07cb70p7 (drop=_type_ _freq_) 
       maxid(GYI(c1))=c1 
    maxid(GYI(c2))=c2  maxid(GYI(c3))=c3 
       max=MGYI 
       maxid(GYI(Sensitivity))= Sensitivity 
       maxid(GYI(FPR))= FPR  
       maxid(GYI(cost))=cost; 
run; 
/**************************************** REV=0.7**/ 
ods rtf file="C:\sim\r0r0\90_90\b1b1\final GYI\75\MGYIcost75bp7.rtf" ; 
ods rtf ; 
proc print data = MGYIcq1p07cb23p7; run; 
ods rtf ; 
proc print data = MGYIcq1p07cb1p7; run; 
ods rtf ; 
proc print data = MGYIcq1p07cb233p7; run; 
ods rtf ; 
proc print data = MGYIcq1p07cb70p7; run; 
ods rtf close; 
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